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“We	are	guilty	of	many	errors	and	many	 faults,	 but	our	
worst	 crime	 is	 abandoning	 the	 children,	 neglecting	 the	
fountain	of	life.	Many	of	the	things	we	need	can	wait.	The	
child	 cannot.	 Right	 now	 is	 the	 time	 his	 bones	 are	 being	
formed,	his	blood	is	being	made,	and	his	senses	are	being	
developed.	 To	 him	 we	 cannot	 answer	 ‘Tomorrow’,	 his	
name	is	today.”	 Gabriela	Mistral,	1948								Aos	meus	filhos,	Carolina,	Diogo	e	Maria.		
		 vi	|	Ana	Faria	|	2017	
	
	 	
		 |	vii	
ACKNOWLEDGEMENTS			À	Professora	Doutora	Luísa	Diogo,	pelos	ensinamentos	e	apoio	constante	e	por	me	incentivar	a	nunca	desistir.	À	 Doutora	 Paula	 Garcia,	 por	 tudo	 o	 que	 me	 transmitiu,	 conhecimentos	 e	amizade.	À	Doutora	Maria	do	Carmo	Macário,	à	Professora	Doutora	Esmeralda	Martins,	ao	Professor	Doutor	Júlio	Rocha,	à	Doutora	Manuela	Almeida,	à	Doutora	Elisa	Leão	 Teles,	 á	 Doutora	 Esmeralda	 Rodrigues,	 à	 Doutora	 Carla	 Vasconcelos,	 à	Doutora	 Ana	 Gaspar	 e	 à	 Doutora	 Patrícia	 Janeiro,	 pela	 disponibilidade	 e	colaboração	na	concretização	do	projeto.		À	BioMarin	Ltd.	(nas	pessoas	do	Doutor	Tiago	Barros	e	da	Professora	Doutora	Sónia	 Albuquerque)	 e	 à	 Shire	 pelo	 apoio	 financeiro,	 fundamental	 para	 a	realização	da	investigação.		À	 Professora	 Doutora	 Florbela	 Vitória,	 por	 toda	 a	 ajuda	 e	 celeridade	 nas	respostas.	À	Ana	Serpa	Oliveira,	pela	ajuda	na	revisão	e	por	 toda	a	disponibilidade	que	sempre	demonstrou.	À	Maria	Armanda	por	toda	a	colaboração	cientifica,	e	pelo	apoio	neste	ultimo	ano.	 	Aos	meus	verdadeiros	Amigos,	que	estão	sempre	lá	quando	grito	“socorro!”.	Aos	 meus	 Pais,	 por	 estarem	 sempre	 e	 incondicionalmente	 disponíveis,	abdicando	de	tudo	para	tudo	nos	proporcionar.		Ao	Rui,	por	estar	ao	meu	lado	e	dos	nossos	filhos,	apesar	de	todas	as	horas	que	não	estive	por	perto.	Aos	meus	filhos,	Carolina,	Diogo	e	Maria,	pelos	momentos	em	que	precisavam	de	mim,	mas	em	que	não	pude	estar	presente.			 Muito	Obrigada!	
		 viii	|	Ana	Faria	|	2017	
	 	
		 |	ix	
ABSTRACT	
	
Background:	Mucopolysaccharidosis	 (MPS)	 are	 a	 group	 of	 rare,	 genetic,	 multisystem,	progressive	 diseases.	 They	 are	 characterized	 by	 lysosomal	 accumulation	 of	glycosaminoglycans,	 due	 to	 congenital	 enzymatic	 deficiencies.	 Patients	 are	susceptible	to	nutritional	status	deterioration	as	a	consequence	of	poor	quality	of	 health	 (inherent	 to	 the	 degenerative	 character	 of	 the	 disorders),	 and/or	inadequate	food	habits.	Treatment,	which	is	far	from	optimal,	has	been	focused	in	 symptoms	 alleviation	 and	 search	 for	 specific	 (“curative”)	 therapies.	Nutritional	issues	have	not	been	a	major	concern	in	the	majority	of	the	studies.		
	
Aim:		The	 main	 objective	 of	 this	 study	 was	 to	 evaluate	 nutritional	 status	 of	 MPS	patients,	in	relation	to	their	food	and	nutritional	intake	and	quality	of	health.			
Methods:	This	 is	 a	 cross-sectional	 study	 that	 included	 patients	 from	 four	 Portuguese	Lysosomal	Disorders	Treatment	Centers.	Demographic,	recent	(24-hour	recall)	and	 usual	 (food-frequency	 questionnaire)	 food	 intake	 data	 were	 collected.		Anthropometric	results	(weight,	height,	body	mass	index)	were	compared	with	WHO	references.	Body	composition	was	assessed	by	tetrapolar	biompedance	analysis.	Plasma	proteins,	vitamins,	minerals,	 lipids	 levels	and	essential	 fatty	acids,	 as	 well	 as	 renal	 and	 liver	 function	 tests,	 total	 blood	 count	 and	phosphocalcium	 metabolism	 were	 evaluated.	 The	 Health	 Assessment	Questionnaire	 (HAQ)	was	 applied	 to	 patients	 (or	 caregivers).	 	 The	 6-minute	walking	test	(6-MWT)	was	performed	by	a	subgroup	of	patients.		This	study	was	approved	by	the	Ethical	Committees	of	each	Treatment	Centre,	and	Comissão	Nacional	de	Proteção	de	Dados.	Patients,	parents	or	other	 legal	guardians	gave	a	written	informed	consent.	
	
Results:	Thirty-one	patients	(five	MPS	I;	four	MPS	II;	nine	MPS	III;	three	MPS	IV;	nine	MPS	VI;	one	MPS	VII),	aged	between	1.7	and	32.7	years,	were	included.	Mean	age	at	diagnosis	was	3.2	(SD=3.0)	years.	Nineteen	patients	(nine	MPS	VI)	were	under	 enzyme	 replacement	 therapy	 (ERT).	 Ten	 were	 taking	 nutritional	supplements,	 mainly	 vitamin	 D	 formulas.	 A	 high	 number	 of	 patients	 drank	sugar-rich	beverages	on	a	weekly	basis	and/or	did	not	eat	fruits	and	vegetables	regularly.		Caloric,	 protein,	 carbohydrates	 and	 fiber	 intakes	were	 lower	 than	 estimated	average	requirements	(EAR)	in	56.0%,	32.0%,	64.0%	and	76.0%	of	the	subjects,	
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respectively.	Fat	intake	was	adequate	in	52.0%	and	high	in	36.0%.	The	intake	of	vitamins	and	minerals	was	high	in	most	patients.			Weight	z-score	varied	from	-1.7	to	2.6,	height	z-score,	from	-10.1	to	1.5	and	BMI	z-score,	from	-4.6	to	3.4.	The	lowest	values	were	observed	in	MPS	VI,	MPS	IV	and	 MPS	 I	 groups	 for	 weight,	 height	 and	 BMI,	 respectively.	 Two	 patients	presented	a	status	of	severe	thinness	and	six	showed	overweight,	(one	obese).	Minimum	 mean	 body	 fat	 mass	 (16.6%)	 and	 body	 lean	 mass	 (13.8%)	 were	displayed	 in	MPS	 VI	 and	 in	MPS	 IV	 groups,	 respectively.	 Phase-angle	 varied	from	3.0	to	6.2°.	Pre-albumin,	 retinol	 binding	 protein	 (RBP),	 creatinine	 and	 HDL-cholesterol	were	 low	 in	 59.3%,	 75.0%,	 77.4%	 and	 48.4%,	 of	 the	 patients,	 respectively.	Vitamin	D	insufficiency	was	presented	in	38.7%	and	deficiency	in	48.4%.	MPS	III	group	showed	significantly	higher	plasma	pre-albumin	RBP	and	vitamin	A	levels,	than	the	other	groups.	MPS	VI	group	exhibited	lower	RBP,	vitamin	A	and	vitamin	E	than	the	others.	MPS	IV	group	presented	higher	vitamin	E	levels	than	the	remainder.	Plasma	pre-albumin	and	vitamin	A	were	significantly	lower	in	patients	submitted	to	ERT,	compared	to	others.	Mean	 total	 HAQ	 score	 (part	 I)	 was	 6.6/11	 (SD=3.8)	 (11=total	 inability).	Activities	 related	 to	 dressing	 and	 bathing	were	 associated	with	 the	 greatest	difficulties.	 Moderate	 positive	 correlations	 were	 detected	 between	 age	 and	scores	 of:	 “eating	 and	 drinking”	 “toileting”,	 “mobility”,	 and	 “walking	 and	climbing	 stairs”.	 A	 moderate	 positive	 and	 significant	 correlation	 was	 found	between	age	and	total	HAQ	score.	Strong	negative	correlations	were	displayed	between	 “walking	 and	 climbing	 stairs”	 scores	 and	 plasma	 creatinine	 and	araquidonic	acid	levels.	MPS	type	III	patients	had	higher	scores	in	“eating	and	drinking”,	 “dressing”	 and	 total	 HAQ	 than	 the	 other	 MPS	 groups.	 Caregiver	assistance	total	score	(HAQ	-	part	II)	presented	a	mean	of	3.0/11	(SD=1.1).	MPS	type	 II	patients	showed	significantly	higher	results	 in	6-MWT	than	 the	other	groups.	
	
Discussion	and	conclusion	Healthy	food	(fruits	and	vegetables)	is	not	regularly	consumed	by	most	of	the	patients,	whereas	sugar-rich	drinks	are	often	present	in	the	patients’	diet.	The	majority	 had	 lower	 caloric,	 carbohydrates	 and	 fiber	 intake	 and	 a	 great	 part	showed	lower	protein	and	higher	fat	intake	than	recommendations.		A	 great	 number	 of	 patients	 presented	 nutritional	 status	 indicators	 in	 levels	lower	than	normal:	phase-angle,	pre-albumin,	RBP	and	creatinine.	Low	levels	of	plasma	vitamin	D	were	most	prevalent.		MPS	VI	patients	showed	lower	RBP,	vitamin	A	and	vitamin	E.	The	former	two	were	also	lower	in	the	group	submitted	to	ERT	(where	about	half	of	the	patients	were	MPS	VI).	A	 high	 level	 of	 difficulties	 was	 found	 in	 the	 sample,	 associated	 with	 high	dependence	scores.	Older	patients	showed	more	difficulties,	in	general.	MPS	III	patients	were	the	ones	were	difficulties	were	the	greatest	in	global	test,	namely	
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in	“eating	and	drinking”	and	“dressing”	domains.	Higher	levels	of	dependence	were	 also	 present	 in	 patients	with	 lower	plasma	 creatinine	 and	 araquidonic	acid	levels.		A	 high	 level	 of	 disease	 severity	 was	 found	 in	 this	 group	 of	 patients.	 In	 a	substantial	 part	 of	 them,	 nutritional	 status	 indicators	 were	 found	 to	 be	abnormal,	pointing	 to	a	hypothetical	malnutrition	status,	which	could	not	be	proved	 by	 our	 results.	 A	 concurrent	 factor	 for	 the	 abnormalities	 found	 in	nutritional	status	indicators	could	be	the	latent	status	of	chronic	inflammation,	known	to	be	associated	to	these	diseases.	Unfortunately,	inflammation	status	of	the	patients	was	not	 included	 in	 the	 aims	of	 the	present	 investigation.	More	studies,	with	 larger	samples	and	 including	other	parameters	are	required,	 in	order	to	better	clarify	our	results.		A	 protocol	 of	 nutritional	 surveillance	 for	 the	 adequate	 follow-up	 of	 MPS	 is	suggested.	 The	 multidisciplinary	 team	 in	 charge	 of	 these	 patients	 should	include	a	specialized	nutritionist.			
	
Keywords:	mucopolysaccharidosis;	 nutrition;	 body	 composition;	 quality	 of	health.	
	
	
	
		 	
		 xii	|	Ana	Faria	|	2017	
	
	 	
		 |	xiii	
RESUMO	
	
Introdução	
As	 mucopolissacaridoses	 (MPS)	 são	 um	 grupo	 de	 doenças	 genéticas,	 raras,	
progressivas	 com	 envolvimento	 multisistémico.	 Caraterizam-se	 por	 uma	
acumulação	 lisosomal	de	glicosaminoglicanos,	causada	por	défices	enzimáticos	
específicos.	A	debilidade	do	estado	de	saúde	(inerente	à	natureza	degenerativa	
destas	doenças)	e/ou	hábitos	alimentares	possivelmente	desadequados,	conferem	
a	estes	doentes	grande	suscetibilidade	de	deterioração	do	seu	estado	nutricional.	
O	tratamento,	 longe	de	ser	o	mais	adequado,	tem-se	focado	essencialmente	nas	
co-morbilidades,	 enquanto	 se	 investe	 ativamente	 no	 desenvolvimento	 e	
aperfeiçoamento	 de	 terapêuticas	 especificas,	 “curativas”.	 O	 estado	 nutricional	
destes	doentes	não	tem,	de	um	modo	geral,	sido	objeto	de	investigação.		
	
Objetivos:	
O	principal	objetivo	deste	estudo	foi	avaliar	o	estado	nutricional	de	doentes	com	
MPS,	relacionando-o	com	a	ingestão	alimentar	e	nutricional	e	com	o	seu	estado	
de	saúde.	
	
Métodos:	
Trata-se	 de	 um	 estudo	 transversal	 para	 o	 qual	 foram	 convidados	 a	 participar	
doentes	de	quatro	Centros	de	Tratamento	de	Doenças	do	Lisossoma	Portugueses.	
Recolheu-se	 dados	 demográficos,	 assim	 como	 informação	 sobre	 a	 ingestão	
alimentar	recente	(24	horas	anteriores)	e	habitual	(questionário	de	 frequência	
alimentar).	 Os	 dados	 antropométricos	 foram	 avaliados	 com	 recurso	 aos	
parâmetros	de	referencia	da	OMS.		A	composição	corporal	foi	estimada	através	
de	 bioimpedância	 elétrica	 tetrapolar.	 Analisou-se	 igualmente:	 proteínas,	
vitaminas,	minerais,	lípidos	e	ácidos	gordos	essenciais	plasmáticos,	hemograma	e	
alguns	parâmetros	de	função	renal	e	hepática	e	do	metabolismo	fosfo-cálcico.	O	
Questionário	de	Avaliação	do	Estado	de	Saúde	(HAQ)	foi	igualmente	respondido	
pelos	 doentes	 (ou	 cuidadores).	 Um	 subgrupo	 dos	 doentes	 executou	 o	 teste	 de	
caminhada	de	6	minutos.	
Este	estudo	foi	aprovado	pelas	Comissões	de	Ética	de	cada	Centro	de	Tratamento	
e	pela	Comissão	Nacional	de	Proteção	de	Dados.	Todos	os	doentes,	pais	ou	tutores	
legais	deram	consentimento	informado	escrito	para	a	participação.	
	
Resultados:	
Foram	avaliados	trinta	e	um	doentes	(cinco	MPS	I;	quatro	MPS	II;	nove	MPS	III;	
três	MPS	IV;	nove	MPS	VI;	um	MPS	VII),	com	idades	compreendidas	entre	1,7	e	
32,7	anos.	O	diagnostico	foi	realizado	em	média	aos	3,2	anos	(DP=3,0).	Dezanove	
doentes	(nove	MPS	VI)	estavam	sob	terapia	de	substituição	enzimática	(ERT).	Dez	
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referiram	 a	 toma	 de	 suplementos	 nutricionais,	 principalmente	 de	 fórmulas	 de	
vitamina	D.	Um	significativo	numero	de	doentes	 consumia	bebidas	açucaradas	
semanalmente	 e	 /	 ou	 não	 ingeria	 fruta	 e	 legumes	 regularmente.	 	 A	 ingestão	
calórica,	proteica,	glicídica	e	de	fibras	era	inferior	às	recomendações	(“EAR”)	em	
56,0%,	 32,0%,	 64,0%	 e	 76,0%	 dos	 indivíduos,	 respetivamente.	 A	 ingestão	 de	
lípidos	era	adequada	em	52,0%	e	superior	ao	recomendado	em	36,0%.	A	maioria	
dos	 doentes	 apresentava	 uma	 ingestão	 de	 vitaminas	 e	 minerais	 superior	 às	
necessidades.		
Os	indicadores	z-score	do	peso	variaram	de	-1,7	a	2,6,	os	do,	z-score	da	estatura,	
entre	-10,1	e	1,5		e	os	do	z-score	do	índice	de	massa	corporal,	de	-4,6	a	3,4.		foram	
os	 mais	 baixos,	 respetivamente	 Os	 valores	 mais	 baixos	 foram	 observados	 nos	
grupos	com	MPS	VI,	MPS	IV	e	MPS	I,	respetivamente	para	o	peso,	a	estatura	e	o	
índice	de	massa	 corporal.	Dois	 doentes	apresentavam	magreza	 extrema	e	 seis,	
excesso	de	peso	(um	obeso).	Os	grupos	com	MPS	VI	e	MPS	IV	tinham	os	mínimos	
valores	 médios	 de	 massa	 gorda	 (16,6%)	 e	 de	 massa	 magra	 (13,8%),	
respetivamente.	 O	 ângulo	 de	 fase	 variou	 entre	 3,0	 e	 6,2°.	 Os	 níveis	 de	 pré-
albumina,	proteína	transportadora	do	retinol	(RBP),	creatinina	e	colesterol-HDL	
eram	 baixos	 em,	 respetivamente,	 59,3%,	 75,0%,	 77,4%	 e	 48,4%	 dos	 doentes.	
Encontrou-se	insuficiência	de	vitamina	D	em	38,7%	dos	indivíduos	e	deficiência	
em	48,4%.	
Os	doentes	com	MPS	III	apresentaram	valores	de	pré-albumina,	RBP	e	vitamina	A	
plasmáticos	 significativamente	 superiores	 aos	 dos	 restantes	 grupos.	 No	 grupo	
com	MPS	VI	foram	encontrados	valores	de	RBP,	vitamina	A	e	vitamina	E	inferiores	
aos	 restantes.	 Os	 doentes	 com	 MPS	 IV	 apresentaram	 níveis	 de	 vitamina	 E	
plasmática	superiores	aos	dos	restantes	grupos.	A	pré-albumina	e	a	vitamina	A	
plasmáticas	 eram	 significativamente	 inferiores	 nos	 doentes	 submetidos	 a	 ERT,	
relativamente	aos	restantes.		
A	 pontuação	 média	 do	 questionário	 HAQ	 (parte	 I)	 foi	 de	 6,6/11	 (DP=3,8)	
(11=incapacidade	 total).	 As	 atividades	 relacionadas	 com	 o	 vestir	 e	 a	 higiene	
pessoal	 estavam	 associadas	 a	 maiores	 dificuldades.	 Foram	 encontradas	
correlações	 positivas	 moderadas	 entre	 a	 idade	 e	 as	 pontuações	 de:	 “comer	 e	
beber”,	“higiene	pessoal”,	“mobilidade”,	“caminhar	e	subir	escadas”.		Entre	a	idade	
e	 a	 pontuação	média	 total	 do	 HAQ	 foi	 identificada	 uma	 correlação	 positiva	 e	
moderada,	estatisticamente	significativa.		Foram	ainda	estabelecidas	correlações	
negativas	fortes	entre	a	pontuação	do	domínio	“caminhar	e	subir	escadas”	e	os	
valores	plasmáticos	de	creatinina	e	do	ácido	araquidónico.	Os	doentes	com	MPS	
III	 apresentaram	 pontuações	 mais	 elevadas	 nos	 domínios	 “comer	 e	 beber”	 e	
“vestir”	 e	 na	 pontuação	 global	 do	HAQ,	 relativamente	 aos	 restantes	 grupos.	 A	
pontuação	média	relativamente	à	dependência	do	cuidador	(HAQ	–	parte	II)	foi	
de	3,0/11	 (DP=1,1).	Os	doentes	 com	MPS	 II	mostraram,	 em	relação	aos	outros	
grupos,	resultados	significativamente	superiores	na	prova	da	caminhada.		
	
Discussão	e	conclusão	
A	 generalidade	 dos	 doentes	 não	 consumia	 regularmente	 alimentos	 saudáveis,	
como	frutas	e	vegetais	e	ingeria	bebidas	açucaradas	com	regularidade.	A	ingestão	
energética,	 glicídica	 e	 de	 fibras	 era	 inferior	 às	 recomendações	 na	maioria	 dos	
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casos.	 Uma	grande	 parte	 dos	 indivíduos	 tinha	 uma	 ingestão	 de	 proteínas	 e	 de	
lípidos,	respetivamente	inferior	e	superior	às	necessidades.		
Alguns	indicadores	do	estado	nutricional	encontravam-se	baixos	em	muitos	dos	
doentes	analisados,	nomeadamente	o	ângulo	de	fase	e	a	pré-albumina,	a	RBP	e	a	
creatinina	 plasmáticas.	 Igualmente	 prevalentes,	 foram	 os	 níveis	 diminuídos	 de	
vitamina	D	no	plasma.	Os	doentes	com	MPS	VI	apresentavam	valores	plasmáticos	
baixos	de	RBP,	vitamina	A	e	vitamina	E.	No	grupo	submetido	a	ERT	(no	qual	cerca	
de	metade	dos	doentes	era	MPS	VI),	havia	igualmente	valores	dos	dois	primeiros.		
A	 amostra	 estudada	 demonstrou	 um	 alto	 nível	 de	 dificuldade:	 média	 de	 6,6,	
associado	com	altos	níveis	de	dependência	do	cuidador.	Os	doentes	mais	velhos	
manifestaram	globalmente	maiores	dificuldades.	Nos	doentes	com	MPS	III,	estas	
dificuldades	foram	superiores	às	dos	restantes,	e	particularmente	nos	domínios	
“comer	e	beber”	e	“vestir”.	Nos	indivíduos	com	baixos	valores	de	creatinina	e	de	
ácido	araquidónico	plasmáticos,	foram	igualmente	encontrados	maiores	níveis	de	
dependência.		
Este	 grupo	 de	 doentes	 apresenta	 um	 elevado	 nível	 de	 gravidade.	 Numa	 parte	
significativa	da	amostra	foram	encontradas	alterações	nos	indicadores	do	estado	
nutricional,	apontando	para	um	possível	estado	de	desnutrição,	que	não	pudemos	
provar	com	os	resultados	obtidos.	Concomitantemente,	poderá	existir	um	estado	
de	inflamação	crónica,	reconhecidamente	associado	a	estas	doenças.	No	entanto,	
a	avaliação	do	estado	inflamatório	dos	doentes	não	foi	incluída	nos	objetivos	da	
presente	investigação.		
São	 necessários	mais	 estudos,	 com	 amostras	 de	maior	 dimensão	 e	 inclusão	 de	
outros	parâmetros,	de	modo	a	clarificar	os	dados	obtidos.		
Propõe-se	um	protocolo	de	vigilância	nutricional	para	o	seguimento	dos	doentes	
com	MPS.	A	equipa	multidisciplinar	que	acompanha	estes	doentes	deve	incluir	um	
nutricionista	com	formação	especifica	em	doenças	hereditárias	do	metabolismo.		
	
Palavras-chave:	mucopolissacaridoses;	 nutrição;	 composição	 corporal;	 estado	
de	saúde.	
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Mucopolysaccharidosis		
Mucopolysaccharidosis	 (MPS)	 are	 a	 group	 of	 genetic,	 progressive	 diseases,	 caused	 by	enzymatic	deficiencies	on	lysosomal	degradation	of	glycosaminoglycans	(GAGs)	(1).		MPS	are	orphan	diseases,	 (incidence	 lower	 than	1:2	000	 live	births).	Their	global	 incidence	ranges	from	1.4/10	000	to	1/18	000	(2,	3).	It	is	estimated	to	be	about	1:25	000	in	Portugal	(4).		GAGs	are	part	of	the	structure	of	the	proteoglycans,	which	are	important	components	of	the	extracellular	matrix	(or	connective	tissue)	(5,	6).	They	are	subject	to	constant	turnover,	which	is	much	slower	in	adults	than	in	children.		Several	 acid	 hydrolases	 act	 sequentially	 in	 lysosomal	 degradation	 of	 GAGs.	 Deficiency	 of	several	 of	 those	 enzymes	 are	 known	 to	 cause	 a	 block	 in	 GAGs	 catabolic	 pathways,	 with	progressive	 accumulation	 of	 the	 respective	 substrate	within	 cells	 of	 various	 organs.	 These	include	liver,	spleen,	bone,	skin	and	central	nervous	system.	Phenotypes	vary	according	to	the	specific	 enzymatic	 deficiency	 and	 its	 severity,	 which	 determine	 the	 type,	 intensity	 and	localization	of	GAGs	storage	(5,	7).		Seven	 major	 types	 of	 MPS	 are	 recognized,	 according	 to	 the	 enzyme	 defect	 and	 the	glycosaminoglycans	 excreted	 in	 urine:	Hurler-Scheie	 (MPS	 IH	 and	MPS	 IS),	Hunter	 (MPS	 II),	Sanfilippo	(MPS	III;	subtypes	A,	B,	C	and	D),	Morquio	(MPS	IV;	subtypes	A	and	B),	Maroteaux-Lamy	(MPS	VI),	Sly	 (MPS	VII)	and	Hyaluronidase	deficiency	(MPS	 IX)	 (5)	 (Table	1).	 	All	MPS	types	are	autosomal	recessive	disorders,	except	for	MPS	II,	which	is	X-linked	(8).	Diagnosis	of	MPS	is	based	on	clinical	suspicion	and	confirmed	by	urine	GAGs	quantification	and	electrophoresis	analysis,	enzymatic	assay	of	lysosomal	hydrolases	in	leucocytes	or	fibroblasts	and	genetic	molecular	study	(1,	5)	(Table	1).			GAGs	 accumulation	 affect	 predominantly	 liver	 and	 spleen	 (hepatosplenomegaly),	 skeletal	structure	 (dysostosis	 multiplex)	 and	 general	 morphogenesis,	 with	 progressive	 coursing	 of	features,	 specifically	 facial.	 Eye	 (corneal	 clouding	 and	 glaucoma),	 brain	 (psychomotor	development	 delay	 and/or	 regression,	 intellectual	 deficiency,	 behavioural	 disturbances	and/or	dementia)	and	heart	(cardiomyopathy	and	valve	disease)	involvement	are	also	seen,	mostly	in	specific	types.	Clinical	phenotypes	are	protean	concerning	age	onset,	type	and	degree	of	affected	organs	and	disease	severity.	In	general,	severity	correlates	inversely	with	age	at	presentation	(9).			
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MPS	type	 Disease	name	 Enzymatic	defect	 Urinary	metabolites	
MPS	I	 Hurler,	Scheie,	
Hurler-Scheie	
a-L-Iduronidase	 Dermatan	sulfate,	heparan	sulfate	
MPS	II	 Hunter	 Iduronate	sulfatase	 Dermatan	sulfate,	heparan	sulfate	
MPS	IIIA	 Sanfilippo	A	 Heparan	sulfate	N-sulfatase	(sulfamidase)	 Heparan	sulfate	
MPS	IIIB	 Sanfilippo	B	 a-N-Acetylglucosaminidase	 Heparan	sulfate	
MPS	IIIC	 Sanfilippo	C	 Acetyltransferase	 Heparan	sulfate	
MPS	IIID	 Sanfilippo	D	 N-Acetylglucosamine	6-sulfatase	 Heparan	sulfate	
MPS	IVA	 Morquio	A	 Galactosamine	6-sulfatase	 Keratan	sulfate,	chondroitin	6-sulfate	
MPS	IVB	 Morquio	B	 b-Galactosidase	 Keratan	sulfate	
MPS	VI	 Maroteaux-Lamy	 N-Acetylglucosamine	4-sulfatase	(arylsulfatase	B)	 Dermatan	sulfate	
MPS	VII	 Sly	 b-Glucuronidase	 Dermatan	sulfate,	heparan	sulfate,	chondroitin	4-sulfate,	chondroitin	6-sulfate	
MPS	IX	 -	 Hyaluronidase		 Hyaluronic	acid	
Table	1.	Biochemical	defects	and	urinary	metabolites	for	diagnosis	of	different	types	of	MPS	(adapted	from	Inborn	
metabolic	diseases	(1)).		Usually,	affected	subjects	seem	normal	in	early	life	and	develop	the	typical	clinical	phenotypes	progressively	 after	 a	 few	 months	 or	 years.	 However,	 in	 the	 most	 severe	 forms,	 they	 may	present	typical	signs	in	the	neonatal,	or	even	antenatal	period.	On	the	other	end	of	the	disease	spectrum,	manifestations	emerge	in	youth	or	even	adult	life	(10).		Characteristically,	MPS	 IH,	MPS	 II	 and	MPS	VI	 are	more	 severe,	with	 coarse	 facies	 and	ENT	obstructive	disease.	MPS	VII	is	frequently	associated	with	hydrops	foetalis	or	neonatal	massive	hepatosplenomegaly	and	abdominal	hernia,	although	late-onset	forms	are	known	(5).			Severe	 skeletal	 dysplasia,	 leading	 to	 impairment	 of	 growth	 (stature),	 and	 preserved	intellectual	function,	are	typically	seen	in	MPS	IV	and	also	MPS	VI	(5).	Cognitive	impairment	is	variable	 and	 typical	 of	 MPS	 I,	 MPS	 II,	 all	 subtypes	 of	 MPS	 III	 and	 MPS	 VII	 patients,	 and	progressive	deterioration	can	occur.	Behavioural	disturbances	and	dementia	occur	mostly	in	MPS	III	(A,	B	or	C)	(1).		MPS	IX	is	extremely	rare,	and	patients	commonly	present	with	joint	involvement	(5).		With	 the	 improvement	 of	 diagnosis	 techniques,	 less	 severely	 affected	 patients	 are	 being	detected,	 without	 significant	 dysmorphism	 or	 organomegaly	 and	 normal	 to	 borderline	cognitive	levels	(11,	12).		In	MPS	patients,	several	issues	inherent	to	the	consequences	of	cell	storage	of	GAGs,	such	as	frequent	 ear	 infections,	 sleep	 apnoea	 and	 mechanical	 compression	 of	 the	 stomach	 by	 the	
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enlarged	liver	and	spleen	contribute	to	nutritional	deficiencies	and	failure	to	thrive,	commonly	seen	in	these	subjects.	Behavioural	disturbances	with	hyperkinesia	and	insomnia,	depression,	cognitive	impairment/dementia	and	heart	failure	are	additional	risk	factors	to	malnutrition.	Treatment	of	MPS	patients	is	mostly	supportive,	regardless	the	type.	Hematopoietic	stem	cell	transplantation	 is	 an	 available	 possibility.	 It	 has	 been	 used	 with	 some	 success	 in	 MPS	 IH	patients,	 less	 than	 2	 years	 of	 age.	 Enzymatic	 replacement	 therapy	 (ERT)	 is	 accessible	 for	patients	with	MPS	IH/S,	MPS	II,	MPS	IVA	and	MPS	VI,	and	in	progress	for	MPS	VII	and	MPS	IIIB	(5,	 6,	 13-15).	 Although	 some	 clinical	 improvement	 has	 been	 achieved	 with	 both	 therapeutic	methods,	 they	 do	 not	 halt	 or	 revert	 all	 aspects	 of	 disease	 progression.	 In	 fact,	 none	 of	 the	available	therapeutic	options	is	disease	curative,	but,	at	their	best,	disease	modifiers.	Independently	 from	 the	 MPS	 type	 and	 available	 specific	 treatment,	 all	 patients	 need	symptomatic	 treatment	 and	 support	 conducted	 by	 multidisciplinary	 teams,	 in	 order	 to	promote	well-being	and	improve	quality	of	life	(16-20).	Adequate	nutrition	is	one	of	the	pillars	of	the	therapeutic	strategy.				
Nutritional	status	and	quality	of	life	in	chronic	diseases		
Growth	and	nutritional	status	are	excellent	indicators	of	health	in	children	and	adolescents.	When	 a	 chronic	 disease	 like	 MPS	 is	 present,	 both	 growth	 and	 nutritional	 status	 may	 be	impaired	due	to	changes	in	metabolism	secondary	to	disease,	associated	with	other	factors	like	inability	to	suck,	chew,	swallow	and	digest	food	properly,	oesophageal	reflux	or	the	effects	of	prolonged	use	of	medications		(21-23).		Chronic	symptoms	(like	pain,	insomnia,	abdominal	distension,	intellectual	disability,	feeding	or	mobility	difficulties,	to	mention	a	few)	and	their	negative	repercussion	in	nutritional	status	may	have	 consequences	on	 the	quality	of	 life	of	patients	and	 their	 families.	Providing	good	nutritional	 monitoring	 and	 support,	 as	 well	 as	 careful	 symptomatic	 treatment,	 along	 with	anticipation	of	complications,	can	contribute	to	improve	patients	and	families’	quality	of	life.		
Assessment	of	nutritional	status	
Assessment	 of	 nutritional	 status	may	 lead	 to	 identification	 of	 the	 impact	 of	 the	 disease	 on	nourishment,	 enabling	 a	 prompt	 intervention	 if	 needed.	 It	 can	 be	 achieved	 through	anthropometrics,	 body	 composition	 and	 laboratorial	 parameters	 evaluation.	 Additionally,	
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information	on	usual	food	and	nutritional	intake	may	also	help	to	identify	the	possible	role	of	unhealthy	food	choices	enhancing	disease	related	factors	in	nutritional	deficiency.		Growth	impairment	(short	stature)	due	to	skeletal	dysplasia	present	in	many	patients	is	one	of	the	 main	 debated	 issues	 on	 MPS.	 However,	 their	 nutritional	 status	 is	 rarely	 discussed,	literature	on	that	subject	being	scarce.	This	occurs	probably	because	these	patients	have	so	many	other	life	threatening	complications	that	nutrition	comes	second.	On	the	other	hand,	the	“puffy”	appearance	of	most	MPS	patients	due	to	skin	storage	may	mask	nutritional	problems,	at	some	extent.																					
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AIMS																									
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This	investigation	aimed	to:	- Assess	nutritional	status	of	patients	with	MPS	of	different	types;	- Characterize	food	habits	and	usual	nutritional	intake	in	these	individuals;	- Evaluate	their	health	status	in	association	with	disease	type	and/or	progression;	- Clarify	the	impact	of	disease	in	dietary	intake	and	nutritional	status;	- Establish	the	link	between	nutritional	intake	and	nutritional	status	in	patients;	- Correlate	autonomy	with	dietary	intake	and	nutritional	status;		- Propose	a	nutritional	protocol	to	care	MPS	patients	in	daily	clinics.		 	
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PATIENTS	
	MPS	patients	from	four	Lysosomal	Disorders	Treatment	Centers	in	Portugal	were	invited	to	participate	 in	 the	 present	 study:	 Centro	 Hospitalar	 Universitário	 de	 Coimbra,	 E.P.E.,	 Centro	
Hospitalar	de	São	João	-	Porto,	Centro	Hospitalar	do	Porto,	E.P.E.	and	Centro	Hospitalar	de	Lisboa	
Norte,	E.P.E..	A	 preliminary	 contact	 was	 made	 between	 the	 investigator	 and	 the	 medical	 teams	 of	 the	Lysosomal	Disorders	Treatment	Centers	collaborating	in	the	study.		Demographic	data,	MPS	type	and	age	at	diagnosis	were	collected.	A	code	composed	by	MPS	type	and	a	digit	(i.e.	MPS	III1)	was	attributed	to	each	patient	(Table	S1).	
	
METHODS	
I. FOOD	AND	NUTRITIONAL	INTAKE		
The	investigator	applied	a	24-hour	recall	questionnaire,	adapted	to	parents	or	patients,	when	possible.	Information	was	collected	using	the	available	Manual	of	Quantification	of	Portuguese	Foods	 (FCNAUP)	 (24).	 Data	 analysis,	 detailed	 by	 different	 nutrients,	 was	 done	 according	 to	Portuguese	Food	Composition	Table	(INSA)	(25).	After	accomplishing	the	previous	assessments,	in	order	to	assess	usual	dietary	intake	over	the	previous	12	months,	a	food	frequency	questionnaire	was	delivered	and	its	fulfilment	was	asked	for,	as	recommended	by	the	authors	(26-28).	Specific	guidelines	were	explained.	No	intervention	of	the	investigator	occurred	during	the	time	patients	or	parents	answered	the	questionnaires.		Eighty-two	food	items	were	included	in	the	questionnaire.	Others	were	included,	if	consumed	in	 a	 frequency	 higher	 than	 once	 per	 week.	 Nine	 possibilities	 of	 frequency	 of	 intake	 were	considered,	 from	 “never	 or	 less	 than	 once	 per	 month”	 to	 “six	 or	 more	 times	 per	 day”,	considering	the	medium	serving	size	presented	next	to	the	item.	When	analysing	data,	foods	with	mentioned	intake	as	“never	or	less	than	once	per	month”	were	excluded.	Food	intake	was	calculated	multiplying	frequencies	by	standard	portion	size	of	the	food	item.	An	extra	seasonal	factor	of	0.25	was	used,	considering	seasonality	as	corresponding	to	3	months	per	year	(26,	27).	
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Food	 intake	 conversion	 into	 nutrients	 was	 made	 using	 an	 adapted	 Portuguese	 version	 of	software	Food	Processor	Plus	(ESHA	Research,	USA)	and	Portuguese	Food	Composition	Table	(INSA)	(25,	29).	Nutritional	 intake	was	 compared	with	Estimated	Average	Requirement	 (EAR),	 or	 adequate	intake	(AI)	if	EAR	was	inexistent	(30-35).	Intakes	were	considered	adequate	when	found	between	90	to	110%	of	EAR	/	AI,	inclusive.	Ingestion	lower	than	90%	of	EAR	/AI	and	higher	than	100%	were	considered	lower	and	higher	than	recommendations,	respectively	(36).		
II. ANTHROPOMETRICS	AND	BODY	COMPOSITION	
In	each	Hospital,	patient’s	weight	and	height	were	obtained	by	standard	techniques	in	the	same	day	of	the	remaining	protocol	procedures	(37).	For	weight	determination,	different	scales	were	used,	 according	 to	 local	 availability	 and	 the	patient’s	 capacity	 to	 stand	on	vertical	 position.	Equipment	 adapted	 to	 bed	 was	 used	 when	 ability	 to	 stand	 up	 was	 impaired.	 Weight	 was	recorded	in	kilograms	(Kg),	adjusted	to	one	decimal	place.	Height	was	measured	by	standard	techniques	with	the	stadiometers	available	in	each	centre,	or	estimated	by	wingspan,	when	needed.	Height	was	recorded	in	centimetres	(cm),	adjusted	to	one	decimal	place	(37).	Body	mass	index	(BMI)	was	calculated	using	the	appropriate	formula	and	data	was	recorded,	with	accuracy	of	one	decimal	place	(37).	Weight	for	age,	height	for	age	and	BMI	for	age	were	coded	into	z-scores,	according	to	World	Health	Organization	standard	growth	references	 [WHO	standards	 (birth	 to	60	months)	and	WHO	reference	2007	(61	months	to	19	years)]	(37).	For	individuals	older	than	19	years,	z-scores	standardized	to	19	years	were	given.	In	individuals	older	than	10	years,	weight	wasn’t	analysed	based	on	z-score,	in	accordance	with	WHO	recommendations	(37).			In	the	adult	group,	patients	were	also	classified	according	to	the	International	Classification	of	BMI	in	underweight,	overweight	and	obesity	(adapted	from	WHO	1995,	WHO	2000	and	WHO	2004)	(38).	When	available,	disease	specific	growth	charts	were	used:	for	MPS	II	(weight,	stature	and	BMI	for	age),	MPS	III	(stature	for	age),	MPS	IV	(weight,	stature	and	BMI	for	age)	and	MPS	VI	(stature	for	age)	(39-42).			
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Body	composition	analysis	was	made	using	the	bioelectrical	impedance	analyser	AKERN	BIA-101	 Anniversary®	 (single	 frequency	 50Hz).	 Recommendations	 for	 its	 use	 with	 maximum	accuracy	were	applied:	discouragement	of	alcohol	intake	and	physical	activity	in	the	previous	8	hours	and	4	hours	fasting	prior	to	the	analysis	(43).	Patients	 with	 prosthetics	 or	 catheters	 of	 unknown	 composition	 were	 excluded	 from	 this	assessment.	Resistance	and	reactance	were	recorded	with	accuracy	of	0,1	ohms.	Phase	angle	was	calculated	using	the	appropriate	equation,	like	previously	described	in	other	studies,	and	recorded	with	accuracy	of	0,1°	(44).			
III. RESISTANCE	TEST	
The	 six-minute	 walking	 test	 (6-MWT),	 a	 resistance	 test	 to	 assess	 ability	 to	 walk	 without	support,	 unless	mentioned,	was	 performed	 in	 a	 30	meter	 corridor,	 according	 to	 published	guidelines	(45).	The	test	was	accomplished	after	bio	impedance	analysis.	Results	were	recorded	with	an	accuracy	of	0.1	m.		
IV. LABORATORIAL	ANALYSIS	
Collection	 of	 biological	 samples	 occurred	 in	 each	 hospital,	 in	 the	 same	 visit	 as	 the	 other	procedures.	Morning	fast	was	recommended.			Data	of	each	test	result	was	displayed	with	an	accuracy	of	0.1	and	presented	in	international	standard	units,	except	for	a	few,	where	other	units	are	more	commonly	used:	cholesterol	(total,	LDL	 and	 HDL),	 triglycerides,	 alanine	 aminotransferase,	 aspartate	 aminotransferase	 and	gamma-glutamyl	transferase	(46).	Since	reference	values	 for	some	parameters	were	slightly	different	according	to	 the	diverse	hospital	laboratories,	results	are	described	as	normal,	high	or	low	in	relation	to	the	reference	values	of	each	specific	laboratory.		In	the	case	of	c-reactive	protein	and	folic	acid	levels,	in	which	results	were	presented	as	higher	or	lower	than	a	certain	threshold,	that	value	was	used	as	the	result	for	the	purpose	of	statistical	analysis.		
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V. QUALITY	OF	HEALTH	ASSESSMENT	
The	MPS	Health	Assessment	Questionnaire	(HAQ),	an	instrument	to	assess	functional	status,	capabilities	 and	 performance,	 was	 applied	 to	 patients	 older	 than	 14	 years	 of	 age,	 unless	cognitive	impairment	was	present	(47,	48).		In	these	cases,	parents	or	legal	guardians	provided	answers,	as	with	children	younger	than	14	years	of	age.	The	questionnaire	is	composed	by	two	parts,	concerning	daily	living	activities	(part	I)	and	the	need	for	assistance	(part	II).	Part	I	consists	of	a	series	of	39	questions	related	to	activities	of	daily	 living,	 grouped	 by	 domains.	 To	 each	 question,	 patients	 or	 parents	 should	 attribute,	through	a	Likert	scale	type,	a	score	according	to	the	level	of	difficulty	in	performing	the	activity.	It	ranges	from	“Not	difficult	at	all”	(=0)	to	“Extremely	difficult”	(=10).	When	the	patient	cannot	complete	the	task,	a	check	box	with	the	mention	“Unable	to	do”	is	available	to	point	out.	Part	II	of	 the	questionnaire	corresponds	 to	a	series	of	13	 items	related	 to	categories	of	assistance.	Each	 present	 four	 options	 according	 to	 the	 level	 of	 caregiver	 assistance	 needed,	 from	“independent”	to	“need	of	complete	assistance”.			Respecting	 data	 analysis	 of	 Part	 I,	 it	 was	 considered	 the	 desirable	 age	 of	 competence	acquisition	 the	 one	 established	 in	 the	 Vineland	 Scale	 (49).	 When	 it	 is	 presented	 as	 a	 range	(example:	2	 to	3	years),	maximum	age	was	considered	 for	 the	analysis.	When	 the	activities	needed	 competences	 of	 ages	 higher	 than	 the	 present	 age	 of	 the	 individual,	 the	 associated	question	was	not	considered	because	it	was	found	not	appropriate	or	expected	for	that	age.	In	the	case	of	a	patient	who	has	already	acquired	the	competence	although	it	wasn’t	expected	for	that	age,	it	was	still	considered	for	total	score	calculation.	For	each	domain	of	Part	I,	a	score	was	obtained	by	the	sum	of	all	responses	(varying	from	0	to	11,	which	was	credited	when	the	“unable	to	do”	box	was	marked),	divided	by	the	number	of	answered	questions.	Each	 category	 can	be	 compared	 to	 each	other	 since	 all	 have	 the	 same	metrics,	as	well	as	total	score	does.	Part	 II	 score	 was	 obtained	 by	 the	 sum	 of	 scores	 (1=independent;	 2=minimal	 assistance	required;	3=moderate	assistance	required;	4=complete	assistance	required)	of	all	13	domains,	divided	by	number	of	domains.			
STATISTICAL	ANALYSIS	
Statistical	software	IBM	SPSS	Statistics	for	Windows,	Version	22.0	was	used	to	analysis	(50).	
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Mean	 (M),	 standard	 deviation	 (SD),	 minimum	 and	 maximum	 are	 presented	 for	 ordinal	variables.	Nominal	variables	results	are	presented	in	absolute	and	relative	frequencies	(n	and	%).	The	significance	level	of	0.05	was	considered,	when	inferential	statistics	was	performed	(51).	The	 small	 sample	 size	 and	 the	 distribution	 of	 the	 subjects	 by	 the	 categories	 of	 nutritional	intake,	 with	 a	 substantial	 proportion	 in	 only	 one	 option,	 determined	 the	 selection	 of	nonparametric	statistical	tests	(52,	53).	When	it	was	intended	to	compare	the	scores	obtained	by	two	groups,	 the	Mann-Whitney	U	 test	was	 calculated.	Kruskal-Wallis	 test	was	 calculated	 to	compare	 three	 groups.	 In	 both	 cases,	 to	 accommodate	 the	 effects	 of	 a	 reduced	 sample	 and	considering	 that	 some	 groups	 had	 a	 very	 small	 number	 of	 subjects,	 the	 exact	 p	 value	was	calculated	(54).	If	Kruskal-Wallis	results	were	significant,	post	hoc	tests	were	calculated	using	the	pairwise	comparisons	procedure	of	SPSS	22.0	(Dunn-Bonferroni).	Inferential	 statistics	 was	 not	 calculated	 when	 only	 one	 group	 obtained	 more	 than	 one	observation.	Also,	in	cases	where	one	of	the	three	cells	obtained	only	one	observation	this	was	not	considered	to	the	inferential	analysis.	Spearman	correlations	(rho)	were	calculated	in	it	was	intended	to	test	associations	between	variables.	Spearman's	correlation	is	the	nonparametric	alternative	to	Pearson's	correlation	(51).	The	option	for	this	non-parametric	test	had	to	do	with	the	small	sample	size.	The	interpretation	of	 the	Spearman	correlation	 is	 identical	 to	 that	of	Pearson,	and	 its	significance	(p<0.05),	 its	signal	(positive	or	negative)	and	its	magnitude	(-1	to	1)	were	considered.	In	the	interpretation	of	 the	magnitude	was	considered	the	proposal	of	Cohen	(1988):	between	0.10	and	0.29	the	correlation	is	weak;	between	0.30	and	0.49	moderate;	and	between	0.50	and	1.0	strong.	The	magnitudes	of	the	correlations	were	interpreted	even	when	this	was	not	significant,	taking	this	information	 as	 merely	 descriptive	 of	 the	 relationship	 between	 the	 variables	 in	 the	 study	sample.	Some	variables	have	missing	data.	In	order	to	preserve	as	much	as	possible	the	sample	size,	the	pairwise	method	was	used,	which	consists	of	using	all	the	available	information	for	each	pair	of	variables.	In	this	way,	the	n	varies	in	each	cross	between	variables	(correlation	or	test	of	differences).	Considering	that	this	is	an	exploratory	study	of	a	rare	population,	this	method	allows	optimizing	the	data	collected	(55).	To	test	the	independence	of	two	nominal	variables	in	the	distribution,	the	Fisher	Exact	test	was	performed	as	an	alternative	to	the	Chi-square	test	(56).	
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Each	MPS	type	group	(except	MPS	VII)	and	patients	submitted	to	ERT	were	compared	to	others	as	a	set,	in	what	concerns	to	age	at	diagnosis,	selected	nutritional	status	parameters	(BMI	z-score;	phase	angle;	plasma	pre-albumin,	 retinol	binding	protein	 (RBP),	 creatinine,	 essential	fatty	acids	and	vitamins	D,	E	and	A	levels),	nutritional	intake,	HAQ	scores	(by	domain	and	total	score)	 and	6-MWT	results.	MPS	patients	were	also	assembled	according	 to	 skeleton	versus	central	nervous	system	major	involvement	in	two	groups:	MPS	I,	II,	 III	and	MPS	VII	(central	nervous	system)	and	MPS	IV	and	MPS	VI	(skeleton).	Both	groups	were	compared	for	the	same	parameters	mentioned	above.		Differences	were	tested	in	the	categories	of	nutritional	intake	(energy	and	macronutrients)	in	percentage	of	EAR	(<	90%,	90	to	110%,	>	110%),	according	to	patients	age.	This	parameter	was	 also	 correlated	 with	 selected	 nutritional	 status	 parameters	 (BMI	 z-score;	 plasma	 pre-albumin,	RBP,	creatinine,	essential	fatty	acids	and	vitamins	D,	E	and	A	levels),	HAQ	scores	(by	domain	and	total	score)	and	total	distance	walked	in	6-MWT.	Categories	of	nutritional	intake	in	percentage	of	EAR	(<	90%,	90	to	110%,	>	110%)	were	also	correlated	with	results	from	HAQ	(scores	by	domains	and	total).	
	
ETHICAL	APPROVAL	
This	study	was	submitted	to	the	ethical	committees	of	each	Centre,	according	to	the	established	rules.	In	one	of	the	centres	included	in	the	study	(CHSJ),	it	was	mandatory	that	the	investigator	didn’t	have	a	personal	contact	with	patients,	so	there	was	a	need	to	present	the	protocol	to	the	nutritionist	in	that	team,	and	monitor	its	application.	After	invitation,	each	patient	and/or	his	legal	guardian	(parent	or	other)	met	the	investigator	in	order	to	clarify	all	the	protocol	procedures	and	every	possible	doubt.	Parents	or	other	legal	guardians	gave	a	written	informed	consent;	the	patient	himself,	when	aged	more	than	16-year-old	and	with	no	mental	 impairment,	 gave	 the	 consent.	An	appropriate	 consent	 form	with	a	comprehensive	description	of	the	protocol,	signed	by	the	investigator,	was	distributed.		This	investigation	was	also	approved	by	the	Comissão	Nacional	de	Proteção	de	Dados.	
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I. CHARACTERIZATION	OF	THE	SAMPLE		
MPS	 patients	 included	 in	 this	 study	 (31	 individuals)	 were	 recruited	 from	 four	 national	treatment	 centres:	 sixteen	 (51.6%)	 were	 followed	 in	 Centro	 Hospitalar	 Universitário	 de	Coimbra,	E.P.E.,	eight	(25.8%)	in	Centro	Hospitalar	de	São	João	-	Porto,	four	(12.9%)	in	Centro	Hospitalar	do	Porto,	E.P.E.	and	three	(9.7%)	in	Centro	Hospitalar	de	Lisboa	Norte.		The	31	patients,	17	males	(54.8%),	were	aged	between	1.7	and	32.7	years	(mean	15.0;	SD=7.5;	median	14.4)	(Figure	1;	Table	S2).		
	
Figure	1.	Characterization	of	the	sample:	distribution	per	gender	and	age	group	(n=31).		The	sample	included	five	MPS	I	(16.1%),	four	MPS	II	(12.9%),	nine	MPS	III	(29.0%;	six	subtype	B	and	three	subtype	C),	three	MPS	IV	(9.7%),	nine	MPS	VI	(29.0%)	and	one	MPS	VII	(3.2%)	patients	(Figure	2	and	Figure	3).			
	
Figure	2.	Characterization	of	the	sample:	number	of	patients	per	type	of	MPS	(n=31).	
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Figure	3.	Characterization	of	the	sample:	type	of	MPS	by	age	group	(n=31).		Patients	were	diagnosed	with	MPS	at	a	mean	age	of	3.2	(SD=3.0;	median	2.3)	years,	ranging	from	1	month	(0.1	years)	to	12.3	years	(Table	S3).		Diagnosis	occurred	earlier	 in	 the	MPS	VII	patient	 (0.1	years)	and	 in	MPS	 I	 (2.2	±	2.3	years;	median	 2.0)	 and	MPS	 VI	 (2.3	 ±	 1.3	 years;	median	 2.0)	 patient	 groups.	 MPS	 IV	 and	MPS	 II	patients	were	diagnosed	later,	at	5.5	(SD=5.3;	median	5.0)	and	5.7	(SD=5.7;	median	2.6)	years,	respectively	(Table	S3).	MPS	types	(except	MPS	VII)	were	compared	according	to	mean	age	at	diagnosis	(Figure	4).	No	statistical	significant	difference	was	found.			
	
Figure	4.	Characterization	of	the	sample:	age	at	diagnosis	per	type	of	MPS	(n=31).		
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Twenty-six	 patients	 (83.9%)	 in	 this	 study	 were	 under	 chronic	 pharmacological	 treatment	(Table	S1).	Anti-epileptic	drugs	were	regularly	used	by	ten.		Nineteen	patients	were	under	enzymatic	replacement	therapy	(Figure	5	and	Table	S1).			
	
Figure	5.	Characterization	of	the	sample:	enzymatic	replacement	therapy	(ERT),	per	type	of	MPS	(n=31).	
	Ten	 patients	 were	 taking	 nutritional	 supplements.	 Six	 were	 submitted	 to	 vitamin	 D	supplements,	isolated	(MPS	I2,	MPS	I5,	MPS	II1,	MPS	VI4	and	MPS	VI6)	or	associated	with	calcium	(MPS	VI7).	This	patient	was	also	taking	an	iron	supplement.		Folic	acid	was	used	by	two	patients	(MPS	 I2	and	MPS	 I4).	Three	patients	 (MPS	 I5,	MPS	 III1	and	MPS	 III7)	mentioned	 the	use	of	a	“complete	nutritional	supplement”	(Table	S1).		
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II. 	FOOD	AND	NUTRITIONAL	INTAKE	
A. RECENT	NUTRITIONAL	INTAKE		
Recent	nutritional	intake	data,	based	upon	the	information	collected	with	the	24-hour	recall	questionnaire,	was	applied	in	all	cases.	A	mean	caloric	intake	of	65.4	Kcal/Kg/day	was	found	(SD=29.5;	median	52.5),	with	a	minimum	of	20.2	Kcal/Kg/day	in	patient	MPS	VI5	and	a	maximum	of	133.5	Kcal/Kg/day	in	patient	MPS	I5.	 Macronutrients	 distribution	 is	 present	 in	 Figure	 6.	 Additional	 data,	 concerning	 energy,	macronutrients	and	micronutrients	is	displayed	in	Table	S4	and	Table	S5	(Supplements).		
	
Figure	6.	Recent	nutritional	intake:	mean	distribution	(%	of	total	caloric	intake)	of	macronutrients	(n=31).		 	
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B. FOOD	HABITS	AND	USUAL	NUTRITIONAL	INTAKE		
Twenty-five	individuals	(81%	of	the	sample)	answered	the	food-frequency	questionnaire	on	the	day	nutritional	assessment	was	done.	Data	is	summarized	in	Table	2	and	presented	in	detail	in	supplements	section	(Table	S6	to	Table	S18).			
Frequency	of	
intake	 Food	/	group	of	food	 Absolute	frequency	(relative	frequency)	
Daily	 Reduced	fat	milk	Yogurt	Vegetables	soup	
15	(60.0%)	12	(48.0%)	11	(44.0%)	
Weekly	
Chicken	Turkey,	rabbit		Cow,	pork	and	goatling	meats		Ham	and	sausage	Sausages	Fatty	fish	such	as	sardines,	mackerel,	horse	mackerel,	salmon,	etc.		Lean	fish	such	as	hake,	pouting,	gold,	etc.		Cod	Olive	oil	Butter	White	bread	or	toast	Rice	Pasta	like	spaghetti,	macaroni,	etc.		Boiled	potatoes,	baked,	stewed	and	pureed		Maria	type	crackers,	water	and	salt	or	full		Carrots	Apple	and	pear	Ice	tea	
18	(72.0%)	14	(56.0%)	17	(68.0%)	12	(48.0%)	14	(56.0%)	14	(56.0%)		17	(68.0%)	10	(40.0%)	12	(48.0%)	11	(44.0%)	11	(44.0%)	20	(80.0%)	20	(80.0%)	22	(88.0%)	13	(52.0%)	13	(52.0%)	9	(36.0%)	10	(40.0%)	
Monthly	 Eggs	Other	soft	drinks,	fruit	juices	or	nectars	packed		Hamburger	
10	(40.0%)	7	(28.0%)	11	(44.0%)	
Never	(or	less	
than	once	a	
month)	 Other	food	 10	(40.0%)	-	25	(100.0%)	
Table	2.	Food	habits	(mode):	absolute	and	relative	frequencies	(n=25).		Data	concerning	energy	and	macronutrients,	obtained	through	food-frequency	questionnaire	results,	is	shown	in	Figure	7	and	in	Table	S19	in	supplements	section.			
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Figure	7.	Usual	nutritional	intake:	mean	distribution	(%	of	total	caloric	intake)	of	macronutrients	(n=25).		A	mean	caloric	intake	of	77.5	Kcal/Kg/day	was	found	(SD=38.7;	median	72.6),	ranging	from	395.2	Kcal	in	a	12-year-old	MPS	III	boy	(MPS	III6)	to	3910.1	Kcal	in	an	11-	years-old	MPS	II	boy	(MPS	II4)	(Table	S19).	Fifty	 six	 percent	 of	 the	 subjects	 showed	 a	 lower	 caloric	 intake	 than	 recommendations.	 	 In	28.0%	the	intake	was	higher	than	recommended.	In	4	patients	(MPS	I1,	MPS	I3,	MPS	II2,	MPS	VI2),	caloric	intake	was	considered	adequate	(Figure	8;	Table	S20	to	Table	S22).		Data	related	to	energy	intake	adequacy	per	type	of	MPS	is	displayed	in	Figure	9	and		Table	S23.	
Protein	intake	was	considered	adequate	in	44.0%	of	the	subjects,	with	a	mean	ingestion	of	97.8	grams	per	day	(Table	S25).	A	minimum	intake	of	23.5g	and	a	maximum	of	160.6g	were	found	in	the	same	patients	in	whom	caloric	intake	was	the	lowest	and	the	highest,	respectively	MPS	III6	and	MPS	II4	(Table	S19).		Eight	patients	showed	inadequate	 intake	of	this	nutrient;	 in	the	total	sample,	adequacy	was	102.6%.	Inadequate	intake	was	more	prevalent	in	patients	with	5	to	11	years	of	age	(55.6%)	and	in	MPS	VI	patients	(55.6%)	(Figure	8;	Table	S26	to	Table	S29).		Concerning		carbohydrates,	64.0%	of	the	subjects	had	an	intake	lower	than	recommendations	(Table	S25).	The	lowest	was	44.6g	and	the	highest	was	626.6g,	in	the	same	patients	mentioned	above	(MPS	III6	and	MPS	II4,	respectively)	(Table	S19).		Mean	adequacy	was	87.9%	in	the	total	sample	(Table	S25).	Inadequate	intake	of	carbohydrates	was	of	77.8%	among	patients	aged	between	12	and	18	years,	and	100.0%	in	adults	(Table	S26	and	Table	S27).	All	MPS	I	patients	and	66.7%	of	MPS	VI	showed	an	inadequate	carbohydrate	intake	(Figure	8;	Table	S28	and	Table	S29).	
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Fiber	intake	ranged	from	5.1	to	76.2	grams	per	day	(mean	20.6;	SD15.8)	(Table	S19).	Nineteen	patients	(76.0%)	showed	lower	intake	than	recommendations.		The	mean	adequacy	of	fat	intake	was	110.6	%	(SD	20.0)	in	the	total	sample	tested	(25	patients)	(Table	S25	to	Table	S29).	It	was	adequate	in	52.0%	(mean	69.9g;	SD	24.5g)	(Table	S19).	The	lowest	intake	(11.3g)	was	found	in	MPS	III6,	the	boy	mentioned	above,	which	was	considered	adequate	in	percentage	of	the	caloric	intake.	The	highest	(364.4g)	was	observed	in	a	6-year-old	 MPS	 I	 girl	 (MPS	 I2).	 	 Regarding	 omega	 3	 fatty	 acids,	 18	 patients	 (63.8%)	 showed	 an	inadequate	 intake,	 reaching	 the	 lowest	 mean	 of	 adequacy	 in	 MPS	 VI	 patients	 group.	 Two	patients	showed	adequate	intake	of	omega	6	fatty	acids	(MPS	VI7	and	MPS	VI9),	whereas	23	had	an	intake	lower	than	EAR	(Figure	8	and	Table	S25).			
	
Figure	8.	Usual	nutritional	intake	in	MPS	patients	(energy	and	macronutrients):	number	of	patients	consuming	lower,	
adequate	and	higher	than	recommendations	(n=25).		In	 Figure	 9,	 presented	 next,	 adequacy	 of	 energy	 and	 macronutrients	 intake	 is	 displayed	according	 to	 type	 of	 MPS.	 No	 statistical	 significant	 differences	 were	 found	 in	 energy	 and	macronutrients	intake	between	different	groups	of	MPS	types.	More	detailed	data	is	showed	in	Table	S24	and	Table	S28.		Adequacy	of	energy	and	macronutrients	intake	was	similar	in	MPS	patients	with	major	central	nervous	system	involvement	(MPS	I,	II,	III	and	VII)	and	major	skeleton	involvement	(MPS	IV	and	VI).					
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Figure	9.	Usual	nutritional	intake	in	MPS	patients	(energy,	macronutrients	and	essential	fatty	acids):	number	of	
patients	consuming	lower,	adequate	and	higher	than	recommendations,	per	type	of	MPS	(n=25).			Energy	 and	macronutrients	 intake	 adequacy	 in	 percentage	 of	 EAR	 (<	 90%,	 90	 to	 110%,	 >	110%)	did	not	vary	with	age.		Adequacy	of	energy	and	macronutrients	intake	was	similar	in	patients	under	ERT	and	others.			
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Vitamins		
Vitamins	 intake	 was	 higher	 than	 recommendations	 in	 the	 majority	 of	 patients	 for	 most	vitamins,	 namely,	 vitamin	A,	 vitamin	B1,	 vitamin	B3,	 vitamin	B6,	 vitamin	B12	 and	 vitamin	 C,	reaching	adequacies	between	227.1%	and	825.2%	(Figure	10;	Table	S30	to	Table	S35).		Twenty	patients	(80.0%)	showed	an	insufficient	intake	of	biotin.	Folate	and	pantothenic	acid	intakes	were	insufficient	in	nine	patients,	of	whom,	six	had	MPS	VI.		One	18-year-old	MPS	II	boy	(MPS	II3)	showed	an	adequate	intake	of	vitamin	D;	the	remaining	24	patients	showed	an	insufficient	intake.		Vitamin	 K	 intake	 was	 considered	 adequate	 in	 the	 MPS	 III6	 boy.	 The	 remainder	 presented	insufficient	intake,	which	contributed	to	a	mean	of	adequacy	of	26.3%.			
	
Figure	10.	Usual	nutritional	intake	in	MPS	patients	(vitamins):	number	of	patients	consuming	lower,	adequate	and	
higher	than	recommendations	(n=25).			
Minerals	and	oligoelements	
Manganesium	intake	was	insufficient	in	all	25	patients	(mean	of	adequacy	0.2%).	Seventeen	patients	 showed	 an	 insufficient	 potassium	 intake.	 For	 the	 remaining	 minerals	 and	oligoelements,	mean	adequacy	was	found	to	be	between	114.6%	for	calcium	(lowest	75.1%	in	12	to	18	years)	and	335.4%	for	copper	intake.	Sodium	intake	was	lower	than	recommendations	in	two	patients,	one	9-year-old	MPS	III	girl	(MPS	III4)	and	one	12-year-old	MPS	III	boy	(MPS	III6).	More	data	is	displayed	in	Figure	11	and	in	supplements	(Table	S36	to	Table	S41).			
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Figure	11.	Usual	nutritional	intake	in	MPS	patients	(minerals	and	oligoelements):	number	of	patients	consuming	
lower,	adequate	and	higher	than	recommendations	(n=25).		
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III. ANTHROPOMETRICS	AND	BODY	COMPOSITION			Patients’	weight	ranged	from	12.3	to	56.8	Kg	(mean	30.2;	SD	10.3;	median	29.5).	Weight	z-score	extended	from	-1.7	to	2.6	(Table	S42).	Weight	z-score	was	the	lowest	in	MPS	VI	(-1.0)	and	the	highest	in	MPS	III	(1.5)	patients	group	(Table	S42	and	Figure	12).	Mean	weight	z-scores	in	the	different	age	groups	were:	0.0	(SD=0.9)	under	4	years	of	age	and	-0.1	(SD=1.8)	from	5	to	11	years.	A	minimum	weight	z-score	of	-2.8	was	found	in	a	6-year-old	female	patient	with	MPS	 I	 (MPS	 I2).	A	5-year-old	boy	with	MPS	 III	 (MPS	 III8)	presented	 the	maximum	weight	z-score	of	1.8	(Table	S43).		
	
Figure	12.	Anthropometrics:	weight,	in	z-score,	according	to	MPS	type	(n=9:	three	MPS	I;	one	MPS	II;	two	MPS	III;	two	
MPS	VI;	one	MPS	VII).		Patients’	height	ranged	from	83.3	to	170.0	cm	(mean	124.2	±	20.5	cm)	and	z-score	from	-10.1	to	1.5	(Table	S44).	Minimum	mean	height	z-score	was	found	in	MPS	IV	patients	group	(-7.3)	(Figure	13).	At	the	youngest	group,	mean	z-score	was	-0.3	(SD=0.0),	from	5	to	11	years,	-1.7	(SD=2.7),	from	12	to	18	years,	-5.1	(SD=2.0),	and	in	the	oldest	group,	-5.6	(SD=3.9)	(Table	S45).	A	strong	negative	correlation	was	found	between	height	z-score	and	age	(rho=-0.555;	p=0.001)	(Figure	14).	The	lowest	height	z-score	(-10.1)	was	detected	in	a	32-year-old	MPS	IV	woman	(MPS	IV3).			
-0,9 
1,2 1,5
-1 
-0,3 
-1,5 
-1 
-0,5 
00,5
11,5
2 MPS	I MPS	II MPS	III MPS	IV MPS	VI MPS	VII
Weight
	(z-sco
re)
MPS	I MPS	II MPS	III MPS	IV MPS	VI MPS	VII
Nutritional	status	of	patients	with	mucopolysaccharidosis		
	 |	29	
	
	
Figure	13.	Anthropometrics:	height,	in	z-score,	according	to	type	of	MPS	(n=30:	five	MPS	I;	four	MPS	II;	nine	MPS	III;	
three	MPS	IV;	eight	MPS	VI;	one	MPS	VII).		
	
Figure	14.	Anthropometrics:	height,	in	z-score,	according	to	age	(n=30:	five	MPS	I;	four	MPS	II;	nine	MPS	III;	three	
MPS	IV;	eight	MPS	VI;	one	MPS	VII).	A	trend	line	is	displayed	in	blue.		Concerning	BMI,	the	sample	showed	a	mean	value	of	19.3	Kg/m2	(SD=3.9),	ranging	from	13.0	to	28.8	Kg/m2.	Mean	BMI	z-score	was	0.0	(SD=1.6),	varying	from	-4.6	in	a	25-year-old	MPS	III	man	(MPS	III7)	to	3.4	in	the	9-year-old	boy	with	MPS	VII	(MPS	VII1)	(Table	S46	and	Table	S47).	A	moderate	 negative	 correlation	 was	 detected	 between	 age	 and	 BMI	 z-score	 (rho=-0.353)	(Figure	15). The	lowest	mean	BMI	z-score	was	found	in	MPS	I	group	(-1.1)	and	the	highest,	in	the	patient	with	MPS	VII	(3.4)	(Figure	16	and	Table	S46).	BMI	z-score	was	similar	between	groups	with	low,	adequate	or	higher	intakes	of	energy	and	macronutrients.	
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Figure	15.	Anthropometrics:	BMI,	in	z-score,	according	to	age	(n=30:	five	MPS	I;	four	MPS	II;	nine	MPS	III;	three	MPS	
IV;	eight	MPS	VI;	one	MPS	VII).	A	trend	line	is	displayed	in	blue.		
	
Figure	16.	Anthropometrics:	BMI,	in	z-score,	per	MPS	type	(n=30:	five	MPS	I;	four	MPS	II;	nine	MPS	III;	three	MPS	IV;	
eight	MPS	VI;	one	MPS	VII).		The	great	majority	of	patients	(73.3%)	showed	normal	growth	according	with	World	Health	Organization	BMI	z-score	tables.	In	two	individuals	(MPS	I5	and	MPS	III7),	a	status	of	severe	thinness	was	found	(6.7%).	Six	patients	(MPS	II2,	MPS	III3,	MPS	III4,	MPS	III8,	MPS	VI5	and	MPS	VII1)	 presented	 overweight,	 one	 being	 obese	 (MPS	 VII1)	 (Figure	 17	 and	 Table	 3).	 When	comparing	with	disease	specific	BMI	growth	curves	(available	for	MPS	II,	MPS	III	and	MPS	IV),	only	patient	MPS	III3	presents	overweight.		
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Figure	17.	Distribution	of	individuals	(number	of	patients),	according	to	BMI	and	WHO	z-score	tables	(n=30:	five	MPS	
I;	four	MPS	II;	nine	MPS	III;	three	MPS	IV;	eight	MPS	VI;	one	MPS	VII).		
Group	of	
disease	
Severe	
thinness	
Thinness	 Normal	 Overweight	 Obesity	
MPS	I	 1	 0	 4	 0	 0	MPS	II	 0	 0	 3	 1	 0	MPS	III	 1	 0	 5	 3	 0	MPS	IV	 0	 0	 3	 0	 0	MPS	VI	 0	 0	 7	 1	 0	MPS	VII	 0	 0	 0	 0	 1	
Total	 2	(6.7%)	 0	(0.0%)	 22	(73.3%)	 5	(16.7%)	 1	(3.3%)	
Table	3.	Anthropometrics:	classification	of	nutritional	status	according	to	BMI	(n=30:	five	MPS	I;	four	MPS	II;	nine	
MPS	III;	three	MPS	IV;	eight	MPS	VI;	one	MPS	VII).		
Body	composition	was	evaluated	by	bioimpedance	in	21	patients:	one	MPS	I,	four	MPS	II(1-4),	seven	MPS	III(1-3;	5;	7-9),	three	MPS	IV(1-3)	and	six	MPS	VI(2;	4-8).	Body	fat,	body	lean	mass	and	total	body	water	were	calculated	in	18	patients.	Minimum	mean	body	fat	mass	was	displayed	in	MPS	VI	group	of	patients	(16.6%).	Mean	values	of	total	body	water	varied	between	62.4	and	65.3%	(Figure	18).	Additional	data	is	presented	in	Table	S48.		
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Figure	18.	Body	composition:	mean	values	of	body	fat	mass,	body	lean	mass	and	total	body	water,	in	MPS	types	II	
(four	patients),	III	(six),	IV	(three)	and	VI	(five)	(n=18).		
Phase-angle	results	(n=21)	varied	from	a	minimum	of	3.0°	in	MPS	III2	patient,	to	a	maximum	of	6.2°	in	MPS	VI2,	presenting	a	mean	value	of	4.6°	(SD=0.8)	(Figure	19	and	Table	S49).					A	correlation	between	age	and	phase	angle	was	found	to	be	positive	and	moderate	(rho=0.353).	No	statistical	significant	difference	in	phase	angle	between	groups	consuming	lower,	adequate	or	higher	amounts	of	energy	and	macronutrients	than	recommendations	was	found.			
	
Figure	19.	Phase	angle:	mean	values	(°),	in	MPS	types	I	(one	patient),	II	(four),	III	(seven),	IV	(three)	and	VI	(six)	
(n=21).		 	
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IV. RESISTANCE	TEST			Sixteen	patients	(51.6%)	performed	the	6-minute	walking	test.	Twelve	were	unable	to	walk	and	in	three	cases,	the	test	was	not	feasible	due	to	structural	conditions	of	the	hospital	building.		The	patients	who	completed	the	test	walked	a	mean	distance	of	304.6	meters	(SD=147.1	m;	26.9	 to	660.0	meters)	 (Figure	20	and	Table	S50).	MPS	 type	 II	patients	showed	significantly	higher	results	in	this	test	(U=0.0;	p=0.026)	(Figure	20).		No	statistical	differences	were	found	between	MPS	group	with	major	central	nervous	system	involvement	and	that	with	major	skeleton	involvement,	concerning	6-MWT	achievements.	No	correlation	was	found	between	age	and	6-MWT	results.		
	
Figure	20.	Total	distance	walked	(in	meters):	mean	values	for	each	type	of	MPS	(n=16).		 	
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V. LABORATORIAL	DATA	
Plasma	proteins	
Plasma	 total	 protein	 was	 analysed	 in	 27	 patients	 (Table	 S51	 and	 Figure	 21).	 Twenty-five	(92.6%)	presented	normal	 values.	Two	adults,	MPS	 III1	 and	MPS	 III7,	 showed	 lower	 results	(both	64.0	g/L).		All	 patients	were	 submitted	 to	 plasma	albumin	 analysis.	 Twenty-seven	 had	normal	 values	(87.1%),	whereas	two	individuals,	MPS	I5	and	MPS	III2,	showed	hypoalbuminemia	(34.3	and	36.6g/L)	and	in	other	two	values	were	higher	than	reference	(51.0	and	52.0	g/L).	Plasma	ferritin	was	normal	in	all	patients	(n=30)	submitted	to	analysis.	Normal	values	of	pre-albumin	were	detected	in	11	of	27	patients	(40.7%).	Levels	were	low	in	the	remaining	16	patients.	One	of	the	patients	with	low	pre-albumin	(172	mg/L)	was	MPS	I5,	who	was	 taking	a	 “complete	nutritional	 supplement”.	Plasma	pre-albumin	was	 significantly	higher	 in	MPS	 III	 patients	 (U=21.0;	 p=0.012)	 (Figure	 22).	 Plasma	 pre-albumin	 levels	 were	lower	 (U=35.0;	 p=0.028)	 in	 patients	 submitted	 to	 ERT,	 when	 compared	 to	 patients	 not	performing	ERT	(Figure	23).	Eighteen	of	24	individuals	showed	low	levels	of	RBP,	from	0.0	to	38.4	mg/L.	The	lowest	value	was	detected	in	the	only	MPS	VII	patient;	levels	were	above	10.0	mg/L	in	the	other	17	patients.	The	patient	mentioned	above	(MPS	I5),	showed	low	plasma	RBP	(32.0	mg/L).	MPS	III	patients	showed	 significantly	higher	RBP	 levels	 than	other	MPS	patients	 (U=15.0;	 p=0.018).	MPS	VI	patients	showed	lower	results	than	other	patients	(U=27.5;	p=0.024)	(Figure	24).	
Transferrin	was	normal	in	21	of	23	individuals.	One	14-year-old	boy	(MPS	VI3)	and	one	adult	man	with	MPS	VI	(MPS	VI6)	presented	low	and	elevated	values,	respectively.	
C-reactive	protein	was	normal	in	30	of	31	patients	(96.8%).	One	man	aged	26	years	(MPS	III9)	presented	a	value	above	the	reference	range	(11.1	nmol/L).		No	statistical	correlations	(weak	negative)	were	found	between	age	and	plasma	pre-albumin,	retinol	binding	protein,	and	creatinine	levels.		No	statistical	significant	difference	was	found	between	groups	consuming	lower,	adequate	or	higher	 amounts	 of	 energy	 and	 macronutrients	 than	 recommendations	 in	 what	 concerns	plasma	pre-albumin,	retinol	binding	protein	and	creatinine.		
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Figure	21.	Plasma	proteins	-	classification	according	to	reference	values	(RBP=retinol	binding	protein;	CrP=c-reactive	
protein;	labels	correspond	to	the	number	of	patients).		
	
Figure	22.	Plasma	proteins	–	pre-albumin	levels	(mg/L),	according	to	MPS	type	(n=	27:	five	MPS	I;	four	MPS	II;	six	
MPS	III;	two	MPS	IV;	nine	MPS	VI;	one	MPS	VII).		
	
Figure	23.	Plasma	pre-albumin	levels	of	ERT	patients	(n=19),	when	compared	to	the	group	not	performing	this	
treatment	(no-ERT,	n=8).	
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Figure	24.	Plasma	proteins	–	RBP	levels	(mg/L),	according	to	MPS	type	(n=	24:	five	MPS	I;	three	MPS	II;	five	MPS	III;	
two	MPS	IV;	eight	MPS	VI;	one	MPS	VII).		
Lipids			
Lipid	profile	analysis	was	performed	in	all	(31)	patients	(Table	S52	and	Figure	25).			
Total	cholesterol	was	normal	in	30	individuals	(96.8%).	The	remaining	patient,	a	14-year-old	boy	(MPS	VI3)	showed	a	value	of	208.0	mg/dL.	
LDL-cholesterol	was	normal	in	28	(90.3%).	In	3	patients,	it	was	above	reference	range	(9.7%),	with	 a	maximum	 of	 151.0	mg/dL	 detected	 in	MPS	 VI3,	 the	 boy	with	 high	 total	 cholesterol	indicated	above.		
HDL-cholesterol	was	normal	 in	14	 (45.2%)	and	 low	 in	15	 individuals	 (48.4%),	 reaching	a	minimum	of	10.0	mg/dL	in	a	9-year-old	girl	(MPS	III2).	In	the	remaining	two	patients	(6.5%),	MPS	 I4	 and	MPS	 II1,	 high	 values	 of	 HDL-cholesterol	 were	 disclosed	 (76.0	 and	 66.0	mg/dL,	respectively).			Normal	 plasma	 triglycerides	 were	 detected	 in	 29	 individuals	 (93.5%).	 MPS	 III2	 showed	hypertriglyceridemia	(159.0	mg/dL)	and	MPS	II1	presented	a	low	value	(36.0mg/dL).	These	patients	had	low	and	high	HDL-cholesterol,	respectively.		
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Figure	25.	Lipid	profile	-	classification	according	to	reference	values	(n=31)	
																					(LDLc=LDL	cholesterol;	HDLc=HDL	cholesterol;	TG=triglycerides;	
	labels	correspond	to	the	number	of	patients).		
Essential	fatty	acids	
Plasma	essential	 fatty	acids	 levels	were	evaluated	in	12	patients	(Table	S53	and	Figure	26).	None	was	taking	a	specific	essential	fatty	acids	supplement.	
Araquidonic	acid	level	was	normal	in	8	individuals	(66.7%).	Four	presented	high	values:	from	270.0	μg/mL	in	MPS	IV1	to	369.0	μg/mL	in	MPS	VI3	patients.	Plasma	araquidonic	acid	levels	were	significantly	higher	in	MPS	VI	patients	(U=2.0;	p=0.036)	(Figure	27).			
Docosahexaenoic	acid	was	normal	in	10	individuals	(83.3%)	and	low	in	two	(16.7%),	MPS	III2	and	MPS	VI1	with,	respectively,	15.3	and	21.5	μg/mL.				All	patients	showed	normal	values	for	eicosapentaenoic	acid.		Correlations	 between	 age	 and	 plasma	 araquidonic	 (rho=0.308)	 and	 docosahexaenoic	(rho=0.336)	acids	were	positive	and	moderate.	Essential	fatty	acids	levels	did	not	show	any	statistical	significant	difference	between	groups	consuming	different	amounts	of	energy	and	macronutrients.	
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Figure	26.	Plasma	essential	fatty	acids	levels	in	12	MPS	patients	(three	MPS	I;	four	MPS	III;	two	MPS	IV;	three	MPS	VI)	
-	classification	according	to	reference	values	(labels	correspond	to	the	number	of	patients)	
	(AA=araquidonic	acid;	DHA=docosahexaenoic	acid;	EPA=eicosapentaenoic	acid).	
 	
	
Figure	27.	Plasma	essential	fatty	acids	in	12	patients	–	araquidonic	acid	(AA)	levels	(μg/mL)	per	type	of	MPS	(three	
MPS	I;	four	MPS	III;	two	MPS	IV;	three	MPS	VI).		
Vitamins	
Data	from	plasma	vitamins	levels,	analysed	in	most	patients,	is	displayed	in	Table	S54.	Results	of	vitamin	D	analysis	are	disclosed	in	the	phosphocalcium	metabolism	section.	
Folic	acid	plasma	levels,	evaluated	in	20	patients	(Figure	28),	were	normal	in	17	(85.0%).	Two	showed	high	values	(45.0	and	54.0	nmol/L)	and	one	(MPS	VI4)	displayed	values	 lower	than	local	references	(4.0	nmol/L).		The	patient	taking	folic	acid	supplement	was	not	submitted	to	this	analysis.	
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Vitamin	B12	 levels	were	 adequate	 in	 19	 of	 30	 patients	 (63.3%)	whereas	 the	 remaining	 11	individuals	presented	plasma	levels	higher	than	normal,	ranging	from	542.0	to	884.0	pmol/L	(maximum	in	patient	MPS	III2)	(Figure	28).	No	specific	supplementation	was	being	taken	by	any	of	the	participants;	two	patients	taking	complete	nutritional	supplements	(MPS	I5	and	MPS	III7)	presented	two	of	the	highest	levels.	
Vitamin	A	was	considered	adequate	in	17	of	23	patients	(73.9%)	(Figure	28).	Six	individuals	showed	low	levels.	None	of	these	were	taking	vitamin	A	supplementation.	A	minimum	of	0.4	µmol/L	was	found	in	a	26-year-old	woman	(MPS	VI4).	The	MPS	III	group	showed	significant	higher	 vitamin	 A	 levels	 than	 the	 remaining	 subjects	 (U=21.5;	 p=0.019),	 whereas	 MPS	 VI	patients	showed	lower	significant	results	than	others	(U=12.5;	p=0.001)	(Figure	29).	Vitamin	A	 levels	were	 lower	 in	 ERT	 patients	 group	 (p=0.02),	 than	 in	 patients	 not	 under	 enzymatic	therapy.	
Vitamin	E	was	normal	in	13	of	22	individuals	(59.1%),	whereas	6	presented	low	levels	(min.	13.9	µmol/L	 in	patient	MPS	 III7)	 (Figure	28).	These	 six	are	not	 the	 same	as	 those	with	 low	vitamin	A	 levels.	Three	patients	had	elevated	values,	 even	without	nutritional	 supplements	(max.	38.2	µmol/L	in	MPS	IV1	patient).	Vitamin	E	 levels	were	significantly	higher	 in	MPS	IV	patients	(U=7.0;	p=0.040)	and	significantly	lower	in	MPS	VI	patients	(U=19.0;	p=0.016)	(Figure	30).	A	moderate	negative	correlation	was	detected	between	age	and	vitamin	E	levels	(rho=-0.385)	(Figure	31).		Vitamin	A	and	vitamin	E	levels	were	similar	between	groups	with	low,	adequate	and	higher	intakes	of	energy	and	macronutrients	than	recommendations.		
	
	
Figure	28.	Plasma	vitamins*	-	classification	according	to	reference	values.	
(labels	correspond	to	the	number	of	patients)	
(*)	Vitamin	D	–	in	the	phosphocalcium	metabolism	section		
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Figure	29.	Plasma	vitamins	-	vitamin	A	levels	(µmol/L),	per	type	of	MPS	(n=23:	four	MPS	I;	one	MPS	II;	seven	MPS	III;	
three	MPS	IV;	eight	MPS	VI).			
	
Figure	30.	Plasma	vitamins	-	vitamin	E	levels	(µmol/L),	per	type	of	MPS	(n=22:	four	MPS	I;	one	MPS	II;	seven	MPS	III;	
three	MPS	IV;	seven	MPS	VI).		
	
Figure	31.	Plasma	vitamins	-	vitamin	E	(µmol/L),	according	to	age	(n=22:	four	MPS	I;	one	MPS	II;	seven	MPS	III;	three	
MPS	IV;	seven	MPS	VI).	A	trend	line	is	displayed	in	blue.	
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Minerals		
Data	 concerning	 plasma	 concentration	 of	 minerals	 in	 patients	 is	 depicted	 in	 Table	 S55.	Adequacy	of	levels	is	displayed	in	Figure	32.	Results	of	calcium	and	phosphorus	analysis	are	disclosed	in	the	phosphocalcium	metabolism	section.	Twenty-one	 in	 27	 patients	 (77.8%)	 showed	 normal	 plasma	 magnesium	 results.	 Four	individuals	 had	 hypomagnesemia:	 one	 of	 them	 (MPS	 III7)	 presented	 the	minimum	 of	 0.70	mmol/L.	Two	patients	had	high	values:	MPS	II4	(0.86	mmol/L)	and	MPS	I5	(1.03	mmol/L).	The	later	was	taking	a	complete	nutritional	supplement.	Eleven	individuals	were	analysed	for	plasma	selenium.	Normal	values	were	detected	in	eight	(72.7%).	The	other	showed	low	values,	with	a	minimum	of	0.10	mmol/L	in	MPS	III8,	a	5-year-old	boy.	Selenium	was	present	in	the	complete	nutritional	supplement	of	patient	MPS	I5,	who	displayed	normal	levels.		
Zinc	levels	were	normal	in	23	of	24	patients	(95.8%).	One	18-year-old	male	(MPS	II3)	showed	a	low	plasma	concentration	of	9.5	µmol/L.		Twenty-four	of	26	analysed	patients	showed	normal	results	for	potassium	in	plasma	(92.3%).	Hyperkaliaemia	was	found	in	two	individuals:	5.6	mmol/L	in	MPS	III4	and	6.6	mmol/L	in	MPS	II2.		Plasma	sodium	was	normal	 in	24	of	 28	patients	 (85.7%).	 Four	presented	hyponatremia:	 a	minimum	of	129.0	mmol/L	was	detected	in	MPS	III7	patient.			
	
Figure	32.	Plasma	minerals	-	classification	according	to	reference	values.	
(labels	correspond	to	the	number	of	patients)		
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Liver	function	
Alanine	aminotransferase	(ALT)	was	normal	in	24	of	31	patients	(77.4%)	(Figure	33).	Seven	(22.6%)	presented	high	values,	with	a	maximum	of	79.0	IU/L	found	in	MPS	III2	girl.	Twenty-three	of	29	(79.3%)	patients	presented	normal	aspartate	aminotransferase	(AST)	activity	(Figure	33).	Elevated	values	were	detected	in	six	patients	(20.7%),	with	a	maximum	of	95.2	IU/L,	in	the	patient	mentioned	above	(MPS	III2).			Normal	 activity	 of	 gamma-glutamyl	 transferase	 was	 found	 in	 18	 of	 28	 patients	 (64.3%)	(Figure	 33).	 In	 seven	 patients’	 results,	 lower	 values	 were	 found	 (25.0%).	 Three	 patients	(10.7%)	showed	results	higher	than	references;	the	highest	(952.1	IU/L)	was	detected	in	the	25-year-old	MPS	III7	patient.	Detailed	data	of	liver	function	is	shown	in	Table	S56.			
	
Figure	33.	Liver	function:	classification	according	to	reference	values		
(ALT=alanine	transaminase;	AST=aspartate	transaminase;	GGT=gamma-glutamyl	transferase)		
(labels	correspond	to	the	number	of	patients)	
		
Renal	function	
Plasma	urea	and	creatinine	were	analysed	in	all	(31)	patients	(Table	S57).		
Urea	was	normal	in	28	(90.3%)	and	low	in	one	patient	(1.1	mmol/L)	(Figure	34).	Two	MPS	I	patients	 (MPSI1	 and	MPS	 I2)	 showed	 plasma	 concentrations	 of	 urea	 higher	 than	 reference	values,	8.1	and	6.6	mmol/L,	respectively.	Twenty-four	 patients	 (77,4%)	 presented	 low	 levels	 of	 plasma	 creatinine	 (minimum	 12.0	µmol/L)	(Figure	34).	The	other	had	normal	values.		
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Results	of	calciuria	and	tubular	phosphorus	reabsorption	rate	analysis	are	disclosed	later	in	phosphocalcium	metabolism	section.		
	
Figure	34.	Renal	function:	classification	according	to	reference	values	(n=31).		
(labels	correspond	to	the	number	of	patients)			
Total	blood	count	
All	 individuals	 (31)	 were	 tested	 for	 complete	 haemoglobin,	 leucocytes	 and	 platelets.	Lymphocytes	were	assessed	in	27	(Table	S58).		
Haemoglobin	was	normal	 in	 twenty-six	 (83.9%),	whereas	 five	patients	 showed	 low	 levels,	ranging	from	113.0	to	126.0	g/L	(Figure	35).	The	lowest	value	was	found	in	a	9-year-old	female	patient	(MPS	III2).	A	woman	(MPS	VI7)	with	normal	levels	of	haemoglobin	was	taking	an	iron	supplement.			Twenty-seven	subjects	(87.1%)	presented	normal	leucocytes	count	(Figure	35).	Two	(MPSIII7	and	MPS	VI4)	displayed	leucopoenia	presenting	a	sum	of	2.9	and	3.6	x103/µL,	respectively.	In	other	two,	high	numbers	of	these	cells	were	detected,	specifically	11.8	x103/µL	in	MPS	VI9	and	11.5	x103/µL	in	the	youngest	patient,	MPS	I1.	Total	 count	of	 lymphocytes	was	normal	 in	21	of	27	patients	 (87.1%)	 (Figure	35).	MPS	 III8	showed	a	low	level	of	3.1	x103/µL.		Normal	platelets	 count	was	detected	 in	22	of	31	patients	 (71.0%).	Thrombocytopenia	was	found	 in	 7	 patients	 (22.6%),	 with	 a	 minimum	 of	 78.0	 x103/µL	 in	 the	 MPS	 III9	 patient	Thrombocytosis	was	present	in	two	patients	(510.0	in	MPS	IV3	and	562.0	x103/µL	in	MPS	I1).	(Figure	35).		
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Figure	35.	Total	blood	count:	classification	according	to	reference	values.	
(labels	correspond	to	the	number	of	patients)			
Phosphocalcium	metabolism		
Plasma	calcium	and	phosphorus	were	normal	in	25	(86.2%)	and	24	(82.8%)	of	29	patients,	respectively	 (Figure	36).	Two	 individuals,	MPS	 II2	and	MPS	 III9	 showed	 low	plasma	calcium	(2.07	 mmol/L	 and	 2.10	 mmol/L,	 respectively).	 Hypercalcemia	 was	 detected	 in	 two:	 2.53	mmol/L	 in	MPS	II1,	who	was	under	vitamin	D	supplementation	and	2.55	mmol/L	 in	MPS	I4.	Hyperphosphoremia	was	found	in	five	patients,	with	a	maximum	of	1.68	mmol/L	in	MPS	II3	(Figure	36).	None	were	taking	nutritional	supplements.	
Vitamin	D	(25-hydroxy-cholecalciferol)	plasma	levels,	evaluated	in	all	(31)	patients,	ranged	from	10.0	to	86.6	nmol/L.	Non-adequate	values	were	detected	in	27	individuals	(87.1%),	15	of	whom	presented	a	status	of	vitamin	deficiency	(48.4%	of	the	total)	(Figure	36	and	Figure	37).	Four	patients	presented	normal	vitamin	D	status:		the	youngest	included	(a	two-year-old,	MPS	I1),	two	other	who	were	taking	vitamin	D	supplements	(MPS	VI6	and	MPS	I5)	and	the	one	under	a	homeopathic	supplement	of	unknown	composition	(MPS	IV3).	Plasma	vitamin	D	levels	were	lower	 in	 the	 group	 of	 patients	 with	 protein	 adequate	 intake	 [H(2)=6.806;	 p=0.033)],	 as	compared	to	the	groups	consuming	lower	or	higher	amounts	of	this	macronutrient.	
Alkaline	 phosphatase	 activity	 was	 normal	 in	 21	 of	 27	 cases	 (77.8%)	 (Figure	 36).	Hypophosphatasemia	 (minimum	 of	 1.6	 µkat/L	 in	 MPS	 IV2),	 and	 hyperphosphatasemia	(maximum	of	2.5	µkat/L	in	MPS	III9)	were	found	in	three	patients	each.		Nineteen	of	the	23	(83.0%)	individuals	submitted	to	parathormone	analysis	showed	normal	values	(Figure	36).	Four	presented	high	parathormone	levels,	specifically:	MPSII1	(a	boy	with	vitamin	D	deficiency),	MPS	VI4	 (a	woman	with	 insufficient	 levels	of	vitamin	D)	 (both	under	
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supplementation),	MPS	I4	(a	3-year-old	boy	with	vitamin	D	insufficiency)	and	MPS	I3	(a	girl	with	vitamin	D	deficiency).	The	first	two	were	taking	supplements.		
Urinary	calcium	/	creatinine	was	normal	in	all	patients	analysed	(18),	except	for	MPS	I5,	who	was	taking	a	complete	nutritional	supplement	and	showed	a	high	ratio	(0.89)	(Figure	36).		
Tubular	 reabsorption	 of	 phosphate	 was	 normal	 in	 all	 17	 patients	 investigated	 for	 that	parameter	(Figure	36).		Data	concerning	phosphocalcium	metabolism	indicators	is	presented	in	Table	S59.		
	
Figure	36.	Phosphocalcium	metabolism	biochemical	analysis:	classification	according	to	reference	values	
(p=plasmatic;	25	(OH)	D	=	plasma	25-hydroxy-cholecalciferol;	AP=alkaline	phosphatase;	PTH=parathormone;	Ca	/	
creat	u=	urinary	calcium	/	creatinine	ratio;	TRP=tubular	reabsorption	of	phosphate)	
(labels	correspond	to	the	number	of	patients)		
	
Figure	37.	Phosphocalcium	metabolism	analytical	indicators:	plasma	25-hydroxy-cholecalciferol	(nmol/L),	according	
to	age	(n=31).	A	trend	line	is	displayed	in	blue.		
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No	 statistical	 differences	 were	 found	 concerning	 nutritional	 status	 parameters	 analysed	between	 the	 patients	 group	with	major	 central	 nervous	 system	 involvement	 and	 that	with	major	skeleton	involvement	nor	between	the	groups	under	ERT	or	not.					 	
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VI. QUALITY	OF	HEALTH	
All	patients	or	their	guardians	(31)	answered	the	quality	of	health	questionnaire	(HAQ).	Eight	patients	answered	by	themselves;	the	remaining	questionnaires	were	answered	by	mothers	(n=18),	fathers	(n=2)	or	other	caregivers	(n=3).			
A. DIFFICULTIES	ASSESSMENT		
Eating	and	drinking	
The	results	of	the	difficulties	in	eating	and	drinking	are	summarized	in	Table	S60.		Globally,	 the	 activity	 that	 was	 associated	 with	 greater	 difficulty	 was	 “Open	 a	 jar	 or	 food	container	by	twisting	lid”	(M=8.7;	Mdn=11)	and	the	easiest	was	“Eat	using	fingers	to	pick	up	food	item”	(M=3.2;	Mdn=0).	The	activities	“Use	a	knife	to	butter	bread	or	cut	soft	foods”	and	“Pour	liquid	from	carton	or	jug”	were	frequently	associated	with	moderately	difficulty.		MPS	type	III	patients	had	higher	scores	in	“eating	and	drinking”	when	compared	to	the	other	MPS	patients	group	(U=47.5;	p=0.023)	(Figure	38).		A	moderate	positive	correlation	was	detected	between	age	and	 “eating	and	drinking”	 score	(rho=0.334).			
	
Figure	38.	Difficulties	assessment	–	“eating	and	drinking”	domain,	per	type	of	MPS	(n=31).		
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Dressing	
Answers	concerning	dressing-related	activities	are	summarized	in	Table	S61.	“Tie	shoelaces”	was	 the	most	difficulty-reported	activity.	 	 “Put	on	a	 front-opening	shirt,	not	including	fasteners”	was	the	easiest	(mean	of	difficulty:	7.3	(SD=4.8);	median:11	points).		MPS	type	III	patients	had	higher	scores	in	the	“dressing”	domain,	comparing	to	the	remaining	patients	group	(U=48.0;	p=0.040)	(Figure	39).			
	
Figure	39.	Difficulties	assessment	–	“dressing”	domain,	per	type	of	MPS	(n=31).		
Bathing	
Results	on	bathing-related	activities	are	depicted	in	Table	S62.		The	activity	presenting	the	highest	difficulty	among	patients	was	“Cut	fingernails	with	clippers”	(M=9.6;	SD=3.3;	Mdn=11);	other	activities	related	to	“Wash	and	dry	upper	body	thoroughly	(neck,	arms,	chest,	upper	back)”,	“Wash	and	dry	lower	body	thoroughly	(abdomen,	lower	back,	legs,	 feet)”	 and	 “Brush	or	 comb	hair	 thoroughly	 (including	hair	on	 top	of	head	and	back	of	neck)”	presented	high	difficulty,	as	well	(Mdn=	11).	“Turn	 tap	on	and	off”	was	 the	easiest	activity	 to	 these	 individuals	 (M=5.4;	SD=5.3;	Mdn=5),	followed	by	“Brush	teeth,	even	if	not	thoroughly”	(M=5.6;	SD=5.3;	Mdn=4).				
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Toileting	
Answers	concerning	toileting-related	activities	are	described	in	Table	S63.	“Get	on	and	off	toilet	without	assistance”	was	the	most	accessible	activity	to	individuals	(M=4.9;	SD=5.2;	 Mdn=1)	 whereas	 the	 hardest	 was	 “Wipe	 self	 thoroughly	 after	 bowel	 movements”	(M=7.2;	SD=7.8;	Mdn=11).		Still,	the	activities	“Manage	clothes	before	and	after	toileting”	and	“Manage	toilet	seat,	get	toilet	paper	 and	 flush	 toilet”	 presented	median	 of	 10,	 demonstrating	 also	 a	 high	 difficulty	when	performing	these.	“Toileting”	 domain	 score	 showed	 a	 moderate	 positive	 correlation	 with	 age	 of	 patients	(rho=0.328).		
 
Mobility	
Results	related	to	mobility	are	described	in	Table	S64.	“Get	in	and	out	of	the	front	seat	of	a	car”	was	the	easiest	activity	to	perform	for	these	individuals	(M=5.9;	SD=4.5;	Mdn=11).		The	activity	with	more	difficulty	associated	was	“Manage	a	seat	belt	or	restraint	in	car”	(M=6.7;	SD=4.8;	Mdn=11).	Two	patients	(6.5%)	used	walking	aids,	namely	crutches	and	cane,	for	more	and	for	less	than	half	 the	 time	of	ambulation,	respectively.	Twelve	 individuals	(38.7%)	used	a	wheelchair	 for	their	daily	activities,	nine	in	a	permanent	way.		One	patient	had	an	electric	wheelchair.	A	moderate	positive,	significant	correlation	between	age	and	HAQ	scores	on	“mobility”	was	found	(rho=0.474;	p<0.01).			
Walking	and	climbing	stairs		
Answers	related	to	walking	and	climbing	stairs	are	summarized	in	Table	S65.	“Walk	across	 level	 surfaces,	 such	as	 smooth	pavements	or	driveways”	was	 the	 less	difficult	activity	(M=5.7;	SD=4.8;	Mdn=6.5),	while	the	more	complex	activity	was	“Walk	across	rough	or	uneven	surfaces,	such	as	a	lawn	or	a	gravel	driveway”	(M=6.7;	SD=4.7;	Mdn=10).	HAQ	 scores	 on	 “walking	 and	 climbing	 stairs”	 domain	 showed	 a	 moderate,	 positive	 and	significant	correlation	with	age	of	patients	(rho=0.481;	p<0.01).	
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Patients	with	higher	scores	in	“walking	and	climbing	stairs”	domain	presented	lower	values	of	plasma	 creatinine	 (rho=-0.510;	 p<0.05)	 and	 araquidonic	 acid	 (rho=-0.713;	 p<0.05)	 (both	strong	correlations).		Mean	difficulty	score	reported	for	all	and	each	domain	is	presented	in	Figure	40	and	detailed	in	Table	S66.			
	
Figure	40.	HAQ:	mean	score	obtained	in	each	domain	(ranging	from	0	“not	difficult	at	all”	to	11	points	“unable	to	do”)	
(n=31).		Higher	 scores	 in	 total	 HAQ	 score	 (all	 domains)	 were	 detected	 in	 MPS	 type	 III	 patients,	compared	to	the	other	MPS	patients	group	(U=54.0;	p=0.049)	(Figure	41).	No	other	significant	differences	in	total	HAQ	score	results	were	found	among	MPS	type	groups.	It	was	found	a	moderate	positive	and	significant	correlation	between	age	and	total	HAQ	score	(rho=0.404;	p<0.05).	Six	patients	(MPS	I5,	MPS	III1,	MPS	III2,	MPS	III7,	MPS	III9	and	MPS	VI4)	were	not	able	to	perform	(11	points)	any	of	the	activities	mentioned	in	the	questionnaire.		
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Figure	41.	Difficulties	assessment	–	all	domains,	per	type	of	MPS	(n=31).		
B. CAREGIVER	ASSISTANCE	
Results	 about	 need	 for	 caregiver	 assistance	 (independent;	 minimal,	 moderate	 and	 total	assistance)	are	displayed	per	domain	in	Figure	42.	Detailed	data	is	displayed	in	Table	S67.		Caregiver	assistance	total	score	presented	a	mean	of	3.0	(SD=1.1)	and	a	median	of	3,	ranging	from	a	minimum	of	1	(corresponding	to	independent)	to	a	maximum	of	4	(consistent	with	total	assistance).			
	
Figure	42.	HAQ	(caregiver	assistance):	mode	of	answers,	by	domain	(n=31).	
(labels	correspond	to	the	number	of	patients)	
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The	 activity	 domains	with	maximum	 autonomy	were	 “chair	 and	 toilet	 transfers”	 and	 “bed	mobility	 /	 transfers”	 (“independent”	 for	 41.4%	 and	 44.8%	 of	 the	 patients,	 respectively).	“Bathing”	 and	 “dressing	 lower	 body”	 were	 the	 domains	 where	 dependence	 was	 complete	(“total	assistance”	for	both	in	65.5%	of	the	patients).		Age	and	“caregiver	assistance”	score	showed	a	moderate	positive	correlation	(rho=0.361).		“Caregiver	 assistance”	 scores	 displayed	 a	 moderate	 negative	 correlation	 with	 plasma	creatinine	(rho=-0.440;	p<0.05)	and	araquidonic	acid	levels	(rho=-0.669;	p<0.05).			No	 significant	 statistical	 correlation	 was	 found	 between	 HAQ	 scores	 and	 adequacy	 of	nutritional	intake.	There	was	no	significant	difference	in	HAQ	scores	between	MPS	patients	with	major	central	nervous	system	involvement	and	those	with	major	skeleton	involvement.	No	significant	difference	was	found	between	patients	under	ERT	and	others	concerning	to	HAQ	scores.									
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DISCUSSION	AND	CONCLUSIONS																									
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MPS	are	a	protean	group	of	rare,	chronic	and	progressive	disorders,	associated	with	severe	morbidity	and	reduced	life	expectancy,	which	determine	a	major	impact	in	quality	of	health	and	daily	activities.	It	is	widely	recognized	that	chronic	degenerative	disorders	are	associated	with	nutritional	status	 impairment.	However,	 limited	research	has	been	done	 in	the	 field	of	nutrition	of	MPS.		This	is	the	first	comprehensive	study	about	nutritional	status	of	patients	with	MPS	developed	in	 Portugal.	Most	 of	 the	 research	 conducted	 in	 this	 field	 relates	 to	 enhancing	 patients’	 life	expectancy	and	quality,	namely	through	novel	treatments.	Clinicians	have	been	mostly	focused	in	disease	complications	and	survival.	Nutrition	has	not	been	a	concern	until	a	few	years	ago	(42,	57).	In	 the	 last	 decades,	 the	 improvement	 of	 care	 and	 survival	 and	 the	 diagnosis	 of	 less	 severe	phenotypes,	due	 to	enhanced	awareness	of	 these	 rare	disorders,	more	patients	with	a	MPS	diagnosis	are	now	living	until	more	advanced	ages.	 	Since	these	are	degenerative	disorders,	with	several	morbidities,	other	issues,	such	as	nutrition,	are	currently	arising	(58,	59).	Laboratorial	 diagnosis	 of	 MPS	 in	 Portugal	 has	 been	 done	 since	 early	 80’s	 in	 a	 reference	laboratory.	 In	 a	 recent	presentation	at	 the	12th	 International	 Symposium	of	 the	Portuguese	Society	of	Metabolic	Diseases	(SPDM),	held	in	March	2016,	it	was	reported	that	MPS	diagnosis	had	been	achieved	in	a	total	of	159	patients:	37	MPS	I,	35	MPS	II,	38	MPS	III,	19	MPS	IV,	23	MPS	VI	and	7	MPS	VII(60).	Clinical	care	to	MPS	patients	in	Portugal	is	widely	distributed	in	several	hospitals.	Reference	Centres	for	Inherited	Metabolic	Diseases	have	been	recently	recognized,	although	Treatment	Centres	for	Lysosomal	Disorders	have	been	implemented	a	few	years	ago.			The	 patients	 included	 in	 this	 study	 (n=31)	 were	 recruited	 from	 four	 different	 Reference	Centres,	as	a	convenience	method	of	sampling.		The	 above	 mentioned	 recruitment	 method	 enabled	 the	 gathering	 of	 the	 largest	 possible	sample,	corresponding	to	about	20%	of	the	total	MPS	diagnosis	in	our	country	(4).	This	could	correspond	 to	 an	 even	 larger	parcel	 of	 the	 living	MPS	portuguese	patients,	 considering	 the	severity	of	clinical	phenotypes	in	most	diagnosed	patients	and	the	reduced	life	expectancy	in	MPS.		Although	this	is	a	reduced	number	for	statistical	purposes,	namely	for	the	analysis	of	the	different	MPS	 types	and	age	groups,	 it	 can	be	considered	a	 rather	representative	sample	of	living	MPS	patients	in	Portugal.		However,	 the	 accomplishment	 of	 the	 study	 protocol	 became	 more	 difficult	 due	 to	 the	recruitment	from	four	different	Centres.	In	fact,	it	was	not	completely	fulfilled	in	some	of	the	
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centres,	 because	 of	 financial	 or	 logistical	 containments,	 namely	 concerning	 to	 laboratorial	parameters.		
Characterization	of	the	sample	The	sample	was	distributed	equally	through	the	different	age	groups	considered,	except	for	0	to	 4	 years,	which	 included	 only	 two	male	 patients.	Most	 of	 the	 collaborating	 clinicians	 are	paediatricians,	leading	to	a	prevalence	of	children	and	adolescents	in	our	sample.	In	spite	of	that,	 the	median	 follow-up	 (9.4	 years)	was	 long	 enough	 for	 patients	 to	 develop	 the	 typical	clinical	phenotypes	and	complications	and	allowed	to	explore	 the	chronic	and	degenerative	characteristics	of	MPS.	
Considering	 the	global	estimated	prevalence	of	 these	diseases,	 it	was	expected	 to	 see	more	patients	with	MPS	I,	II	and	III	(mainly	type	B)	than	MPS	VI.	This	might	have	been	caused	by	the	convenience	of	recruitment,	which	included	all	patients	followed	at	Coimbra,	mainly	with	MPS	VI.	MPS	II	is	an	x-linked	recessive	condition,	justifying	the	existence	of	only	male	patients	in	this	group	of	disease	(1,	61).		The	maximum	proportion	of	adult	patients	was	found	in	MPS	VI	group.	It			might	be	the	cause	of	a	higher	degree	of	impairment	and	dependence	detected	in	this	group.		The	absence	of	patients	older	than	35	years	might	be	justified	by	the	reduced	life	expectancy	of	these	patients,	who	frequently	die	before	reaching	adulthood.	Diagnosis	of	these	patients	was	made	early	in	life	in	most	cases,	which	may	indicate	a	cluster	of	severe	forms	of	MPS.	This	is	most	relevant	for	MPS	I	and	MPS	VI	patients.	In	MPS	I	registry	published	 in	 2012,	 there	was	 a	 consistency	 of	 ages	 at	 onset	 and	 at	 diagnosis	 with	 clinical	severity	(9).	Diagnosis	occurred	before	1	year	of	age	in	severe,	around	4	years	in	moderate	and	around	10	years	of	age	in	mild	phenotypes.	In	our	results,	diagnosis	of	MPS	I	patients	occurred	around	2	years	of	age,	consistent	with	moderate	to	severe	phenotypes.		Still,	 in	 this	sample	some	were	diagnosed	 later	 in	 life,	possibly	due	to	be	a	 less	severe	 form	(MPS	IV	for	instance)	or	to	the	inability	to	recognise	these	diseases	some	years	ago.		A	high	amplitude	of	ages	at	diagnosis	was	 found	mainly	 in	MPS	 II	and	MPS	 IV	groups,	with	maximum	in	patients	MPS	II1	and	MPS	IV1.	These	were	the	only	patients	where	diagnosis	was	made	after	10	years	of	age.			
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In	a	previous	study,	age	at	diagnosis	and	age	at	onset	of	symptoms	was	evaluated	in	a	group	of	113	MPS	patients	(62).	Median	age	at	onset	of	symptoms	was	18	months	and	diagnosis	came	about	5	years	later,	similarly	between	MPS	I,	MPS	II,	MPS	IV	(subtype	A)	and	MPS	VI.	In	MPS	II	group	developmental	delay	was	established	before	diagnosis,	that	happened	later	than	others,	around	8	years	of	age,	in	median.	As	reported	in	literature,	it	is	common	a	diagnostic	delay	of	about	two	to	three	years	after	onset	of	symptoms	(63),	even	in	MPS	with	severe	cognitive	and	somatic	disease	(61).	Unfortunately,	age	at	 clinical	 presentation	was	not	 recorded	 in	 the	present	 study,	which	 constitutes	one	of	 its	limitations.	MPS	 patients	 are	 frequently	 submitted	 to	 chronic	 pharmacological	 therapy,	 due	 to	 the	numerous	 associated	 morbidities.	 In	 the	 recent	 years,	 as	 these	 patients’	 life	 expectancy	extended	 due	 to	 new	 treatments	 and	 appropriative	 palliative	 care,	 other	morbidities	 have	arisen,	 as	 a	 consequence	 of	 the	 degenerative	 profile	 of	 the	 disorders	 (64).	 Conditions	 like	epilepsy,	musculoskeletal	 impairment	and	cardiac	dysfunction	are	becoming	more	common	with	advances	in	age.	Anti-epileptic	drugs	were	used	by	almost	a	third	of	our	patients.	Using	these	 and	 other	 chronic	 medications	 might	 cause	 digestive	 symptoms	 and	 interfere	 with	appetite,	impairing	the	nutritional	status	of	these	patients.	Only	 three	 patients	 (less	 than	 10%	 of	 the	 sample)	 were	 taking	 a	 complete	 nutritional	supplement.	These	were	followed	at	our	centre,	where	a	nutritionist	is	permanently	part	of	the	multidisciplinary	team.		Vitamin	D	supplements	were	frequently	used,	but	probably	not	in	the	adequate	dosage,	taking	into	consideration	the	high	number	of	patients	with	deficiency.	It	may	be	 hypothesised	 that	 these	 patients	might	 not	 absorb	 nutritional	 supplements	 correctly	 or	might	have	higher	needs	than	normal	population.	
	
Nutritional	intake	Recent	 nutritional	 intake	 was	 collected,	 based	 upon	 the	 24-hour	 recall	 questionnaire.	Considering	 that	 it	 corresponds	 to	 just	 one	 day,	 the	 representability	 of	 usual	 intake	 is	 not	warranted.	 So,	 for	 the	 analysis	 of	 adequacy	 and	 the	 correlations	 with	 other	 data,	 food	frequency	questionnaire	results	were	used,	as	these	are	supposed	to	be	representative	of	the	intake	of	past	year.	Indeed,	macronutrients	distribution	respecting	to	caloric	intake	was	similar	between	both	methods:	protein	21.7	vs	20.5%;	fat	31.0	vs	32.4;	carbohydrates	44.1	vs	48.3%	(24-hour	 recall	 vs	 food-frequency	 questionnaire).	 This	 similarity	 between	 both	 methods	strengthens	the	food	frequency	questionnaire	results,	as	recommended	(65).		
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Food	 habits	 were	 obtained	 through	 the	 food-frequency	 questionnaire,	 which	 reported	patients’	food	intakes	by	themselves	or	as	understood	by	caregivers.	Even	though	this	type	of	questionnaire	may	overestimate	nutritional	 intakes	 (66)	and	is	only	validated	for	Portuguese	adults	with	no	validation	when	answered	by	caregivers,	it	was	used,	associated	with	24-hour	recall	 (67).	Of	course,	it	depends	on	the	caregiver’s	memory	and	accuracy,	which	may	also	be	influenced	by	their	own	habits.		A	 high	 prevalence	 of	 individuals	 that	 do	 not	 eat	 healthy	 food	 regularly,	 namely	 fruits	 and	vegetables,	was	found.	Milk	is	a	daily	consumed	food,	especially	reduced-fat	milk,	as	well	as	yogurts,	which	are	components	of	the	portuguese	usual	diet.	These	are	also	very	common	in	our	culture.	There	is	a	high	intake	of	sugar-rich	beverages,	namely	iced	tea,	which	is	consumed	on	a	weekly	basis	by	most	of	the	patients.	These	findings	bring	a	lot	of	concern	not	only	because	of	the	unhealthy	pattern	in	MPS	patients	but	also	because	this	might	replicate	what	is	common	in	our	culture.		It	could	be	anticipated	that	a	healthy	eating	pattern	would	be	beneficial	in	these	chronic,	 progressive	 diseases	 preventing	 and	 helping	 to	 treat	 some	 of	 the	 associated	morbidities.	On	the	other	hand,	an	emotional	compensation,	common	in	caregivers	of	patients	with	a	reduced	life	expectancy,	could	contribute	to	the	diet	deviation,	attempting	to	attenuate	the	 psychological	 effects	 of	 the	 diagnosis,	 with	 its	 gloomy	 prognosis.	 Another	 factor	 that	determines	 food	habits	 is	 the	 restriction	of	 specific	 foods	 (e.g.	milk,	 due	 to	 gastrointestinal	disturbances),	and	its	replacement	by	others.	In	fact,	it	was	quite	frequent	in	these	patients	to	see	a	refusal	of	dairy	foods	and	intake	of	vegetables	substitutes.		Some	caregivers	try	to	provide	a	pattern	of	feeding	as	healthy	as	possible	(as	they	think	it	is),	in	order	to	ameliorate	or	even	halt	disease	progression,	by	using	seeds	and	grains	in	high	proportions,	which	in	many	cases	may	worsen	the	gastrointestinal	function.			Examining	usual	nutritional	intake,	most	of	the	patients	showed	lower	energy,	carbohydrates	and	 fiber	 intake	 than	 recommendations.	 This	 might	 be	 associated	 with	 eating	 difficulties,	preferences	of	inadequate	food	or	even	lower	appetite.	It	was	not	MPS	type	specific	and	did	not	vary	with	 age.	 Contrary	 to	what	might	 be	 expected,	 there	was	 not	 a	 statistical	 correlation	between	this	reduced	intake	and	nutritional	status	parameters,	despite	of	an	apparently	high	prevalence	of	patients	with	analytical	signs	of	malnutrition.	Even	though,	it	is	recognized	that	this	questionnaire	does	not	 include	prepared	and	cooked	food,	neglecting	the	amount	of	 fat	used	(e.g.),	for	the	nutritional	intake	calculation.	Protein	intake	was	adequate	in	almost	half	of	the	sample,	though	some	still	presented	lower	intakes,	and	this	is	more	significant	in	MPS	VI	patients.	Patients	aged	between	5	to	11	years	of	
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age	 tend	 to	 eat	 lower	 protein	 than	 recommendations	 and	 this	 might	 pose	 a	 problem	 in	accomplishing	growing	needs.		Fat	 intake	was	 adequate	 in	most	 of	 the	 patients.	Nevertheless,	most	 of	 them	did	 not	 reach	recommendations	for	omega	3	fatty	acids.	Omega	6	fatty	acid	intake	was	also	insufficient	in	most	of	the	individuals.		Age	 did	 not	 seem	 to	 bring	 any	 influence	 to	 eating	 patterns,	 what	 reinforces	 the	 need	 to	implement	a	healthy	pattern	of	eating	since	early	ages.	Besides	 there	was	not	a	correlation	between	level	of	assistance	and	adequacy	of	intake,	which	means	that	whether	these	patients	eat	by	their	own	or	depend	on	a	caregiver,	results	of	adequacy	are	similar.	Except	for	vitamin	D,	vitamin	intake	was	adequate	in	most	of	the	patients.	In	fact,	almost	all	patients	showed	an	inadequate	intake	of	vitamin	D,	even	though	there	was	not	a	correlation	between	ingestion	of	this	vitamin	and	its	plasma	levels.	Besides	intake,	other	factors,	such	as	sun	exposure,	are	known	to	contribute	to	plasma	levels.		Minerals	intake	was	generally	adequate,	except	for	manganesium,	potassium	and	calcium.	Due	to	calcium	role	 in	bone	metabolism,	deficient	 intake	 in	patients	 in	ages	with	high	needs	 for	growth,	 namely	 in	 adolescence,	 should	 be	 corrected.	 It	 can	 be	 achieved	 through	 diet	modification	or	calcium	supplementation,	if	necessary.		
	
Anthropometrics	and	body	composition		In	what	relates	 to	anthropometric	data,	 significant	shifts	were	detected	 in	height	z-score	of	these	group	of	patients.	Except	for	MPS	III	group,	all	MPS	types	showed	a	mean	shorter	stature	than	references.	Height	z-score	was	significantly	 lower	 in	older	patients.	These	 findings	are	consistent	 with	 a	 generalized,	 progressive	 disease	 with	 bone	 involvement.	 This	 is	 quite	significant	 in	MPS	 IV	 and	MPS	VI	 groups,	 the	 ones	with	major	 skeletal	 involvement,	where	height	 z-score	 reached	values	 of	 -10.1	 (in	 the	oldest	 patient)	 and	 -8.8,	 respectively.	 In	 fact,	dysostosis	multiplex	 is	most	 severe	 in	 those	MPS	 types	 and	 it	 is	 certainly	 associated	with	marked	short	stature.		Analysis	of	BMI	data,	using	z-score	for	WHO	references,	disclosed	eutrophy	in	the	majority	of	the	 patients.	 Two	 presented	 severe	 thinness	 and	 six	 were	 overweighed	 (one	 obese).	 The	patients	with	high	BMI	z-score	were	aged	mainly	between	6	to	10	years	of	age,	except	for	one	23-year-old	MPS	VI	man	(MPS	VI5).	Nevertheless,	BMI	z-score	showed	a	negative	correlation	with	age,	crossing	z-score	0	in	middle	of	adolescence	ages.	Indeed,	two	patients,	aged	20	(MPS	I5)	and	25	years	(MPS	III7),	were	classified	with	severe	thinness	(BMI	z-scores	of	-3.9	and	-4.6).	
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Even	though,	when	this	data	was	compared	with	specific	BMI	growth	curves	(available	for	MPS	II,	MPS	 III	 and	MPS	 IV),	 only	 one	patient	with	MPS	 III	 showed	overweight.	 Specific	 growth	curves	are	not	available	for	MPS	VI	and	MPS	VII,	so	this	critical	analysis	is	hindered.	Contrary	to	what	would	be	expected,	neither	nutritional	intake	of	energy	and	macronutrients	seemed	to	affect	BMI	scores,	nor	differences	in	BMI	were	found	between	MPS	types.			Body	composition	was	assessed	using	a	tetrapolar	bioelectrical	impedance	analyser	in	most	of	the	patients	(68).	Minimum	body	lean	mass	was	found	in	MPS	IV	group,	one	of	the	types	with	major	 skeletal	 involvement.	 These	 results	 were	 compared	 with	 data	 published	 in	 healthy	individuals,	enabling	the	identification	of	three	patients	with	overfat	and	three	with	extremely	low	fat-free	mass	index.	Two	of	these	were	classified	with	severe	thinness,	one	using	BMI	z-score	 and	 the	 other	with	 specific	 curves	 for	 disease.	 These	 results	 are	 arguable,	 since	 this	method,	 as	 well	 as	 the	 predictive	 equations	 used,	 may	 not	 be	 adequate	 to	 estimate	 body	composition	 in	 these	patients.	MPS	 is	a	group	of	diseases	with	phenotypical	characteristics,	including	somatic	morphological	modifications,	which	bring	to	discussion	the	possible	body	asymmetry.	This	might	impair	the	validity	of	this	method	as	an	evaluation	tool	in	MPS	patients,	though	it	can	be	used	in	the	longitudinal	follow	up.	Still,	 it	was	the	only	technique	available.	Phase	 angle	was	 also	 acquired	 and	 considering	 it	 is	 a	 parameter	 obtained	 almost	 directly,	without	the	need	of	predictive	equations,	results	were	reviewed	and	used	in	statistical	analysis.		In	 this	 sample,	 most	 of	 the	 patients	 (13	 in	 19)	 showed	 lower	 phase	 angle	 than	 published	references,	 when	 stratified	 for	 BMI.	 Indeed,	most	 of	 the	 results	 are	 lower	 than	 5.0°,	 value	frequently	associated	with	bad	prognosis	in	critical	status	of	chronic	disease	patients.	Phase	angle	was	not	assessed	in	MPS	I	and	MPS	VII	individuals.	MPS	IV	group	was	the	only	one	where	all	 the	 patients	were	 found	 to	 have	 low	 angles.	 The	 three	 patients	mentioned	 before,	who	presented	 extremely	 low	 fat-free	mass	 index	 (MPS	 II4;	MPS	 III7;	MPS	 III9)	 also	 showed	 low	phase	angle.	All	of	them	displayed	low	plasma	creatinine;	one	(MPS	II4)	also	showed	low	pre-albumin	and	normal	RBP.	In	the	other	two	(MPS	III7;	MPS	III9)	pre-albumin	and	RBP	were	not	measured.	In	 line	with	other	publications,	phase	angle	 results	 showed	a	positive	moderate	correlation	with	age	and	with	lean	body	mass.	Nevertheless,	nutrient	intake	was	not	related	to	phase	angle	results.	So,	low	phase	angle	values	found	in	this	study	population	may	be	a	consequence	of	the	severity	 of	 disease	more	 than	 just	 an	 indicator	 of	 a	 poor	nutritional	 status	 associated	with	inadequate	intake.	A	 possible	 link	 with	 low	 phase	 angle	 values	 found	 in	 our	 sample	 is	 the	 existence	 of	 an	inflammatory	 status,	 common	 in	 MPS	 patients	 (69,	 70).	 In	 this	 study	 c-reactive	 protein	 was	
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normal	in	the	majority	of	the	patients,	though	the	c-reactive	protein	assay	used	was	not	the	high	sensitivity	one	(71).	It	would	have	been	interesting	to	have	tested	for	other	inflammation	markers	such	as	tumor	necrosis	factor	–	alpha,	interleukin-1	or	interleukin-6	in	these	patients	(70,	72).		
Resistance	test		A	 resistance	walking	 test	was	 performed	 aiming	 to	 relate	 functional	 abilities	 to	 nutritional	status.	MPS	II	patients	were	the	group	with	higher	results	in	6-MWT.		Most	of	the	patients	walking	a	shorter	distance	(<25th	centile),	are	older	than	12	years	of	age,	showing	a	tendency	in	functional	skills	deterioration	associated	with	age.	This	is	in	accordance	to	 the	 chronic	 and	 degenerative	 characteristic	 of	 MPS,	 although	 it	 was	 not	 a	 statistically	significant	correlation.		Twelve	patients	were	unable	to	walk,	due	to	their	severe	clinical	status.	Eight	are	completely	dependent	on	wheel	chair.	All	of	these	were	older	than	20	years,	except	for	one	10-year-old	patient,	which	corroborates	the	progressive	severity	of	this	disease	with	age.		
	
Laboratorial	data	Some	laboratorial	parameters	were	analysed	with	the	purpose	of	better	characterization	of	the	patients’	nutritional	status.	Although	there	was	a	pre-defined	protocol,	some	of	the	parameters	were	not	analysed	in	all	cases.	Some	of	them,	more	specific	and	not	routinely	performed	in	the	hospital	 laboratories,	 dependent	 of	 administrative	 authorization	 to	 be	 done	 in	 external	laboratories,	 such	 as	 essential	 fatty	 acid	 profile,	 were	 sometimes	 missed.	 Laboratorial	parameters	used	regularly	for	assessment	of	patients	were	generally	requested,	although	with	a	few	exceptions.		The	lack	of	full	accomplishment	of	the	pre-defined	laboratorial	protocol	is	a	limitation	of	this	study,	disabling	some	of	the	potential	 findings.	Besides	this,	 the	analysis	were	performed	in	diverse	laboratories,	raising	the	discussion	of	uniformity	of	procedures,	analytic	methods	and	reference	values.		Total	protein,	albumin	and	transferrin	plasma	levels	were	normal	in	most	of	individuals.	Two	individuals	showed	moderate	hypoalbuminemia.	One	of	them	(MPS	III2)	presented	the	highest	values	of	ALT	and	AST	and	the	lowest	phase	angle	result,	without	any	significant	modification	of	body	composition.	The	other	(MPS	I5)	showed	severe	thinness	as	well	as	low	levels	of	plasma	pre-albumin	and	RBP,	even	though	she	was	the	one	with	the	highest	recent	caloric	intake	and	
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was	 taking	a	 complete	nutritional	 supplement	 regularly.	Unfortunately,	 this	patient	did	not	perform	 body	 composition	 assessment.	 Nevertheless,	 plasma	 albumin	 is	 not	 a	 reliable	parameter	 to	 nutritional	 status	 assessment,	 as	 it	 can	 be	 influenced	 by	 numerous	 factors,	namely	liver	dysfunction	and	renal	losses	(73).		Most	of	the	patients	who	performed	pre-albumin	and	RBP	analysis	showed	low	levels.	As	these	two	 proteins	 are	 reliable	 markers	 of	 nutritional	 status,	 this	 may	 indicate	 the	 presence	 of	malnutrition	status	in	most	of	them.	However,	other	factors	may	contribute	to	the	low	levels,	namely	the	presence	of	an	inflammatory	status,	which	has	been	described	in	MPS	patients.	As	stated	before,	it	was	not	adequately	evaluated	in	this	sample,	since	C-reactive	protein	was	the	only	parameter	studied.	Phase	angle	and	plasma	fatty	acid	results	corroborate	the	malnutrition	status	in	most	of	the	study	population.	It	is	well	known	that	pre-albumin	and	RBP	are	highly	sensitive	to	protein	intake	(74).	However,	a	significant	correlation	between	 these	 laboratorial	parameters	and	recent	or	usual	protein	intake	was	not	present	in	this	sample,	which	may	be	due	to	its	limited	number.	Age	did	not	seem	to	influence	plasma	pre-albumin	and	retinol-binding	protein	levels.	Though,	a	 tendency	 line	 to	 lower	values	 in	older	patients	was	 identified	 in	 these	parameters,	not	 in	agreement	with	published	data	for	healthy	subjects	(75).		Concerning	to	lipid	profile,	total	cholesterol,	LDL-cholesterol	and	triglycerides	were	normal	in	most	 of	 the	 patients.	 The	 three	 patients	 who	 showed	 higher	 LDL-cholesterol	 values	 than	references	 (MPS	 III7;	 MPS	 IV1;	 MPS	 VI3),	 presented	 normal	 HDL-cholesterol	 levels.	Interestingly,	 HDL-cholesterol	was	 low	 in	 the	majority	 of	 analysed	 patients,	which	may	 be	associated	with	poor	nutritional	status	or	an	inflammatory	and	oxidative	phenotype		(76,	77).	Low	HDL-cholesterol	levels	are	a	risk	factor	for	atherosclerosis,	which	has	not	been	a	problem	in	MPS	 patients,	 probably	 due	 to	 the	 reduced	 life	 span.	 However,	 it	 would	 be	 interesting	 to	analyse	 the	 lipid	 profile	 in	 a	 larger	 cohort	 in	 order	 to	 conclude	 if	 low	HDL-cholesterol	 is	 a	consistent	finding	in	MPS.	Concerning	to	plasma	essential	fatty	acids,	the	majority	of	patients	showed	normal	values	of	araquidonic,	docosahexaenoic	and	eicosapentaenoic	acid	levels.		Still,	 older	 patients	 showed	 significantly	 higher	 levels	 of	 araquidonic	 and	 docosahexaenoic	acids.	The	ratio	araquidonic	acid	:	(docosahexaenoic	acid	+	eicosapentaenoic	acid)	tends	to	be	higher	 in	 older	 patients	 and,	 even	 without	 statistical	 significance,	 in	 patients	 with	 worst	performances	 in	6-MWT	and	 in	 those	with	higher	dependence	 scores	 in	HAQ.	 In	a	 recently	published	study,	this	fatty	acid	pattern	was	associated	with	lower	physical	performances	(78),	
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which	is	in	line	with	these	results.		Nevertheless,	the	role	of	these	fatty	acids	in	inflammatory	status	and	immune	response	is	well	known	(79,	80).	No	correlation	was	found	between	plasma	essential	fatty	acids	levels	and	nutritional	intake.	However,	this	analysis	was	only	performed	in	a	small	part	(38.7%)	of	the	study	sample,	which	impaired	the	adequate	statistical	analysis.	Most	patients	 showed	normal	plasma	values	of	 vitamins,	 except	 for	 vitamin	D.	Only	 two	of	eleven	patients	with	high	plasma	levels	of	B12,	were	taking	a	nutritional	supplement.	These	were	the	ones	with	the	highest	values.	High	levels	of	this	vitamin	have	been	associated	with	cancer	 and	 considered	 a	 mortality	 risk	 factor	 in	 patients	 with	 a	 few	 severe	 diseases	 (81).	However,	 the	 mechanisms	 underlying	 this	 association	 are	 not	 yet	 elucidated,	 and	 some	controversial	data	has	been	published	(82-84).	To	our	knowledge,	MPS	patients	are	not	prone	to	cancer	development.	On	the	other	hand,	only	the	long-term	follow-up	of	those	patients	with	high	vitamin	B12	levels	might	confirm	the	link	with	higher	mortality.	Low	levels	of	vitamin	A	(6	in	23	patients)	or	vitamin	E	(6	 in	22	patients)	were	found.	Since	those	were	different	patients,	 it	corresponds	to	more	than	half	(12)	of	the	analysed	sample.	Apparently,	the	levels	of	these	vitamins	were	not	related	with	the	nutritional	intake.	The	low	levels	of	vitamins	A	and	E	may	be	an	indirect	evidence	of	oxygen	free	radicals	damage,	possibly	correlated	with	a	potential	inflammatory	status	associated	to	MPS.	This	fact,	as	well	as	negative	correlation	of	vitamin	E	levels	with	age,	would	support	the	use	of	anti-oxidants	supplements	as	a	co-adjuvant	therapy	in	these	patients	(69,	70,	72,	85-90).	In	this	context,	evaluation	of	vitamin	C	status	would	have	been	interesting.	Plasma	concentrations	of	sodium,	potassium,	magnesium,	selenium	and	zinc	were	normal	in	the	majority	of	patients.	The	only	two	patients	with	high	values	of	magnesium	were	taking	a	nutritional	supplement.	The	great	proportion	of	analysed	patients	showed	normal	liver	and	renal	parameters,	as	well	as	total	blood	count	analysis,	as	anticipated	in	MPS	(1).	Creatinine	 levels	 are	 associated	 with	 muscle	 mass	 and	 glomerular	 renal	 function	 and,	 as	expected,	did	not	show	any	statistical	correlation	with	nutritional	intake.	The	majority	of	the	31	patients	(77.4%)	showed	low	levels	of	plasma	creatinine.	This	might	be	due	to	poor	muscle	bulk	 in	 these	 patients.	 Contrary	 to	 what	 was	 predictable	 in	 the	 sample	 age	 range,	 a	 weak	negative	 correlation	 (although	with	 no	 statistical	 significance)	was	 found	 between	 age	 and	creatinine	 levels.	Also,	 patients	with	higher	 scores	 in	 “walking	and	 climbing	 stairs”	domain	
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presented	lower	values	of	plasma	creatinine	(strong	correlations).	 It	would	be	 important	to	understand	if	those	are	independent	or	related	factors	in	those	correlations.		One	of	the	most	characteristic	involvements	in	MPS	is	bone	dysplasia,	which	determines	the	low	stature	in	many	patients,	mostly	those	with	MPS	IV	and	MPS	VI	types.	Low	bone	mineral	density	 and	muscle	 and	 skeletal	 pain	 have	 been	 reported	 in	 MPS	 (59,	 91-94).	 Although	 a	 few	patients	had	 chronic	pain	and	 in	 some,	bone	mineral	density	evaluation	had	been	done,	 its	analysis	was	not	one	of	the	objectives	of	the	present	study.	In	this	sample,	phosphocalcium	metabolism	parameters	were	globally	normal,	except	for	high	PTH	(4	in	23	patients)	and	vitamin	D	(27	in	31	patients)	levels.	Vitamin	D	deficiency	is	rather	common	in	general	population	and	also	in	MPS	patients	(59,	93,	95,	96).	Low	vitamin	D	values	were	present	 in	 87.1%	 of	 the	 patients	 and	 deficiency	 status	 was	 detected	 in	 about	 half	 of	 the	analysed	 sample.	 Three	 of	 the	 four	 patients	 with	 normal	 vitamin	 D	 values	 were	 taking	 a	supplement	of	this	vitamin.		Considering	 that	 MPS	 is	 a	 degenerative	 disease	 and	 consequently	 patients	 are	 frequently	dependent	on	caregiver	to	have	sun	exposure,	vitamin	D	status	should	be	regularly	monitored	and	supplemented	as	needed	(59).	
	
Quality	of	health	Quality	of	health	questionnaires	are	 important	 tools	 for	 the	evaluation	of	disease	 impact	 in	daily	activities	and	need	for	caregiver	assistance	 in	chronical	diseases	 (47).	Unexpectedly,	no	correlation	was	found	between	quality	of	health	and	nutritional	intake.		In	our	sample,	a	significant	number	of	patients	showed	high	levels	of	difficulty	for	several	daily	tasks	 associated	 with	 high	 levels	 of	 caregiver	 dependence,	 as	 expected.	 Six	 in	 31	 patients	(19.4%)	were	not	able	 to	perform	any	of	 the	questioned	activities.	As	could	be	anticipated,	older	 patients	 presented	 higher	 significant	 levels	 of	 difficulty	 in	 most	 tasks	 (“walking	 and	climbing	stairs”;	“mobility”;	“toileting”;	“eating	and	drinking”),	in	total	HAQ	score	and	need	of	caregiver	assistance	(47,	97).	Patients	with	higher	scores	in	“walking	and	climbing	stairs”	domain	and	“caregiver	assistance”	presented	 significant	 lower	 values	 of	 plasma	 creatinine	 and	 araquidonic	 acid	 (strong	correlations),	which	could	be	associated	to	muscle	wasting	and	/	or	inflammation.						
		 64	|	Ana	Faria	|	2017	
Nutrition	across	MPS	types	MPS	 are	 a	 heterogeneous	 group	 of	 multisystem	 diseases,	 which	 differ	 on	 major	 organ	involvement.	Age	at	presentation	and	survival	are	also	variable,	not	only	among	MPS	types,	but	also	between	patients	of	each	type.	ERT,	which	began	in	2003	for	MPS	I,	is	now	available	for	most	MPS	types	(1,	98).	Despite	current	intense	clinical	investigation	in	this	field,	which	includes	gene	therapy	for	some	MPS	types,	the	efficacy	of	ERT,	as	well	as	other	available	treatments,	like	stem	cell	transplantation,	is	far	from	optimal	(99).	With	the	attempt	to	identify	possible	differences	in	nutritional	status,	nutritional	intake	and	quality	of	health	between	MPS	types,	 the	corresponding	parameters	were	analysed	 in	more	detail.	MPS	VII	was	excluded	from	this	analysis,	due	to	the	existence	of	only	one	patient.	Despite	being	expected	that	age	at	diagnosis	is	more	dependent	on	disease	severity	and	age	of	presentation	of	first	symptoms	(as	well	as	clinical	skill)	than	on	the	MPS	type,	in	a	previously	study	in	a	group	of	113	MPS	patients,	diagnosis	happened	in	similar	ages	in	MPS	I,	MPS	IV	and	MPS	VI	groups	and	later	in	MPS	II	patients	(62).	In	the	present	study,	age	at	diagnosis	was	similar	across	the	several	MPS	types,	though	in	MPS	I	and	MPS	VI	group,	 lower	ages	were	referred,	without	statistical	significance.	This	may	be	associated	with	the	presence	of	more	severe	forms	of	the	disease	in	these	groups,	as	expected	(9).	Other	factors,	like	less	awareness	about	these	disorders	and	difficulties	in	performing	the	laboratorial	diagnosis	in	the	past	may	be	relevant	in	this	issue.	MPS	patients	have,	characteristically,	growth	impairment	compared	to	healthy	subjects.	Across	the	different	types,	some	(distinctly	MPS	IV	and	VI)	are	distinguished	by	more	severe	skeletal	involvement	and	a	shorter	final	stature.	In	this	study,	except	for	MPS	III	group,	all	types	of	MPS	showed	a	mean	stature	shorter	than	WHO	references,	worsening	with	age,	as	anticipated	due	to	the	progressive	feature	of	the	diseases.	This	was	noteworthy	in	MPS	IV	and	MPS	VI	groups,	the	ones	with	major	skeletal	involvement	as	previously	referred,	where	height	z-score	reaches	values	of	-10.1	(in	the	oldest	patient)	and	-8.8,	respectively,	in	agreement	to	other	studies	(58).	On	the	other	hand,	weight	and	BMI	were	similar	along	the	different	MPS	types.	Body	composition	results	were	analogous	across	the	different	MPS	types,	with	minimum	body	lean	mass	in	the	MPS	IV	group,	although	this	difference	was	not	statistically	significant.	Phase	angle	was	not	assessed	in	MPS	I	and	MPS	VII	patients.	Low	values	were	predominant	in	the	entire	analysed	sample.		No	significant	differences	in	phase	angle	were	found	between	MPS	types.	However,	all	MPS	IV	patients	showed	low	values,	possibly	conditioned	by	their	reduced	stature,	which	has	been	described	as	a	predictive	factor	for	phase	angle	(100).		
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Other	 parameters	 might	 sustain	 these	 results	 about	 nutritional	 status	 assessment.	 Some	laboratorial	 results	 were	 compared	 through	 the	 different	 MPS	 types,	 as	 mentioned	 in	 the	methods	section.		The	group	of	MPS	VI	patients	presented	significantly	lower	values	of	plasma	RBP	and	vitamins	A	and	E,	as	well	as	higher	araquidonic	acid	levels	than	the	others.	Although	there	was	not	a	significant	difference,	most	of	the	patients	showing	lower	results	of	plasma	magnesium	were	MPS	VI	patients.		In	accordance	with	these	results,	many	MPS	patients,	mostly	in	MPS	VI	individuals,	may	have	a	subclinical	status	of	undernutrition	and/or	a	chronic	inflammatory	situation	(5).		Although	 energy	 intake	 is	 inadequate	 in	 most	 of	 the	 patients	 in	 analysis,	 there	 were	 no	significant	 difference	 between	 the	 several	 MPS	 types.	 Besides	 this,	 protein	 intake	 was	inadequate	in	almost	half	of	the	sample	and	this	is	significant	among	MPS	VI	patients,	but	not	significantly	different	from	the	other	MPS	groups.		Also,	plasma	levels	of	vitamin	E	were	higher	in	MPS	IV	patients,	which	does	not	corroborate	the	previously	formulated	hypothesis.	Pre-albumin,	RBP	and	vitamin	A	levels	were	significantly	higher	in	MPS	III	patients	compared	to	the	others.	 Indeed,	MPS	III	as	a	group	is	associated	with	 less	somatic	disease	severity,	as	expected	(5).		MPS	III	patients	are	mostly	affected	in	cognitive	and	behavioural	areas.	This	may	lead	to	higher	levels	 of	 assistance	 needed(5),	 despite	 the	 less	 severe	 somatic	 involvement,	 as	 it	 was	demonstrated	 in	 our	 cohort.	 Notwithstanding	 the	 high	 levels	 of	 difficulties	 detected	 in	 all	patients,	MPS	III	individuals	stand	out	with	the	highest	scores	in	HAQ,	when	comparing	with	the	 other	MPS	 groups.	 This	 is	 more	 significant	 in	 the	 domains	 associated	 with	 eating	 and	grooming,	as	expected.	Other	parameter	that	might	be	related	with	disease	type	is	the	performance	on	6-MWT.	In	this	resistance	 test,	 MPS	 II	 patients	 showed	 the	 highest	 results,	 demonstrating	 the	 highest	capability	in	walking	long	distances.	MPS	III	patients	were	expected	to	walk	longer	distances,	due	 to	 less	 physical	 impairment,	 but	 in	 most	 of	 them	 the	 results	 became	 lower	 due	 to	difficulties	in	understanding	the	command	given.		As	 a	 general	 rule,	 MPS	 types	 IV	 and	 VI	 present	 major	 skeletal	 impairment	 with	 relative	preservation	 of	 intellectual	 functions,	 whereas	 MPS	 I,	 II,	 III	 and	 VII	 are	 more	 frequently	associated	with	cognitive	injury(5).		We	have	analysed	the	differences	in	nutritional	intake,	and	nutritional	status,	as	well	as	in	quality	of	health	between	these	two	clusters	of	patients.		
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Patients	with	predominant	skeletal	affection	frequently	have	pain	and	mobility	 impairment.	These	 are	 expected	 to	 cause	 high	 levels	 of	 dependency	 on	 the	 caregiver	 due	 to	 greater	difficulties	in	performing	daily	activities,	as	well	as	less	functional	abilities,	namely	in	mobility	domains,	like	walking	and	climbing	stairs(47).	Besides	this,	the	immobility	may	also	contribute	to	abnormalities	in	some	of	the	nutritional	status	parameters	analysed,	like	phase	angle,	lean	body	mass,	plasma	proteins	and	vitamin	D.	On	 the	 other	 hand,	 patients	 with	 predominant	 cognitive	 impairment	 could	 present	 higher	levels	 of	 need	 for	 caregiver	 assistance	 (47).	 This	 might	 result	 in	 better	 food	 habits,	 as	 the	dependence	of	the	caregivers	may	end	in	better	choices,	and	consequently,	nutritional	intake	might	be	more	adequate.		Notwithstanding	with	those	expectations,	results	from	nutritional	intake	and	nutritional	status	analyses	 were	 similar	 between	 the	 above	 mentioned	 MPS	 patient	 groups.	 Similarly,	 no	differences	were	found	between	both	groups,	relating	to	quality	of	health	and	resistance	test	parameters.		ERT	is	available	for	MPS	I,	MPS	II,	MPS	IV	and	MPS	VI	patients	 (1).	It	would	be	expected	that	patients	 submitted	 to	 ERT	would	 have	 better	 quality	 of	 health	 and	 nutritional	 status	 than	untreated	patients	with	the	same	MPS	type,	corroborating	the	evidence	of	benefits	of	this	kind	of	 therapy.	 	 To	 our	 knowledge,	 no	 studies	 seeking	 for	 that	 evidence	 have	 yet	 been	 done,	perhaps	because	these	are	novel	therapies	and	not	all	the	patients	with	these	rare	diseases	are	still	submitted	to	this	treatment.	On	the	other	hand,	large	cohorts,	needed	for	that	investigation,	are	difficult	to	assembly.		In	this	sample,	patients	treated	with	ERT	showed	lower	levels	of	pre-albumin	and	vitamin	A	than	 those	not	under	ERT.	No	other	differences	relating	 to	nutritional	 intake	and	quality	of	health	were	found	between	the	two	groups.	 	 It	 is	questionable	to	analyse	the	effects	of	ERT	comparing	patients	with	diverse	MPS	 types.	We	did	so,	 since	our	sample	was	small	 for	any	results	 with	 statistical	 significance.	 However,	 since	 the	 no-ERT	 group	 included	 all	 MPS	 III	patients	and	only	a	few	from	the	other	MPS	types	the	lower	levels	of	pre-albumin	and	vitamin	A	might	be	explained	by	the	somatic	severity	of	the	patients	submitted	to	ERT.	
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Conclusion	In	 this	 study,	 a	 comprehensive	 assessment	 of	 nutritional	 status	 of	 31	 MPS	 patients	 was	performed	and	related	to	nutritional	intake	and	quality	of	health.		Anthropometric	 data	 was	 adequate	 to	 growth	 references	 for	 these	 diseases	 and	 body	composition	 (fat	 and	 lean	 mass)	 showed,	 in	 general,	 adequate	 results.	 However,	 other	nutritional	status	indicators	like	phase	angle,	pre-albumin,	RBP,	creatinine,	HDL-cholesterol,	vitamin	A,	D	and	E	and	essential	fatty	acids	were	lower	than	references	in	a	significant	number	of	patients.		Nutritional	 intake	 was	 considered	 adequate	 in	 most	 of	 the	 patients,	 except	 for	 energy,	carbohydrate	and	 fiber	 intake,	which	was	 low	 in	 the	bulk.	The	majority	of	 the	patients	had	inadequate	food	habits,	which	can	enhance	disease	progression.	As	expected,	this	study	cohort	showed	high	levels	of	difficulties	and,	consequently	low	levels	of	autonomy.		Some	findings	(difficulty	and	need	of	caregiver	assistance	and	low	BMI	z-score,	e.g.)	were	more	prominent	in	older	ages,	as	could	be	anticipated	in	degenerative	diseases.		As	 widely	 mentioned	 in	 the	 literature,	 MPS	 patients	 should	 be	 regularly	 monitored	 by	 a	multidisciplinary	 team,	 which	 must	 include	 nutritionists,	 specialized	 in	 inborn	 errors	 of	metabolism,	with	know-how	in	degenerative	diseases	(101-103).		MPS	patients	should	be	subjected	to	anthropometric	surveillance	using	specific	growth	curves,	as	well	as	body	composition	assessment	and	screened	for	abnormalities	in	specific	parameters	like	pre-albumin	and	vitamin	D,	at	least	annually.	If	not	avoided,	deficits	should	be	corrected,	as	earlier	as	possible,	in	order	to	optimize	the	patients’	condition.	Aiming	to	provide	a	better	clinical	surveillance	in	order	to	improve	quality	of	health	of	MPS	patients,	 through	 prevention	 of	 nutritional	 deficits	 and	 other	 treatable	 complications,	 a	nutrition	follow-up	protocol	proposal	follows.			
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Assessment	 Methods	/	indicators	 At	diagnosis	 Follow-up	frequency	 Pre-ERT	
Food	and	nutritional	intake	
24-hour	recall	(representative	day)	Nutritional	intake:		compare	with	recommendationsa		 ✓	 Every	visit	 ✓	
Growthb	
Weight	Height	/	length	Body	mass	index	Head	circumference	(≤	36	months)	 ✓	 Every	visit	 ✓	
Body	compositionc	
Lean	body	mass	Fat	body	mass	Total	body	water	Phase	angle	 ✓	 Annual	(more	often	if	nutritional	therapy	is	implemented)	 ✓	Bone	mineral	densityd	 -	 Annual	or	every	other	year		 -	
Nutritional	blood	biomarkers	e	
Creatinine	Pre-albumin	Retinol	binding	protein	Vitamin	A,	D	and	E	Vitamin	C	Calcium,	phosphorus	Magnesium	Selenium	Zinc	Alkaline-phosphatase	(bone	specific,	if	available)	Calcitonin	Parathormone	
✓	 Annual	 ✓	
Inflammatory	markerse	 Tumour	necrosis	factor	–	α	Interleukin-6	 ✓	 Annual		 ✓	
Table	4.	Nutritional	follow-up	protocol	–	a	proposal	for	MPS	patients.		aDietary	reference	intakes;	bSee	growth	curves	appropriated	to	each	type	of	MPS;	cBioelectrical	impedance	or	dual-
energy	X-ray	absorptiometry;	d	from	6	years	of	age	plasma	analysis;	e	to	screen	for	inflammation
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Finding	 Measure		
Inadequate	food	habits		 Encourage	healthy	food	intake	
Insufficiency	/	deficiency	of	vitamin	D	
Supplement	with	cholecalciferol	or	similar	Encourage	sun	exposure	
Other	vitamin	or	mineral	deficiency	 Consider	correction	
Malnutrition	/	wasting	suspicion	
Optimize	nutritional	intake;	consider	nutritional	supplements	Encourage	physical	activity	
Inflammatory	status	 Consider	anti-oxidant	therapy	
Table	5.	Nutritional	follow-up	protocol	–	major	findings	and	measures							
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SUPPLEMENTS	
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Patient	ID	 Type	of	MPS	 Gender	
Current	
age*	
Age	at	
diagnosis	
ERT	
(yes	/	
no)	
Pharmacological	
treatment	 Nutritional	supplements	
MPS	I1	
MPS	I	
Male	 1.7	 0.8	 Yes	 -	 	
MPS	I2	 Female	 6.8	 0.3	 Yes	 GE,	OT	 VigantolÒ,	FolicilÒ,	Magnesium	BÒ	
MPS	I3	 Female	 15.3	 2.0	 Yes	 D	 	
MPS	I4	 Male	 3.9	 2.0	 No	 GE,	ACEI,	OT	 FolicilÒ,	MagnesonaÒ	
MPS	I5	 Female	 20.8	 6.0	 Yes	 AE,	D,	ACEI,	OT	 Fortini	powderÒ,	VigantolÒ	
MPS	II1	 MPS	II	 Male	 16.6	 12.3	 Yes	
-	 VigantolÒ	
MPS	II2	 Male	 9,0	 2.6	 Yes	 AE,	AP,	OT	 	
MPS	II3	 Male	 18.4	 -	 Yes	 ACEI	 	
MPS	II4	 Male	 11.3	 2.3	 Yes	 AP,	GE,	OT	 	
MPS	III1	
MPS	III	
Female	 23.8	 3.0	 No	 AE,	HP	 CentrumÒ	
MPS	III2	 Female	 10.8	 2.5	 No	 AE,	AP	 	
MPS	III3	 Male	 10.1	 3.5	 No	 AP	 	
MPS	III4	 Female	 9.4	 7.9	 No	 MF	 	
MPS	III5	 Female	 12.9	 1.5	 No	 AP,	HP	 	
MPS	III6	 Male	 12.8	 7.0	 No	 MF,	AP	 	
MPS	III7	 Male	 25.4	 1.1	 No	 AE	 Fresubin	proteinÒ	
MPS	III8	 Male	 6.0	 2.0	 No	 AP	 	
MPS	III9	 Male	 26.3	 2.3	 No	 AE,	D,	ACEI	 	
MPS	IV1	 MPS	IV	 Female	 16.1	 11.0	 Yes	 HP,	GE,	OT	 	MPS	IV2	 Female	 12.0	 5.0	 Yes	 -	 	
MPS	IV3	 Female	 32.7	 0.5	 No	 AN,	D	 R73Ò,	CebiolonÒ	
MPS	VI1	
MPS	VI	
Male	 7.7	 1.0	 Yes	 -	 	
MPS	VI2	 Female	 17.3	 3.0	 Yes	 -	 	
MPS	VI3	 Male	 14.4	 5.0	 Yes	 D,	ACEI	 	
MPS	VI4	 Female	 26.0	 -	 Yes	 AE	 VigantolÒ	
MPS	VI5	 Male	 23.7	 3.0	 Yes	 AE,	ACEI	 	
MPS	VI6	 Male	 21.7	 1.1	 Yes	 AE,	AN,	OT	 VigantolÒ	
MPS	VI7	 Female	 21.2	 2.0	 Yes	 ACEI	 DecalcitÒ,	Ferrum	haussmanÒ	
MPS	VI8	 Female	 7.4	 2.0	 Yes	 ACEI,	OT	 	
MPS	VI9	 Male	 14.4	 1.3	 Yes	 ACEI	 	
MPS	VII1	 MPS	VII	 Male	 9.9	 0.1	 No	 AE	 	
Table	S1.	Characterization	of	sample:	general	description	per	individual	[*	age	at	assessment;	AE=antiepileptic	drugs,	
MF=methylphenidate;	AP=antipsychotic	drugs;	HP=hypnotic	drugs	(melatonine,	HalcionÒ,	antiH1);	AN=analgesic	drugs;	
GE=gastrointestinal	drugs;	D=diuretics;	ACEI=angiotensin	converting	enzyme	inhibitor(ACE	inhibitors);	OT=other]	
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Age	group	 Male	 Female	 Total	
0-4	years	 2	 (11.8%)	 0	 (0.0%)	 2		
5-11	years	 6	 (35.3%)	 5	 (35.7%)	 11	
12-18	years	 5	 (29.4%)	 4	 (28.6%)	 9	
>18	years	 4	 (23.5%)	 5	 (35.7%)	 9	
Total	 17	 (54.8%)	 14	 (45.2%)	 31	
Table	S2.	Characterization	of	sample:	distribution	per	gender	and	age	group.			
Age	group	 n	 Mean	 SD	 Median	 Minimum	 Maximum	
MPS	I	 5	 2.2	 2.3	 2.0	 0.3	 6.0	
MPS	II	 3	 5.7	 5.7	 2.6	 2.3	 12.3	
MPS	III	 9	 3.4	 2.4	 2.5	 1.1	 7.9	
MPS	IV	 3	 5.5	 5.3	 5.0	 0.5	 11.0	
MPS	VI	 8	 2.3	 1.3	 2.0	 1.0	 5.0	
MPS	VII	 1	 0.1	 .	 0.1	 0.1	 0.1	
Total	 29	 3.2	 3.0	 2.3	 0.1	 12.3	
Table	S3.	Characterization	of	sample:	age	at	diagnosis	(in	years),	and	type	of	MPS	(n=29).	
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Nutrient	 Mean	 SD	 Median	 Minimum	 Maximum	
Energy	(Kcal)	 1762.2	 523.3	 1824.3	 840.3	 2577.8	
Energy	(Kcal/Kg/day)	 65.4	 29.5	 52.5	 20.2	 133.5	
Protein	(g)	 93.0	 28.5	 98.3	 31.4	 136.1	
Protein	(%	/	energy)	 21.7	 6.3	 21.1	 11.2	 37.8	
Fat	(g)	 60.3	 22.1	 60.2	 20.3	 115.6	
Fat	(%	/	energy)	 31.0	 6.9	 30.8	 17.4	 43.4	
Saturated	fatty	acids	(g)	 17.5	 8.2	 15.7	 6.0	 44.7	
Saturated	fatty	acids	(%)	 8.9	 2.6	 8.4	 5.1	 15.7	
Monounsaturated	fatty	acids	(g)	 24.3	 9.3	 24.4	 8.3	 41.9	
Monounsaturated	fatty	acids	(%)	 12.6	 3.8	 12.5	 5.1	 22.7	
Polyunsaturated	fatty	acids	(g)	 9.0	 4.8	 7.7	 3.9	 21.9	
Polyunsaturated	fatty	acids	(%)	 4.6	 2.0	 4.0	 1.9	 9.7	
Trans	fatty	acids	(g)	 0.6	 0.4	 0.5	 0.0	 1.6	
Cholesterol	(mg)	 271.3	 173.6	 259.4	 44.8	 911.7	
Total	carbohydrates	(g)	 210.8	 83.1	 208.5	 61.2	 395.3	
Total	carbohydrates	(%)	 44.1	 9.0	 42.5	 21.7	 66.1	
Mono	+	disaccharides	(g)	 94.0	 54.3	 85.3	 13.5	 259.9	
Fiber	(g)	 14.9	 8.3	 14.1	 1.9	 42.9	
Table	S4.	Recent	nutritional	intake	of	31	patients:	energy	and	macronutrients.		
Nutrient	 Mean	 SD	 Median	 Minimum	 Maximum	
Vitamin	A	(μg)	 632.4	 464.0	 510.6	 0.7	 1732.8	
Carotene	(μg)	 2380.6	 2335.9	 1872.0	 27.5	 9711.5	
Vitamin	D	(μg)	 7.4	 7.6	 4.4	 0.3	 34.0	
Vitamin	B6	(mg)	 2.1	 1.6	 1.9	 0.5	 9.8	
Vitamin	B12	(μg)	 2.7	 1.2	 2.7	 0.5	 5.5	
Vitamin	C	(mg)	 110.2	 98.8	 79.3	 .0	 361.6	
Sodium	(g)	 2.8	 1.0	 2.8	 1.0	 6.3	
Potassium	(g)	 2.9	 1.2	 2.9	 1.1	 5.6	
Calcium	(mg)	 817.8	 493.3	 710.2	 58.6	 2484.8	
Phosphorus	(mg)	 1113.9	 433.0	 1041.0	 384.7	 2150.0	
Magnesium	(mg)	 213.8	 80.6	 203.9	 79.9	 383.6	
Iron	(mg)	 12.9	 17.4	 9.6	 2.7	 101.8	
Zinc	(mg)	 9.3	 4.1	 8.9	 2.7	 19.1	
Table	S5.	Recent	nutritional	intake	of	31	patients:	micronutrients.	
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Whole	milk	(250ml)	 22	 0	 0	 0	 1	 0	 2	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	
(88.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (4.0%)	 (0.0%)	 (8.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	Reduced-fat	milk	(250ml)	 3	 1	 1	 3	 2	 9	 5	 0	 1	 0	 0	 0	 0	 0	 0	 0	 0	 0	(12.0%)	 (4.0%)	 (4.0%)	 (12.0%)	 (8.0%)	 (36.0%)	 (20.0%)	 (0.0%)	 (4.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	Skimmed	milk	(250ml)	 23	 1	 0	 0	 0	 0	 0	 0	 0	 0	 1	 0	 0	 0	 0	 0	 0	 0	
(92.0%)	 (4.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (4.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	Yogurt	(one	with	125g)	 8	 0	 0	 4	 1	 9	 3	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	(32.0%)	 (0.0%)	 (0.0%)	 (16.0%)	 (4.0%)	 (36.0%)	 (12.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	
Cheese	(serving	30g)	 14	 2	 3	 4	 0	 1	 1	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	
(56.0%)	 (8.0%)	 (12.0%)	 (16.0%)	 (0.0%)	 (4.0%)	 (4.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	Dairy	desserts	(one	or	a	dessert	plate)	 14	 2	 7	 1	 0	 0	 0	 0	 0	 1	 0	 0	 0	 0	 0	 0	 0	 0	
(56.0%)	 (8.0%)	 (28.0%)	 (4.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (4.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	Ice-cream	(one	or	two	servings)	 13	 1	 0	 1	 0	 0	 0	 0	 0	 3	 0	 4	 1	 2	 0	 0	 0	 0	
(52.0%)	 (4.0%)	 (0.0%)	 (4.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (12.0%)	 (0.0%)	 (16.0%)	 (4.0%)	 (8.0%)	 (0.0%)	 (0.0%)	 (0.0%)	 (0.0%)	
Table	S6.	Usual	nutritional	intake:	distribution	of	frequency,	annual	and	seasonal	of	dairy	products.	
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Eggs	(one)	 9 10 4 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(36.0%) (40.0%) (16.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Chicken	(two	pieces	or	1/4	chicken)	 5 2 7 9 2 0 0 0 0 0 0 0 0 0 0 0 0 0 
(20.0%) (8.0%) (28.0%) (36.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Turkey,	rabbit	(one	portion	or	two	pieces)	 8 3 6 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(32.0%) (12.0%) (24.0%) (32.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Cow,	pork	and	goatling	meats	(120g)	 3 3 8 7 2 1 0 0 0 0 0 1 0 0 0 0 0 0 
(12.0%) (12.0%) (32.0%) (28.0%) (8.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Liver	(cow,	pork	or	chicken)		(120g)	 17 3 1 2 0 0 0 0 0 0 1 1 0 0 0 0 0 0 
(68.0%) (12.0%) (4.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Viscera	or	entrails	(100g)	 22 0 0 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 
(88.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Ham	and	sausage	(two	slices	or	three	slices)	 10 1 3 8 1 2 0 0 0 0 0 0 0 0 0 0 0 0 
(40.0%) (4.0%) (12.0%) (32.0%) (4.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Sausages	(3	medium)	 5 5 9 5 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
(20.0%) (20.0%) (36.0%) (20.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Bacon	(two	slices)	 24 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(96.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 
Table	S7.	Usual	nutritional	intake:	distribution	of	frequency,	annual	and	seasonal	of	egg,	meat	and	derivatives.	
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Fatty	fish	such	as	sardines,	mackerel,	horse	mackerel,	salmon,	etc.	(a	portion	of	125g)	 4 6 5 9 0 1 0 0 0 0 0 0 0 0 0 0 0 0 (16.0%) (24.0%) (20.0%) (36.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Lean	fish	such	as	hake,	pouting,	gold,	etc.	(a	portion	of	125g)	 4 4 7 8 2 0 0 0 0 0 0 0 0 0 0 0 0 0 
(16.0%) (16.0%) (28.0%) (32.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Cod	(an	average	set)	
7 6 9 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 
(28.0%) (24.0%) (36.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Canned	like	tuna,	sardines,	etc.	(a	can)	 11 7 2 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(44.0%) (28.0%) (8.0%) (20.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Squid	and	octopus	(a	portion	of	100g)	 17 5 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(68.0%) (20.0%) (8.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Shrimp,	clams,	mussels,	etc.	(a	dessert	plate)	 20 2 0 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 
(80.0%) (8.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 
Table	S8.	Usual	nutritional	intake:	distribution	of	frequency,	annual	and	seasonal	of	fish	and	other	sea	products.	
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Table	S9.	Usual	nutritional	intake:	distribution	of	frequency,	annual	and	seasonal	of	oils	and	other	fats	
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olive	oil	(one	tablespoon)	
6 3 7 4 1 4 0 0 0 0 0 0 0 0 0 0 0 0 
(24.0%) (12.0%) (28.0%) (16.0%) (4.0%) (16.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) sunflower	oils,	corn	or	soybean	(a	tablespoon)	 17 4 1 0 0 2 0 0 0 0 1 0 0 0 0 0 0 0 
(68.0%) (16.0%) (4.0%) (0.0%) (0.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) margarine	(one	teaspoon)	
13 1 5 5 0 0 0 0 0 0 0 1 0 0 0 0 0 0 
(52.0%) (4.0%) (20.0%) (20.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) butter	(one	teaspoon)	
9 0 4 4 3 4 0 0 0 0 0 1 0 0 0 0 0 0 
(36.0%) (0.0%) (16.0%) (16.0%) (12.0%) (16.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 
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White	bread	or	toast	(one	or	two	sandwiches)	 4 1 1 8 2 6 3 0 0 0 0 0 0 0 0 0 0 0 
(16.0%) (4.0%) (4.0%) (32.0%) (8.0%) (24.0%) (12.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Bread	(or	toast)	full,	rye	or	mixture	(one	or	two	sandwiches)	 15 2 1 2 1 2 1 0 0 1 0 0 0 0 0 0 0 0 
(60.0%) (8.0%) (4.0%) (8.0%) (4.0%) (8.0%) (4.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Corn	bread	or	corn	bread	of	Avintes	(a	slice	of	80g)	 20 2 1 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(80.0%) (8.0%) (4.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Muesli	cereal	flakes,	corn	flakes,	etc.	Chocapic	(a	cup	without	milk)	 10 2 4 3 1 4 0 0 0 1 0 0 0 0 0 0 0 0 
(40.0%) (8.0%) (16.0%) (12.0%) (4.0%) (16.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Rice	(middle	plate)	
3 0 1 14 5 1 1 0 0 0 0 0 0 0 0 0 0 0 
(12.0%) (0.0%) (4.0%) (56.0%) (20.0%) (4.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Pasta	like	spaghetti,	macaroni,	etc.	(half	plate)	 4 0 2 14 4 0 1 0 0 0 0 0 0 0 0 0 0 0 
(16.0%) (0.0%) (8.0%) (56.0%) (16.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Home	fries	(half	plate)	
11 5 3 5 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
(44.0%) (20.0%) (12.0%) (20.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Tortilla	chips	(small	package)	
13 6 2 2 1 0 0 0 0 0 1 0 0 0 0 0 0 0 
(52.0%) (24.0%) (8.0%) (8.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Boiled	potatoes,	baked,	stewed	and	pureed	(two	medium	potatoes)	 1 1 5 15 2 0 1 0 0 0 0 0 0 0 0 0 0 0 (4.0%) (4.0%) (20.0%) (60.0%) (8.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 
Table	S10.	Usual	nutritional	intake:	distribution	of	frequency,	annual	and	seasonal	of	bread,	cereals	and	similar.	
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Maria	type	crackers,	water	and	salt	or	full	(three	wafers)	 5 2 10 2 1 1 3 0 0 0 1 0 0 0 0 0 0 0 
(20.0%) (8.0%) (40.0%) (8.0%) (4.0%) (4.0%) (12.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Other	crackers	or	biscuits	(three	wafers)	 12 3 5 2 0 1 1 0 0 0 1 0 0 0 0 0 0 0 
(48.0%) (12.0%) (20.0%) (8.0%) (0.0%) (4.0%) (4.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Croissant,	pastries,	bolycao,	donuts	and	homemade	cakes	(one	or	a	slice)	 10 5 2 4 1 2 0 0 0 0 1 0 0 0 0 0 0 0 (40.0%) (20.0%) (8.0%) (16.0%) (4.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Chocolate	in	tablet	or	powder	(three	squares	or	one	tablespoon)	 13 3 2 2 1 1 1 0 0 0 1 1 0 0 0 0 0 0 (52.0%) (12.0%) (8.0%) (8.0%) (4.0%) (4.0%) (4.0%) (0.0%) (0.0%) (0.0%) (4.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Chocolate	snacks	such	as	Mars,	Twix,	Kit	Kat,	etc.	(one)	 15 3 4 2 0 0 0 0 0 0 1 0 0 0 0 0 0 0 
(60.0%) (12.0%) (16.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Marmalade,	jam,	jelly,	honey	(one	tablespoon)	 16 3 1 3 0 0 0 0 0 1 1 0 0 0 0 0 0 0 
(64.0%) (12.0%) (4.0%) (12.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Sugar	(one	dessert	spoon	or	a	package)	 12 1 5 2 0 4 0 0 0 0 1 0 0 0 0 0 0 0 
(48.0%) (4.0%) (20.0%) (8.0%) (0.0%) (16.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 
Table	S11.	Usual	nutritional	intake:	distribution	of	frequency,	annual	and	seasonal	of	sweets	and	pastry.	
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White	cabbage	and	savoy	cabbage	(half	cup)	 14 2 3 4 0 0 2 0 0 0 0 0 0 0 0 0 0 0 
(56.0%) (8.0%) (12.0%) (16.0%) (0.0%) (0.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Cabbage	bunch	and	“tronchuda”	(half	cup)	 17 2 3 2 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
(68.0%) (8.0%) (12.0%) (8.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Kale	(half	cup)	
15 5 4 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
(60.0%) (20.0%) (16.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Broccoli	(half	cup)	
12 5 5 2 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
(48.0%) (20.0%) (20.0%) (8.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Cauliflower	and	Brussels	sprout	(half	cup)	 15 3 3 1 1 0 1 0 0 0 0 1 0 0 0 0 0 0 
(60.0%) (12.0%) (12.0%) (4.0%) (4.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Greens,	turnip	greens	and	spinach	(half	cup)	 18 1 1 3 0 0 1 0 0 0 0 1 0 0 0 0 0 0 
(72.0%) (4.0%) (4.0%) (12.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Green	beans	(half	cup)	
13 3 3 4 0 0 1 0 0 0 0 1 0 0 0 0 0 0 
(52.0%) (12.0%) (12.0%) (16.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Lettuce	and	watercress	(half	cup)	
15 1 1 4 0 2 1 0 0 0 0 1 0 0 0 0 0 0 
(60.0%) (4.0%) (4.0%) (16.0%) (0.0%) (8.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Onion	(half,	an	average)	
13 2 2 4 1 1 1 0 0 0 0 0 0 1 0 0 0 0 
(52.0%) (8.0%) (8.0%) (16.0%) (4.0%) (4.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) 
Table	S12.	Usual	nutritional	intake:	distribution	of	frequency,	annual	and	seasonal	of	vegetables.	
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Carrot	(average)	
7 3 4 7 2 1 1 0 0 0 0 0 0 0 0 0 0 0 
(28.0%) (12.0%) (16.0%) (28.0%) (8.0%) (4.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Turnip	(an	average)	
15 2 2 4 1 0 0 0 0 0 0 1 0 0 0 0 0 0 
(60.0%) (8.0%) (8.0%) (16.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Fresh	tomatoes	(three	slices)	
14 3 0 4 0 1 0 1 0 0 0 0 2 0 0 0 0 0 
(56.0%) (12.0%) (0.0%) (16.0%) (0.0%) (4.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Pepper	(six	slices)	
23 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
(92.0%) (0.0%) (0.0%) (4.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Cucumber	(1/4	medium)	
18 1 0 1 0 0 0 0 0 1 0 0 4 0 0 0 0 0 
(72.0%) (4.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (16.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Beans	and	chickpeas	(a	cup	or	half	plate)	 11 3 8 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(44.0%) (12.0%) (32.0%) (12.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Peas	and	fava	beans	(half	cup	or	1/4	dish)	 11 5 5 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(44.0%) (20.0%) (20.0%) (16.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 
Table	S13.	Usual	nutritional	intake:	distribution	of	frequency,	annual	and	seasonal	of	vegetables	(cont.).	
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Apple	and	pear	(an	average)	
7 3 4 4 1 3 1 0 0 0 0 1 0 1 0 0 0 0 
(28.0%) (12.0%) (16.0%) (16.0%) (4.0%) (12.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) Orange	and	tangerines	(an	average,	two	medium)	 15 3 2 2 0 2 0 0 0 0 0 1 0 0 0 0 0 0 
(60.0%) (12.0%) (8.0%) (8.0%) (0.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Banana	(average)	
12 2 5 5 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
(48.0%) (8.0%) (20.0%) (20.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Kiwi	(average)	
15 2 4 2 0 0 0 0 0 2 0 0 0 0 0 0 0 0 
(60.0%) (8.0%) (16.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Strawberries	(one	cup)	
12 0 2 2 0 0 0 0 0 1 0 4 2 1 0 0 0 0 
(50.0%) (0.0%) (8.3%) (8.3%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.2%) (0.0%) (16.7%) (8.3%) (4.2%) (0.0%) (0.0%) (0.0%) (0.0%) Cherries	(a	cup)	
15 0 1 0 0 0 0 0 0 1 0 3 3 1 0 0 0 0 
(62.5%) (0.0%) (4.2%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.2%) (0.0%) (12.5%) (12.5%) (4.2%) (0.0%) (0.0%) (0.0%) (0.0%) Plum	(three	average)	
11 1 1 2 0 0 0 0 0 2 0 4 1 1 0 0 0 0 
(47.8%) (4.3%) (4.3%) (8.7%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (8.7%) (0.0%) (17.4%) (4.3%) (4.3%) (0.0%) (0.0%) (0.0%) (0.0%) Melon	and	watermelon	(an	average	slice)	 12 0 1 3 0 0 0 0 0 1 0 5 1 0 1 0 0 0 
(50.0%) (0.0%) (4.2%) (12.5%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.2%) (0.0%) (20.8%) (4.2%) (0.0%) (4.2%) (0.0%) (0.0%) (0.0%) 
Table	S14.	Usual	nutritional	intake:	distribution	of	frequency,	annual	and	seasonal	of	fruits.	
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Persimmon	(average)	
16 1 1 0 0 0 0 0 0 2 1 3 0 0 0 0 0 0 
(66.7%) (4.2%) (4.2%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (8.3%) (4.2%) (12.5%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Fresh	figs,	loquats	and	apricots	(average	three)	 19 1 1 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 
(79.2%) (4.2%) (4.2%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.2%) (4.2%) (4.2%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Fresh	grapes	(an	average	bunch)	 13 4 3 1 0 0 0 0 0 1 0 2 1 0 0 0 0 0 
(52.0%) (16.0%) (12.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (8.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Canned	fruits	such	as	peach	and	pineapple	(two	halves	or	slices)	 18 2 3 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 (72.0%) (8.0%) (12.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Almonds,	hazelnuts,	walnuts,	peanuts,	pistachio,	etc.	(half	cup	peeled)	 20 4 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 (80.0%) (16.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Olives	(six	units)	
19 5 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(76.0%) (20.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 
Table	S15.	Usual	nutritional	intake:	distribution	of	frequency,	annual	and	seasonal	of	fruits	(cont.)	
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Wine	(a	glass	of	250ml)	 25 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(100.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Beer	(a	bottle	or	a	can)	 25 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(100.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) White	spirits	such	as	whiskey,	rum,	brandy,	etc.	(one	40	ml	cup)	
25 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(100.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 
Coke,	pepsi	or	other	(a	bottle	or	a	can)	 19 1 0 3 0 1 1 0 0 0 0 0 0 0 0 0 0 0 (76.0%) (4.0%) (0.0%) (12.0%) (0.0%) (4.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Ice	tea	(a	bottle	or	a	can)	 9 3 3 6 1 0 3 0 0 0 0 0 0 0 0 0 0 0 
(36.0%) (12.0%) (12.0%) (24.0%) (4.0%) (0.0%) (12.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Other	soft	drinks,	fruit	juices	or	nectars	packed	(a	bottle	or	a	cup)	
6 7 3 1 1 5 1 1 0 0 0 0 0 0 0 0 0 0 
(24.0%) (28.0%) (12.0%) (4.0%) (4.0%) (20.0%) (4.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 
Coffee,	including	added	to	other	beverages	(coffee	cup)	 20 2 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 (80.0%) (8.0%) (4.0%) (4.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Black	and	green	tea	(one	cup)	 23 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 (92.0%) (4.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 
Table	S16.	Usual	nutritional	intake:	distribution	of	frequency,	annual	and	seasonal	of	drinks.	
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Croquettes,	patties,	codfish	balls,	etc.	(three	units)	 12 6 4 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
(48.0%) (24.0%) (16.0%) (8.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Mayonnaise	(one	tablespoon)	 19 2 3 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(76.0%) (8.0%) (12.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Tomato	sauce,	ketchup	(one	tablespoon)	 19 3 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(76.0%) (12.0%) (8.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Pizza	(half	average	pizza)	
13 10 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(52.0%) (40.0%) (8.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Hamburger	(average)	
10 11 3 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
(40.0%) (44.0%) (12.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Vegetable	soup	(a	dish)	
2 2 0 6 4 5 5 0 1 0 0 0 0 0 0 0 0 0 
(8.0%) (8.0%) (0.0%) (24.0%) (16.0%) (20.0%) (20.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Soup	(a	dish)	
17 5 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(68.0%) (20.0%) (8.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 
Table	S17.	Usual	nutritional	intake:	distribution	of	frequency,	annual	and	seasonal	of	other	foods.	
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Cerelac	baby	food	(a	dish)	 24 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
(96.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Chia	seeds	(a		dessert	spoon)	 24 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
(96.0%) (0.0%) (0.0%) (0.0%) (0.0%) (4.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) “Alheira”	(one	medium)	 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(0.0%) (100.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Candies	(one)	
0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(0.0%) (0.0%) (100.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Lupins	(a	small	dish)	
0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(0.0%) (0.0%) (0.0%) (100.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Sweet	potatoes	(an	average)	 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
(0.0%) (0.0%) (0.0%) (100.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Soymilk	(a	cup	of	200	ml)	 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
(0.0%) (0.0%) (50.0%) (0.0%) (50.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Soy	dessert	(a	unit	of	120g)	 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
(0.0%) (0.0%) (0.0%) (0.0%) (100.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) Soybean	cakes	and	biscuits	(biscuits	3	to	4)	 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 (0.0%) (0.0%) (0.0%) (0.0%) (100.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) (0.0%) 
Table	S18.	Usual	nutritional	intake:	distribution	of	frequency,	annual	and	seasonal	of	other	foods	mentioned	by	individuals.	
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Nutrient	 Mean	 SD	 Median	 Minimum	 Maximum	
Energy	(Kcal)	 1974.6	 742.2	 1889.6	 395.2	 3910.1	
Energy	(Kcal/Kg/day)	 77.5	 38.7	 72.6	 13.4	 179.1	
Protein	(g)	 97.8	 31.8	 96.9	 23.5	 160.6	
Protein	(%	/	energy)	 20.5	 3.7	 20.2	 14.2	 28.7	
Fat	(g)		 69.9	 24.5	 74.4	 14.1	 120.4	
Fat	(%	/	energy)	 32.4	 5.4	 32.1	 21.9	 46.7	
Saturated	fat	(g)	 22.7	 9.1	 21.0	 3.3	 36.5	
Monounsaturated	fat	(g)	 29.0	 10.9	 28.8	 6.8	 57.2	
Polyunsaturated	fat	(g)		 12.2	 4.2	 12.0	 2.5	 20.2	
Omega	3	fatty	acid	(g)	 1.5	 0.6	 1.3	 0.4	 3.4	
Omega	6	fatty	acid	(g)		 8.8	 3.6	 8.3	 1.8	 17.6	
Cholesterol	(g)		 316.6	 144.3	 301.1	 60.1	 728.6	
Carbohydrate	(g)	 245.4	 124.2	 226.6	 44.6	 626.6	
Carbohydrate	(%	/	energy)	 48.3	 6.9	 46.7	 38.9	 64.1	
Sugars	(g)		 109.9	 75.5	 100.3	 11.3	 364.4	
Dietary	fiber	(g)		 20.6	 15.8	 16.1	 5.1	 76.2	
Table	S19.	Usual	nutritional	intake	in	25	MPS	patients:	energy	and	macronutrients.	
	
N=25	
									Low	 				Adequate	 				High	 	 	
n	 %	 n	 %	 n	 %	 Mean	 SD	
Energy	 14	 56.0%	 4	 16.0%	 7	 28.0%	 102.5	 59.3	Table	S20.	Usual	nutritional	intake	in	25	MPS	patients:	patients	consuming	lower,	adequate	and	higher	energy	than	
recommendations.	Mean	(and	SD)	are	presented	in	%	of	EAR.		
	
0-4	y	 5-11	y	 12-18	y	 >18	y	
n	 %	 n	 %	 n	 %	 n	 %	
Energy	
(%	of	EAR)	
	
Low	 0	 0.0%	 4	 44.4%	 6	 66.7%	 4	 80.0%	Adequate		 1	 50.0%	 1	 11.1%	 2	 22.2%	 0	 0.0%	High	 1	 50.0%	 4	 44.4%	 1	 11.1%	 1	 20.0%	Table	S21.	Usual	nutritional	intake	in	25	MPS	patients:	patients	consuming	lower,	adequate	and	higher	energy	than	
recommendations,	according	to	age	group.		
	
0-4	y	 5-11	y	 12-18	y	 >18	y	
Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	
Energy	(%	of	EAR)	 118.4	 37.1	 115.4	 55.7	 84.9	 39.5	 104.5	 101.0	
Table	S22.	Usual	nutritional	intake:	percentage	adequacy	of	energy	intake,	according	to	age	group.	
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MPS	I	 MPS	II	 MPS	III	 MPS	IV	 MPS	VI	 MPS	VII	
n	 %	 n	 %	 n	 %	 n	 %	 n	 %	 n	 %	
Energy	
(%	of	EAR)	
	
Low		 1	 20.0%	 1	 25.0%	 2	 50.0%	 2	 100%	 7	 77.8%	 1	 100%	Adequate		2	 40.0%	 1	 25.0%	 0	 0.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	High		 2	 40.0%	 2	 50.0%	 2	 50.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	
	Table	S23.	Usual	nutritional	intake	in	25	MPS	patients:	patients	consuming	lower,	adequate	and	higher	energy	than	
recommendations,	according	to	MPS	type.	
	
	
	
MPS	I	 MPS	II	 MPS	III	 MPS	IV	 MPS	VI	 MPS	VII	
Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	a	
Energy	(%	of	EAR)	 135.9	 85.8	 124.1	 45.8	 118.7	 84.8	 70.5	 20.2	 76.4	 34.4	 83.2	 .	
Table	S24.	Usual	nutritional	intake:	percentage	adequacy	of	energy	intake,	according	to	MPS	type	(a	n=1).				
									
Table	S25.	Usual	nutritional	intake	in	25	MPS	patients:	patients	consuming	lower,	adequate	and	higher	amounts	of	macronutrients	
than	recommendations.	Mean	(and	SD)	are	presented	in	%	of	EAR.	
Nutrient	
Low	 Adequate	 High	
Mean	 SD	
n	 %	 n	 %	 n	 %	
Protein	 8	 32.0%	 11	 44.0%	 6	 24.0%	 102.6	 27.3	
Carbohydrate	 16	 64.0%	 7	 28.0%	 2	 8.0%	 87.9	 12.6	
Fiber	 19	 76.0%	 3	 12.0%	 3	 12.0%	 74.7	 61.6	
Fat	 3	 12.0%	 13	 52.0%	 9	 36.0%	 110.6	 20.0	
Omega	3	fatty	acid	 18	 72.0%	 6	 24.0%	 1	 4.0%	 77.7	 25.4	
Omega	6	fatty	acid	 23	 92.0%	 2	 8.0%	 0	 0.0%	 55.4	 17.4	
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Nutrient	
0-4	y	 5-11	y	 12-18	y	 >18	y	
n	 %	 n	 %	 n	 %	 n	 %	
Protein	
Low	 0	 0.0%	 5	 55.6%	 1	 11.1%	 2	 40.0%	Adequate	 1	 50.0%	 4	 44.4%	 5	 55.6%	 1	 20.0%	High	 1	 50.0%	 0	 0.0%	 3	 33.3%	 2	 40.0%	
Carbohydrate	
Low	 2	 100.0%	 2	 22.2%	 7	 77.8%	 5	 100.0%	Adequate	 0	 0.0%	 5	 55.6%	 2	 22.2%	 0	 0.0%	High	 0	 0.0%	 2	 22.2%	 0	 0.0%	 0	 0.0%	
Fat	
Low	 0	 0.0%	 2	 22.2%	 0	 0.0%	 1	 20.0%	Adequate	 2	 100.0%	 5	 55.6%	 5	 55.6%	 1	 20.0%	High	 0	 0.0%	 2	 22.2%	 4	 44.4%	 3	 60.0%	
Omega	3	fatty	
acid	
Low	 2	 100.0%	 7	 77.8%	 6	 66.7%	 3	 60.0%	Adequate	 0	 0.0%	 2	 22.2%	 3	 33.3%	 1	 20.0%	High	 0	 0.0%	 0	 0.0%	 0	 0.0%	 1	 20.0%	
Omega	6	fatty	
acid	
Low	 2	 100.0%	 9	 100.0%	 8	 88.9%	 4	 80.0%	Adequate	 0	 0.0%	 0	 0.0%	 1	 11.1%	 1	 20.0%	High	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	
Table	S26.	Usual	nutritional	intake	in	25	MPS	patients:	patients	consuming	lower,	adequate	and	higher	amounts	of	macronutrients	
than	recommendations,	according	to	age	group.			
Nutrient	(%	of	EAR)	 0-4	y	 5-11	y	 12-18	y	 >18	y	
Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	
Protein	 127.5	 24.7	 89.1	 13.6	 102.8	 12.0	 116.7	 51.8	
Carbohydrate	 78.2	 10.3	 97.2	 13.2	 85.5	 10.1	 79.6	 5.4	
Fat	 106.7	 0.0	 100.7	 16.7	 113.4	 12.8	 125.0	 32.0	
Omega	3	fatty	acid	 70.5	 11.1	 68.4	 21.3	 80.1	 18.4	 93.0	 41.8	
Omega	6	fatty	acid	 39.5	 5.8	 50.2	 15.8	 60.0	 18.8	 62.6	 17.1	
Table	S27.	Usual	nutritional	intake:	percentage	adequacy	of	macronutrients	intake,	according	to	age	group.	
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Nutrient	 MPS	I	 MPS	II	 MPS	III	 MPS	IV	 MPS	VI	 MPS	VII	
n	 %	 n	 %	 n	 %	 n	 %	 n	 %	 n	 %	
Protein	 Low	 0	 0.0%	 1	 25.0%	 1	 25.0%	 1	 50.0%	 5	 55.6%	 0	 0.0%	Adequate	 3	 60.0%	 2	 50.0%	 1	 25.0%	 1	 50.0%	 3	 33.3%	 1	 100%	High	 2	 40.0%	 1	 25.0%	 2	 50.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	
Carbohydrate	 Low	 5	 100%	 2	 50.0%	 2	 50.0%	 1	 50.0%	 6	 66.7%	 0	 0.0%	Adequate	 0	 0.0%	 1	 25.0%	 1	 25.0%	 1	 50.0%	 3	 33.3%	 1	 100%	High	 0	 0.0%	 1	 25.0%	 1	 25.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	
Fat	 Low	 1	 20.0%	 1	 25.0%	 1	 25.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	Adequate	 2	 40.0%	 3	 75.0%	 2	 50.0%	 1	 50.0%	 4	 44.4%	 1	 100%	High	 2	 40.0%	 0	 0.0%	 1	 25.0%	 1	 50.0%	 5	 55.6%	 0	 0.0%	
Omega	3	fatty	
acid	
Low	 3	 60.0%	 3	 75.0%	 3	 75.0%	 1	 50.0%	 7	 77.8%	 1	 100%	Adequate	 1	 20.0%	 1	 25.0%	 1	 25.0%	 1	 50.0%	 2	 22.2%	 0	 0.0%	High	 1	 20.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	
Omega	6	fatty	
acid	
Low	 5	 100%	 4	 100%	 4	 100%	 2	 100%	 7	 77.8%	 1	 100%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 2	 22.2%	 0	 0.0%	High	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	
Table	S28.	Usual	nutritional	intake	in	25	MPS	patients:	patients	consuming	lower,	adequate	and	higher	amounts	of	macronutrients	
than	recommendations,	according	to	MPS	type.	
	
	
Nutrient	(%	of	EAR)	 MPS	I	 MPS	II	 MPS	III	 MPS	IV	 MPS	VI	 MPS	VII	
Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SDa	
Protein		 130.4	 43.4	 100.3	 14.4	 100.0	 22.7	 92.8	 24.4	 91.9	 17.3	 100.0	 .	
Carbohydrate		 81.8	 7.3	 96.8	 16.1	 90.5	 17.4	 92.7	 20.6	 84.2	 9.4	 96.4	 .	
Fat		 108.5	 14.9	 97.2	 16.4	 105.8	 16.6	 108.9	 20.4	 122.2	 23.3	 93.3	 .	
Omega	3	fatty	acid		 94.9	 40.4	 80.3	 20.3	 69.4	 22.8	 78.3	 28.0	 72.1	 19.9	 63.8	 .	
Omega	6	fatty	acid		 48.1	 9.6	 48.6	 10.7	 47.44	 9.4	 52.6	 14.7	 63.2	 21.9	 85.7	 	
Table	S29.	Usual	nutritional	intake:	percentage	adequacy	of	macronutrients	intake,	according	to	MPS	type	(a	n=1).	
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Nutrient	 Mean	 SD	 Median	 Minimum	 Maximum	
Vitamin	A	(total.	RE)	 2571.8	 2564.0	 1670.5	 122.6	 11378.3	
Vitamin	B1	(mg)		 1.6	 0.7	 1.5	 0.3	 3.9	
Vitamin	B2	(mg)		 2.2	 1.2	 2.2	 0.3	 5.7	
Vitamin	B3	(mg)		 23.3	 8.3	 22.9	 6.4	 50.7	
Vitamin	B6	(mg)		 2.3	 1.1	 2.1	 0.7	 5.8	
Biotin	(μg)	 10.8	 9.6	 8.0	 0.0	 45.8	
Vitamin	B12	(μg)		 12.2	 8.8	 9.9	 2.8	 41.1	
Folate	(μg)	 314.1	 201.7	 296.3	 47.9	 908.4	
Pantothenic	acid	(mg)	 4.8	 2.3	 4.7	 1.0	 10.5	
Vitamin	C	(mg)		 124.9	 125.2	 86.5	 22.0	 605.3	
Vitamin	D	(μg)			 4.7	 2.3	 4.8	 1.4	 10.1	
Vitamin	E	(mg)		 8.1	 4.0	 6.9	 2.1	 17.6	
Vitamin	K	(μg)			 16.7	 17.1	 11.5	 0.0	 79.3	
Table	S30.	Usual	nutritional	intake	in	25	MPS	patients:	vitamins	(RE=retinol	equivalents).	
	
	
Nutrient	
Low	 Adequate	 High	
Mean	 SD	
n	 %	 n	 %	 n	 %	
Vitamin	A	(total)	 2	 8.0%	 0	 0.0%	 23	 92.0%	 646.2	 833.3	
Vitamin	B1	 2	 8.0%	 1	 4.0%	 22	 88.0%	 227.1	 123.4	
Vitamin	B2	 2	 8.0%	 0	 0.0%	 23	 92.0%	 305.5	 201.7	
Vitamin	B3	 1	 4.0%	 1	 4.0%	 23	 92.0%	 264.1	 123.0	
Vitamin	B6	 2	 8.0%	 0	 0.0%	 23	 92.0%	 316.2	 242.8	
Biotin	 20	 80.0%	 2	 8.0%	 3	 12.0%	 60.6	 59.2	
Vitamin	B12		 0	 0.0%	 0	 0.0%	 25	 100.0%	 825.2	 624.0	
Folate	 9	 36.0%	 4	 16.0%	 12	 48.0%	 139.2	 142.9	
Pantothenic	acid	 9	 36.0%	 4	 16.0%	 12	 48.0%	 127.9	 86.9	
Vitamin	C		 4	 16.0%	 5	 20.0%	 16	 64.0%	 441.7	 914.9	
Vitamin	D			 24	 96.0%	 1	 4.0%	 0	 0.0%	 47.1	 22.6	
Vitamin	E		 13	 52.0%	 3	 12.0%	 9	 36.0%	 81.9	 45.0	
Vitamin	K			 24	 96.0%	 1	 4.0%	 0	 0.0%	 26.3	 28.2	
Table	S31.	Usual	nutritional	intake	in	25	MPS	patients:	patients	consuming	lower,	adequate	and	higher	amounts	of	vitamins	than	
recommendations.	Mean	(and	SD)	are	presented	in	%	of	EAR.		 	
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Nutrient	 0-4	y	 5-11	y	 12-18	y	 >18	y	
n	 %	 n	 %	 n	 %	 n	 %	
Vitamin	A	(total)	 Low	 0	 0.0%	 0	 0.0%	 1	 11.1%	 1	 20.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 2	 100.0%	 9	 100.0%	 8	 88.9%	 4	 80.0%	
Vitamin	B1	 Low	 0	 0.0%	 0	 0.0%	 1	 11.1%	 1	 20.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 1	 20.0%	High	 2	 100.0%	 9	 100.0%	 8	 88.9%	 3	 60.0%	
Vitamin	B2	 Low	 0	 0.0%	 0	 0.0%	 1	 11.1%	 1	 20.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 2	 100.0%	 9	 100.0%	 8	 88.9%	 4	 80.0%	
Vitamin	B3	 Low	 0	 0.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 1	 20.0%	High	 2	 100.0%	 9	 100.0%	 8	 88.9%	 4	 80.0%	
Vitamin	B6		 Low	 0	 0.0%	 0	 0.0%	 1	 11.1%	 1	 20.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 2	 100.0%	 9	 100.0%	 8	 88.9%	 4	 80.0%	
Biotin	 Low	 0	 0.0%	 8	 88.9%	 8	 88.9%	 4	 80.0%	Adequate	 0	 0.0%	 1	 11.1%	 1	 11.1%	 0	 0.0%	High	 2	 100.0%	 0	 0.0%	 0	 0.0%	 1	 20.0%	
Vitamin	B12		 Low	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 2	 100.0%	 9	 100.0%	 9	 100.0%	 5	 100.0%	
Folate	 Low	 0	 0.0%	 2	 22.2%	 5	 55.6%	 2	 40.0%	Adequate	 1	 50.0%	 1	 11.1%	 1	 11.1%	 1	 20.0%	High	 1	 50.0%	 6	 66.7%	 3	 33.3%	 2	 40.0%	
Pantothenic	acid	
		 Low	 0	 0.0%	 3	 33.3%	 4	 44.4%	 2	 40.0%	Adequate	 0	 0.0%	 0	 0.0%	 3	 33.3%	 1	 20.0%	High	 2	 100.0%	 6	 66.7%	 2	 22.2%	 2	 40.0%	
Vitamin	C		 Low	 0	 0.0%	 0	 0.0%	 2	 22.2%	 2	 40.0%	Adequate	 0	 0.0%	 1	 11.1%	 3	 33.3%	 1	 20.0%	High	 2	 100.0%	 8	 88.9%	 4	 44.4%	 2	 40.0%	
Vitamin	D		 Low	 2	 100.0%	 9	 100.0%	 8	 88.9%	 5	 100.0%	Adequate	 0	 0.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	High	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	
Vitamin	E		 Low	 1	 50.0%	 3	 33.3%	 5	 55.6%	 4	 80.0%	Adequate	 1	 50.0%	 1	 11.1%	 1	 11.1%	 0	 0.0%	High	 0	 0.0%	 5	 55.6%	 3	 33.3%	 1	 20.0%	
Vitamin	K		 Low	 1	 50.0%	 9	 100.0%	 9	 100.0%	 5	 100.0%	Adequate	 1	 50.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	
Table	S32.	Usual	nutritional	intake	in	25	MPS	patients:	patients	consuming	lower,	adequate	and	higher	amounts	of	vitamins	than	
recommendations,	according	to	age	group.	
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Nutrient	(%	of	EAR)	 0-4	y	 5-11	y	 12-18	y	 >18	y	
Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	
Vitamin	A	(total)	 647.0	 229.6	 641.6	 525.1	 363.0	 254.3	 1164.0	 1719.5	
Vitamin	B1		 259.4	 102.7	 268.9	 119.7	 198.6	 100.2	 190.3	 179.2	
Vitamin	B2		 629.4	 10.4	 315.4	 130.7	 233.9	 146.1	 287.2	 320.4	
Vitamin	B3		 280.0	 98.0	 282.0	 108.7	 256.2	 116.5	 240.0	 189.4	
Vitamin	B6		 345.0	 103.2	 339.8	 165.3	 262.9	 169.3	 358.4	 478.4	
Biotin		 203.8	 29.3	 58.6	 27.1	 37.4	 31.0	 48.5	 76.0	
Vitamin	B12		 1476.8	 815.6	 728.3	 391.3	 661.5	 479.1	 1033.9	 1027.8	
Folate		 106.2	 15.4	 146.0	 67.4	 99.3	 64.3	 212.1	 306.9	
Pantothenic	acid		 219.1	 12.6	 132.2	 66.8	 92.8	 42.1	 146.8	 159.2	
Vitamin	C		 213.9	 129.4	 346.8	 222.5	 272.7	 349.2	 1007.9	 2040.6	
Vitamin	D		 44.1	 26.3	 41.4	 17.2	 53.2	 27.2	 47.6	 25.9	
Vitamin	E	 67.1	 37.6	 101.1	 40.8	 82.3	 50.9	 52.7	 35.9	
Vitamin	K		 97.3	 12.1	 22.5	 12.2	 17.4	 15.8	 20.6	 34.2	
Table	S33.	Usual	nutritional	intake:	percentage	adequacy	of	vitamins	intake,	according	to	age	group.	
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Nutrient															 MPS	I	 MPS	II	 MPS	III	 MPS	IV	 MPS	VI	 MPS	VII	
n	 %	 n	 %	 n	 %	 n	 %	 n	 %	 n	 %	
Vitamin	A	
(total)	 Low	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 2	 22.2%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 5	 100%	 4	 100%	 4	 100%	 2	 100%	 7	 77.8%	 1	 100%	
Vitamin	B1	 Low	 0	 0.0%	 0	 0.0%	 1	 25.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	High	 5	 100%	 4	 100%	 3	 75.0%	 2	 100%	 7	 77.8%	 1	 100%	
Vitamin	B2	 Low	 0	 0.0%	 0	 0.0%	 1	 25.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 5	 100%	 4	 100%	 3	 75.0%	 2	 100%	 8	 88.9%	 1	 100%	
Vitamin	B3	 Low	 0	 0.0%	 0	 0.0%	 1	 25.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	High	 5	 100%	 4	 100%	 3	 75.0%	 2	 100%	 8	 88.9%	 1	 100%	
Vitamin	B6		 Low	 0	 0.0%	 0	 0.0%	 1	 25.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 5	 100%	 4	 100%	 3	 75.0%	 2	 100%	 8	 88.9%	 1	 100%	
Biotin	 Low	 2	 40.0%	 3	 75.0%	 3	 75.0%	 2	 100%	 9	 100%	 1	 100%	Adequate	 0	 0.0%	 1	 25.0%	 1	 25.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 3	 60.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	
Vitamin	B12		 Low	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 5	 100%	 4	 100%	 4	 100%	 2	 100%	 9	 100%	 1	 100%	
Folate	 Low	 1	 20.0%	 1	 25.0%	 1	 25.0%	 0	 0.0%	 6	 66.7%	 0	 0.0%	Adequate	 1	 20.0%	 0	 0.0%	 1	 25.0%	 1	 50.0%	 1	 11.1%	 0	 0.0%	High	 3	 60.0%	 3	 75.0%	 2	 50.0%	 1	 50.0%	 2	 22.2%	 1	 100%	
Pantothenic	
acid	
		
Low	 1	 20.0%	 1	 25.0%	 1	 25.0%	 1	 50.0%	 5	 55.6%	 0	 0.0%	Adequate	 1	 20.0%	 0	 0.0%	 0	 0.0%	 1	 50.0%	 2	 22.2%	 0	 0.0%	High	 3	 60.0%	 3	 75.0%	 3	 75.0%	 0	 0.0%	 2	 22.2%	 1	 100%	
Vitamin	C		 Low	 0	 0.0%	 1	 25.0%	 1	 25.0%	 0	 0.0%	 2	 22.2%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 5	 55.6%	 0	 0.0%	High	 5	 100%	 3	 75.0%	 3	 75.0%	 2	 100%	 2	 22.2%	 1	 100%	
Vitamin	D		 Low	 5	 100%	 3	 75.0%	 4	 100%	 2	 100%	 9	 100%	 1	 100%	Adequate	 0	 0.0%	 1	 25.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	
Vitamin	E		 Low	 3	 60.0%	 1	 25.0%	 2	 50.0%	 1	 50.0%	 6	 66.7%	 0	 0.0%	Adequate	 2	 40.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	High	 0	 0.0%	 3	 75.0%	 2	 50.0%	 1	 50.0%	 2	 22.2%	 1	 100%	
Vitamin	K		 Low	 4	 80.0%	 4	 100%	 4	 100%	 2	 100%	 9	 100%	 1	 100%	Adequate	 1	 20.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	
Table	S34.	Usual	nutritional	intake	in	25	MPS	patients:	patients	consuming	lower,	adequate	and	higher	amounts	of	vitamins	than	
recommendations,	according	to	MPS	type.	
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Nutrient	 MPS	I	 MPS	II	 MPS	III	 MPS	IV	 MPS	VI	 MPS	VII	
Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SDa	
Vitamin	A	
(total)	 1266.2	 1655.8	 993.7	 660.6	 407.8	 266.7	 383.5	 139.1	 315.9	 224.5	 608.1	 .	
Vitamin	B1		 284.9	 143.8	 299.0	 124.1	 251.3	 189.3	 185.7	 36.3	 155.6	 67.2	 280.0	 .	
Vitamin	B2		 511.9	 279.2	 347.8	 177.5	 305.3	 223.0	 196.7	 5.9	 193.0	 88.5	 336.3	 .	
Vitamin	B3		 327.2	 151.0	 377.2	 115.1	 262.7	 154.6	 235.8	 63.9	 187.6	 62.0	 247.6	 .	
Vitamin	B6		 478.3	 419.3	 466.0	 207.3	 327.6	 210.7	 260.3	 49.1	 170.3	 58.3	 287.5	 .	
Biotin	 130.7	 93.0	 56.6	 31.1	 63.1	 43.4	 21.4	 15.1	 28.8	 21.2	 79.6	 .	
Vitamin	B12	 1297.8	 961.0	 1026.1	 573.4	 827.7	 582.6	 683.4	 185.8	 560.5	 418.8	 316.0	 .	
Folate	 238.7	 291.8	 190.5	 77.3	 110.0	 70.0	 126.4	 26.0	 71.8	 33.8	 187.0	 .	
Pantothenic	
acid	 204.6	 142.4	 147.9	 56.2	 132.6	 100.5	 89.9	 15.4	 83.8	 32.2	 118.3	 .	
Vitamin	C	 1104.0	 1987.3	 579.7	 435.3	 330.3	 303.0	 326.6	 188.1	 114.2	 73.5	 202.6	 .	
Vitamin	D	 52.4	 25.4	 67.5	 33.1	 40.4	 24.1	 47.2	 17.0	 40.2	 14.3	 28.5	 .	
Vitamin	E	 66.7	 32.5	 126.5	 57.1	 79.5	 47.8	 92.8	 40.0	 65.3	 40.3	 117.1	 .	
Vitamin	K	 60.3	 44.3	 20.5	 13.8	 22.6	 19.5	 8.6	 3.9	 13.6	 12.2	 43.5	 .	
Table	S35.	Usual	nutritional	intake:	percentage	adequacy	of	vitamins	intake,	according	to	MPS	type	(a	n=1).	
		
Nutrient	 Mean	 SD	 Median	 Minimum	 Maximum	
Calcium	(mg)		 991.7	 605.4	 767.3	 86.5	 2622.7	
Copper	(mg)		 1.7	 0.9	 1.5	 0.4	 4.9	
Iron	(mg)		 14.8	 6.5	 14.8	 3.0	 38.1	
Magnesium	(mg)		 313.2	 146.2	 299.4	 67.1	 770.9	
Manganesium	(μg)	 3.2	 2.0	 2.9	 0.6	 9.8	
Phosphorus	(mg)		 1430.4	 577.0	 1436.4	 245.4	 2725.6	
Potassium	(mg)		 3556.2	 1803.1	 3304.9	 847.3	 9007.5	
Selenium	(μg)	 96.8	 39.3	 107.6	 21.2	 198.7	
Sodium	(from	food	+	added.	mg)			 3521.0	 1358.4	 3469.0	 1126.6	 7650.0	
Zinc	(mg)		 12.1	 4.8	 12.1	 2.3	 24.9	
Table	S36.	Usual	nutritional	intake	in	25	MPS	patients:	minerals	and	oligoelements.		 	
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Nutrient	
Low	 Adequate	 High	 Mean	 SD	
n	 %	 n	 %	 n	 %	 	 	
Calcium	 11	 44.0%	 4	 16.0%	 10	 40.0%	 114.6	 88.6	
Copper	 2	 8.0%	 0	 0.0%	 23	 92.0%	 335.4	 225.6	
Iron	 2	 8.0%	 1	 4.0%	 22	 88.0%	 266.3	 146.4	
Magnesium	 7	 28.0%	 5	 20.0%	 13	 52.0%	 179.9	 180.4	
Manganesium	 25	 100.0%	 0	 0.0%	 0	 0.0%	 0.2	 0.1	
Phosphorus	 3	 12.0%	 0	 0.0%	 22	 88.0%	 220.2	 126.0	
Potassium	 17	 68.0%	 4	 16.0%	 4	 16.0%	 83.6	 49.8	
Selenium	 1	 4.0%	 1	 4.0%	 23	 92.0%	 288.6	 154.1	
Sodium	(from	food	plus	added)			 2	 8.0%	 0	 0.0%	 23	 92.0%	 253.5	 98.4	
Zinc	 2	 8.0%	 2	 8.0%	 21	 84.0%	 212.0	 140.6	
Table	S37.	Usual	nutritional	intake	in	25	MPS	patients:	patients	consuming	lower,	adequate	and	higher	amounts	of	minerals	and	
oligoelements	than	recommendations.	Mean	(and	SD)	are	presented	in	%	of	EAR.	
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Nutrient	 0-4	y	 5-11	y	 12-18	y	 >18	y	
n	 %	 n	 %	 n	 %	 n	 %	
Calcium	 Low	 0	 0.0%	 2	 22.2%	 6	 66.7%	 3	 60.0%	Adequate	 0	 0.0%	 3	 33.3%	 1	 11.1%	 0	 0.0%	High	 2	 100.0%	 4	 44.4%	 2	 22.2%	 2	 40.0%	
Copper	 Low	 0	 0.0%	 0	 0.0%	 1	 11.1%	 1	 20.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 2	 100.0%	 9	 100.0%	 8	 88.9%	 4	 80.0%	
Iron	 Low	 0	 0.0%	 0	 0.0%	 1	 11.1%	 1	 20.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 1	 20.0%	High	 2	 100.0%	 9	 100.0%	 8	 88.9%	 3	 60.0%	
Magnesium	 Low	 0	 0.0%	 2	 22.2%	 2	 22.2%	 3	 60.0%	Adequate	 0	 0.0%	 1	 11.1%	 4	 44.4%	 0	 0.0%	High	 2	 100.0%	 6	 66.7%	 3	 33.3%	 2	 40.0%	
Manganesium	 Low	 2	 100.0%	 9	 100.0%	 9	 100.0%	 5	 100.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	
Phosphorus	 Low	 0	 0.0%	 0	 0.0%	 2	 22.2%	 1	 20.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 2	 100.0%	 9	 100.0%	 7	 77.8%	 4	 80.0%	
Potassium	 Low	 0	 0.0%	 6	 66.7%	 8	 88.9%	 3	 60.0%	Adequate	 1	 50.0%	 2	 22.2%	 0	 0.0%	 1	 20.0%	High	 1	 50.0%	 1	 11.1%	 1	 11.1%	 1	 20.0%	
Selenium	 Low	 0	 0.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 1	 20.0%	High	 2	 100.0%	 9	 100.0%	 8	 88.9%	 4	 80.0%	
Sodium	(from	food	plus	added)	 Low	 0	 0.0%	 0	 0.0%	 1	 11.1%	 1	 20.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 2	 100.0%	 9	 100.0%	 8	 88.9%	 4	 80.0%	
Zinc	 Low	 0	 0.0%	 0	 0.0%	 1	 11.1%	 1	 20.0%	Adequate	 0	 0.0%	 1	 11.1%	 0	 0.0%	 1	 20.0%	High	 2	 100.0%	 8	 88.9%	 8	 88.9%	 3	 60.0%	
Table	S38.	Usual	nutritional	intake	in	25	MPS	patients:	patients	consuming	lower,	adequate	and	higher	amounts	of	minerals	and	
oligoelements	than	recommendations,	according	to	age	group.	
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Nutrient																
(%	of	EAR)	 0-4	y	 5-11	y	 12-18	y	 >18	y	Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	
Calcium		 233.1	 7.6	 105.5	 26.8	 75.1	 37.4	 154.6	 173.6	
Copper		 392.6	 22.8	 374.8	 199.9	 245.3	 136.3	 403.8	 398.6	
Iron		 239.0	 73.2	 301.4	 109.3	 228.9	 115.3	 281.6	 265.1	
Magnesium		 208.4	 122.4	 178.9	 80.6	 138.0	 103.3	 245.6	 383.9	
Manganesium		 0.1	 0.0	 0.2	 0.1	 0.2	 0.1	 0.2	 0.2	
Phosphorus		 360.8	 148.7	 209.9	 83.9	 184.0	 119.4	 247.8	 182.2	
Potassium		 113.3	 6.0	 91.1	 42.2	 65.0	 28.5	 91.5	 90.7	
Selenium		 324.0	 4.7	 350.9	 167.7	 275.2	 159.3	 186.7	 113.2	
Sodium	(from	food	plus	added)		 257.3	 59.6	 282.7	 108.3	 222.6	 66.1	 255.0	 144.7	
Zinc		 324.3	 42.7	 237.9	 158.5	 168.5	 77.4	 198.7	 209.1	
Table	S39.	Usual	nutritional	intake:	percentage	adequacy	of	minerals	and	oligoelements	intake,	according	to	age	group.	
	
	
Nutrient	 MPS	I	 MPS	II	 MPS	III	 MPS	IV	 MPS	VI	 MPS	VII	
n	 %	 n	 %	 n	 %	 n	 %	 n	 %	 n	 %	
Calcium	 Low	 1	 20.0%	 2	 50.0%	 1	 25.0%	 1	 50.0%	 6	 66.7%	 0	 0.0%	Adequate	 1	 20.0%	 0	 0.0%	 1	 25.0%	 1	 50.0%	 1	 11.1%	 0	 0.0%	High	 3	 60.0%	 2	 50.0%	 2	 50.0%	 0	 0.0%	 2	 22.2%	 1	 100%	
Copper	 Low	 0	 0.0%	 0	 0.0%	 1	 25.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 5	 100%	 4	 100%	 3	 75.0%	 2	 100%	 8	 88.9%	 1	 100%	
Iron	 Low	 0	 0.0%	 0	 0.0%	 1	 25.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	High	 5	 100%	 4	 100%	 3	 75.0%	 2	 100%	 7	 77.8%	 1	 100%	
Magnesium	 Low	 0	 0.0%	 1	 25.0%	 1	 25.0%	 1	 50.0%	 4	 44.4%	 0	 0.0%	Adequate	 1	 20.0%	 0	 0.0%	 1	 25.0%	 0	 0.0%	 3	 33.3%	 0	 0.0%	High	 4	 80.0%	 3	 75.0%	 2	 50.0%	 1	 50.0%	 2	 22.2%	 1	 100%	
Manganesium	 Low	 5	 100%	 4	 100%	 4	 100%	 2	 100%	 9	 100%	 1	 100%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	
Phosphorus	 Low	 0	 0.0%	 0	 0.0%	 1	 25.0%	 0	 0.0%	 2	 22.2%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 5	 100%	 4	 100%	 3	 75.0%	 2	 100%	 7	 77.8%	 1	 100%	
Potassium	 Low	 2	 40.0%	 2	 50.0%	 2	 50.0%	 2	 100%	 8	 88.9%	 1	 100%	Adequate	 1	 20.0%	 0	 0.0%	 2	 50.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	High	 2	 40.0%	 2	 50.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	
Selenium	 Low	 0	 0.0%	 0	 0.0%	 1	 25.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	High	 5	 100%	 4	 100%	 3	 75.0%	 2	 100%	 8	 88.9%	 1	 100%	
Sodium	(from	
food	plus	
added)	 Low	 0	 0.0%	 0	 0.0%	 1	 25.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	High	 5	 100%	 4	 100%	 3	 75.0%	 2	 100%	 8	 88.9%	 1	 100%	
Zinc	 Low	 0	 0.0%	 0	 0.0%	 1	 25.0%	 0	 0.0%	 1	 11.1%	 0	 0.0%	Adequate	 0	 0.0%	 0	 0.0%	 0	 0.0%	 0	 0.0%	 2	 22.2%	 0	 0.0%	High	 5	 100%	 4	 100%	 3	 75.0%	 2	 100%	 6	 66.7%	 1	 100%	
Table	S40.	Usual	nutritional	intake	in	25	MPS	patients:	patients	consuming	lower,	adequate	and	higher	amounts	of	minerals	and	
oligoelements	than	recommendations,	according	to	MPS	type.	
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Nutrient		
(%	of	EAR)	 MPS	I	 MPS	II	 MPS	III	 MPS	IV	 MPS	VI	 MPS	VII	Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SD	 Mean	 SDa	
Calcium		 215.2	 157.5	 110.0	 42.6	 87.2	 53.2	 72.9	 28.8	 82.1	 31.4	 114.5	 .	
Copper	 465.1	 359.8	 470.5	 219.3	 331.4	 242.8	 283.0	 68.6	 226.7	 112.1	 246.3	 .	
Iron	 329.7	 236.2	 379.8	 118.7	 240.1	 143.8	 262.0	 4.3	 187.8	 82.7	 316.5	 .	
Magnesium	 324.9	 346.7	 240.8	 126.2	 158.2	 117.7	 119.8	 50.4	 95.8	 43.7	 174.9	 .	
Manganesium	 0.2	 0.2	 0.3	 0.2	 0.2	 0.1	 0.1	 0.0	 0.1	 0.1	 0.3	 .	
Phosphorus	 338.7	 153.5	 305.5	 92.7	 188.8	 147.8	 112.0	 1.0	 163.0	 65.0	 144.3	 .	
Potassium	 116.5	 79.0	 116.6	 56.0	 77.2	 40.3	 70.2	 5.5	 57.4	 21.2	 74.5	 .	
Selenium	 323.7	 24.6	 465.6	 158.7	 326.7	 262.2	 236.7	 28.5	 180.2	 66.0	 332.9	 .	
Sodium	(from	
food	plus	added)			 264.8	 70.2	 331.1	 126.1	 264.7	 131.4	 213.8	 27.0	 218.2	 95.3	 237.6	 .	
Zinc	 311.7	 167.3	 248.5	 83.9	 266.0	 252.6	 132.2	 19.3	 138.4	 50.1	 173.1	 .	
Table	S41.	Usual	nutritional	intake:	percentage	adequacy	of	minerals	and	oligoelements	intake,	according	to	MPS	type	(a	n=1).	
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Type	of	MPS	 Mean	 SD	 Median	 Minimum	 Maximum	MPS	I	 17.3	 5.4	 14.9	 12.3	 26.1		 (-0.9)	 (1.8)	 (-0.6)	 (-2.8)	 (0.7)	MPS	II	 37.0	 8.5	 33.7	 31.1	 49.6		 (1.2)	 .	 (1.2)	 (1.2)	 (1.2)	MPS	III	 38.0	 8.7	 36.9	 26.3	 56.8		 (1.5)	 (0.4)	 (1.5)	 (1.2)	 (1.8)	MPS	IV	 27.0	 10.0	 22.5	 20.0	 38.5		 	 	 	 	 	MPS	VI	 27.8	 6.9	 29.0	 16.8	 41.5		 (-1.0)	 (1.8)	 (-1.0)	 (-2.3)	 (0.3)	MPS	VII	 29.5	 .	 29.5	 29.5	 29.5		 (-0.3)	 .	 (-0.3)	 (-0.3)	 (-0.3)	
Total	 30.2	 10.3	 29.5	 12.3	 56.8	
	 (-0.1)	 (1.6)	 (0.3)	 (-2.8)	 (1.8)	
Table	S42.	Anthropometrics:	weight,	in	Kg	(z-score),	according	to	MPS	type.		
Weight	z-score	was	calculated	for	9	patients	(three	MPS	I;	one	MPS	II;	two	MPS	III;	two	MPS	VI;	one	MPS	VII).	
		
Age	group	 Mean	 SD	 Median	 Minimum	 Maximum	0-4	years	 13.6	 1.8	 13.6	 12.3	 14.9	
	 (0.0)	 (0.9)	 (0.0)	 (-0.6)	 (0.7)	5-11	years	 28.5	 8.3	 29.5	 14.8	 41.5	
	 (-0.1)	 (1,8)	 (0.3)	 (-2.8)	 (1.8)	12-18	years	 32.0	 8.6	 29.5	 22.0	 49.6	
	 (n.d.)	 (n.d.)	 (n.d.)	 (n.d.)	 (n.d.)	>18	years	 34.2	 12.0	 32.0	 18.3	 56.8	
	 (n.d.)	 (n.d.)	 (n.d.)	 (n.d.)	 (n.d.)	
Total	 30.2	 10.3	 29.5	 12.3	 56.8	
	 (-0.1)	 (1.6)	 (0.3)	 (-2.8)	 (1.8)	
Table	S43.	Anthropometrics:	weight,	in	Kg	(z-score)	(n.d.	–	no	determined).		
Weight	z-score	was	calculated	for	9	patients	(two	0-4	years;	seven	5-11	years).			 	
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Type	of	MPS	 Mean	 SD	 Median	 Minimum	 Maximum	MPS	I	 105.7	 16.0	 102.2	 83.3	 124.0		 (-3.3)	 (3.0)	 (-3.3)	 (-6.9)	 (-0.3)	MPS	II	 136.1	 8.1	 132.8	 130.8	 148.0		 (-2.8)	 (2.1)	 (-2.9)	 (-5.1)	 (-0.2)	MPS	III	 145.2	 15.6	 142.0	 123.4	 170.0		 (-0.7)	 (1.9)	 (0.2)	 (-3.8)	 (1.5)	MPS	IV	 110.1	 15.2	 106.5	 97.0	 126.7		 (-7.3)	 (2.5)	 (-6.5)	 (-10.1)	 (-5.2)	MPS	VI	 114.3	 8.3	 113.4	 99.0	 124.5		 (-6.2)	 (2.9)	 (-7.3)	 (-8.8)	 (-0.1)	MPS	VII	 103.0	 .	 103.0	 103.0	 103.0		 (-5.4)	 .	 (-5.4)	 (-5.4)	 (-5.4)	
Total	 124.2	 20.5	 123.7	 83.3	 170.0	
	 (-3.7)	 (3.3)	 (-3.8)	 (-10.1)	 (1.5)	
Table	S44.	Anthropometrics:	height,	in	cm	(z-score),	according	to	type	of	MPS.		
Height	z-score	was	calculated	in	30	patients	(five	MPS	I;	four	MPS	II;	nine	MPS	III;	three	MPS	IV;	eight	MPS	VI;	one	MPS	VII).	
	
	
Age	group	 Mean	 SD	 Median	 Minimum	 Maximum	0-4years	 92.1	 12.4	 92.1	 83.3	 100.8	
	 (-0.3)	 (0.0)	 (-0.3)	 (-0.4)	 (-0.3)	5-11years	 122.2	 16.8	 124.5	 99.0	 145.0	
	 (-1.7)	 (2.7)	 (-0.2)	 (-6.5)	 (1.5)	12-18years	 127.7	 12.8	 126.7	 109.0	 148.0	
	 (-5.1)	 (2.0)	 (-5.2)	 (-8.8)	 (-2.0)	>18years	 131.2	 27.6	 119.0	 97.0	 170.0	
	 (-5.6)	 (3.9)	 (-7.3)	 (-10.1)	 (0.9)	
Total	 124.2	 20.5	 123.7	 83.3	 170.0	
	 (-3.7)	 (3.3)	 (-3.8)	 (-10.1)	 (1.5)	
Table	S45.	Anthropometrics:	height,	in	cm	(z-score).		
Height	z-score	was	calculated	for	30	patients	(two	0-4	years;	eleven	5-11	years;	nine	12-18	years;	eight	>18	years).	
	
	 	
Nutritional	status	of	patients	with	mucopolysaccharidosis		
		 |	103	
Type	of	MPS	 Mean	 SD	 Median	 Minimum	 Maximum	MPS	I	 15.3	 2.0	 14.7	 13.0	 17.9		 (-1.1)	 (1.8)	 (-0.8)	 (-3.9)	 (1.2)	MPS	II	 19.7	 2.0	 19.1	 18.1	 22.6		 (0.4)	 (1.2)	 (0.4)	 (-1.1)	 (1.8)	MPS	III	 18.0	 2.2	 18.0	 13.8	 21.2		 (-0-3)	 (1.9)	 (-0.3)	 (-4.6)	 (1.9)	MPS	IV	 21.7	 2.1	 21.3	 19.8	 24.0		 (0.5)	 (0.5)	 (0.6)	 (-0.1)	 (0.9)	MPS	VI	 21.0	 4.8	 20.3	 15.9	 28.8		 (0.3)	 (1.2)	 (0.6)	 (-1.9)	 (1.8)	MPS	VII	 27.8	 .	 27.8	 27.8	 27.8		 (3.4)	 	 (3.4)	 (3.4)	 (3.4)	
Total	 19.3	 3.9	 18.3	 13.0	 28.8	
	 (0.0)	 (1.6)	 (0.4)	 (-4.6)	 (3.4)	
Table	S46.	Anthropometrics:	BMI,	in	Kg/m2	(z-score),	according	to	MPS	type.		
BMI	z-score	was	calculated	in	30	patients	(five	MPS	I;	four	MPS	II;	nine	MPS	III;	three	MPS	IV;	eight	MPS	VI;	one	MPS	VII)	
		
Age	group	 Mean	 SD	 Median	 Minimum	 Maximum	0-4	years	 16.3	 2.3	 16.3	 14.7	 17.9	
	 (0.3)	 (1.3)	 (0.3)	 (-0.6)	 (1.2)	5-11	years	 18.8	 3.6	 18.1	 14.2	 27.8	
	 (1.0)	 (1.1)	 (0.9)	 (-0.8)	 (3.4)	12-18	years	 19.5	 3.3	 18.0	 15.9	 24.4	
	 (-0.4)	 (1.0)	 (-0.3)	 (-1.9)	 (1.0)	>18	years	 20.5	 5.3	 20.7	 13.0	 28.8	
	 (-0.9)	 (2.3)	 (-0.3)	 (-4.6)	 (1.8)	
Total	 19.3	 3.9	 18.3	 13.0	 28.8	
	 (0.0)	 (1.6)	 (0.4)	 (-4.6)	 (3.4)	
Table	S47.	Anthropometrics:	BMI,	in	Kg/m2	(z-score).		
BMI	z-score	was	calculated	for	30	patients	(two	0-4	years;	eleven	5-11	years;	nine	12-18	years;	eight	>18	years).		  
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Group	of	
disease	 n	
Body	fat	mass	(%)	 Body	lean	mass	(%)	 Total	body	water	(%)	
Mean	 SD	 Median	 Min.	 Max.	 Mean	 SD	 Median	 Min.	 Max.	 Mean	 SD	 Median	 Min.	 Max.	
MPS	I	 0	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	 -	
MPS	II	 4	 21.5	 16.0	 20.7	 3.9	 40.7	 16.2	 10.4	 18.0	 2.9	 25.7	 62.4	 11.3	 66.4	 46.3	 70.4	
MPS	III	 6	 16.6	 8.1	 17.7	 3.9	 28.6	 18.2	 6.2	 19.4	 10.1	 25.7	 65.3	 5.2	 65.2	 59.4	 70.4	
MPS	IV	 3	 23.8	 10.6	 21.6	 14.5	 35.4	 13.8	 11.3	 17.3	 1.1	 22.9	 62.4	 15.0	 62.6	 47.3	 77.3	
MPS	VI	 5	 11.5	 10.1	 5.4	 3.9	 27.5	 23.2	 3.7	 25.4	 17.0	 25.8	 65.2	 6.4	 69.2	 55.5	 70.3	
MPS	VII	 0	 -	 -	 -	 -	 	 -	 	 -	 -	 -	 -	 	 -	 -	 	
Total	 18	 17.5	 11.1	 16.2	 3.9	 40.7	 18.4	 7.8	 22.1	 1.1	 25.8	 64.1	 8.3	 66.0	 46.3	 77.3	
Table	S48.	Body	composition,	according	to	type	of	MPS	(SD=standard	deviation;	Min=minimum;	Max=maximum) 
	
	
Group	of	disease	 Phase	angle	(°)	n	 Mean	 SD	 Median	 Min.	 Max.	
MPS	I	 1	 3.9	 -	 3.9	 3.9	
MPS	II	 4	 4.5	 1.0	 4.5	 3.3	 5.7	
MPS	III	 7	 4.5	 1.0	 4.7	 3.0	 5.5	
MPS	IV	 3	 4.4	 0.5	 4.2	 4.0	 4.9	
MPS	VI	 6	 5.0	 0.7	 4.8	 4.3	 6.2	
MPS	VII	 0	 -	 -	 -	 -	 -	
Total	 21	 4.6	 0.8	 4.6	 3.0	 6.2	
Table	S49.	Phase	angle,	according	to	type	of	MPS	(SD=standard	deviation;	Min=minimum;	Max=maximum)		
	
	 	
Nutritional	status	of	patients	with	mucopolysaccharidosis		
		 |	105	
	 	 Walked	distance	(m)	
Type	of	MPS	 n	 Mean	 SD	 Median	 Minimum	 Maximum	
MPS	I	 2	 171.2	 114.8	 171.2	 90.0	 252.4	
MPS	II	 2	 554.5	 149.2	 554.5	 449.0	 660.0	
MPS	III	 3	 302.8	 89.3	 332.3	 202.5	 373.7	
MPS	IV	 2	 250.6	 93.3	 250.6	 184.6	 316.5	
MPS	VI	 7	 287.4	 126.4	 350.7	 26.9	 384.0	
Total	 16	 304.6	 147.1	 324.4	 26.9	 660.0	
Table	S50.	Six	minutes	walking	test	results.		 	
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Plasmatic	proteins	 	 n	(%)	 Mean	 SD	 Min	 Max	
Total	protein	
(g/L)	
Normal	 25	 (92.6%)	 72.6	 8.4	 65.8	 110.0	Low	 2	 (7.4%)	 64.0	 0.0	 64.0	 64.0	High	 0	 (0.0%)	 .	 .	 .	 .	
Total	 27	 (100.0%)	 71.9	 8.4	 64.0	 110.0	
Albumin	
(g/L)	
Normal	 27	 (87.1%)	 42.9	 2.9	 36.5	 48.8	Low	 2	 (6.5%)	 35.	5	 1.6	 34.3	 36.6	High	 2	1.1.1.1 (6.5%)	 51.5	 0.7	 51.0	 52.0	
Total	 31	 (100.0%)	 43.0	 4.0	 34.3	 52.0	
Ferritin	
(pmol/L)	
Normal	 30	 (100.0%)	 128.2	 66.9	 47.0	 330.0	Low	 0	 (0.0%)	 .	 .	 .	 .	High	 0	 (0.0%)	 .	 .	 .	 .	
Total	 30	 (100.0%)	 128.2	 66.9	 47.0	 330.0	
Pre-albumin	
(mg/L)		
Normal	 11	 (40.7%)	 252.0	 52.0	 200.0	 370.0	Low	 16	 (59.3%)	 166.2	 23.0	 118.0	 198.0	High	 0	 (0.0%)	 .	 .	 .	 .	
Total	 27	 (100.0%)	 201.2	 56.5	 118.0	 370.0	
Retinol	binding	protein	
(mg/L)	
Normal	 6	 (25.0%)	 31.7	 12.5	 10.0	 49.0	Low	 18	 (75.0%)	 23.3	 9.5	 0.0	 38.4	High	 0	 (0.0%)	 .	 .	 .	 .	
Total	 24	 (100.0%)	 25.4	 10.7	 0.0	 49.0	
Transferrin	
(g/L)	
Normal	 21	 (91.3%)	 2.5	 0.2	 2.2	 3.0	Low	 1	 (4.3%)	 2.0	 .	 	 	High	 1	 (4.3%)	 3.9	 .	 	 	
Total	 23	 (100.0%)	 2.6	 0.4	 2.0	 3.9	
C-reactive	protein	
(nmol/L)	
Normal	 30	 (96.8%)	 4.2	 3.0	 0.3	 11.4	Low	 0	 (0.0%)	 .	 .	 .	 .	High	 1	 (3.2%)	 11.1	 .	 	 	
Total	 31	 (100.0%)	 4.5	 3.2	 0.3	 11.4	
Table	S51.	Plasmatic	proteins	-	classification	according	to	reference	values;	mean,	standard-deviation,	minimum	and	maximum	
(units	mentioned	in	table).		
Performed	analysis	per	type	of	MPS:	total	protein	(four	MPS	I;	three	MPS	II;	nine	MPS	III;	three	MPS	IV;	eight	MPS	VI);	albumin	(all	
patients);	ferritin	(four	MPS	I;	four	MPS	II;	nine	MPS	III;	three	MPS	IV;	nine	MPS	VI;	one	MPS	VII);	pre-albumin	(five	MPS	I;	four	MPS	
II;	six	MPS	III;	two	MPS	IV;	nine	MPS	VI;	one	MPS	VII);	RBP	(five	MPS	I;	three	MPS	II;	five	MPS	III;	two	MPS	IV;	eight	MPS	VI;	one	MPS	
VII);	transferrin	(five	MPS	I;	two	MPS	II;	five	MPS	III;	one	MPS	IV;	nine	MPS	VI;	one	MPS	VII);	C-reactive	protein	(five	MPS	I;	four	MPS	
II;	nine	MPS	III;	three	MPS	IV;	nine	MPS	VI;	one	MPS	VII)	
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Lipids	 	 n	(%)	 Mean	 SD	 Min	 Max	
Total	cholesterol	 Normal	 30	 (96.8%)	 151.1	 28.0	 109.0	 222.0	High	 1	 (3.2%)	 208.0	 .	 208.0	 208.0	
Total		 31	 (100.0%)	 153.0	 29.4	 109.0	 222.0	LDL	–	Cholesterol	 Normal	 28	 (90.3%)	 92.0	 22.0	 48.0	 160.0	High	 3	 (9.7%)	 137.7	 11.7	 129.0	 151.0	
Total		 31	 (100.0%)	 96.4	 25.2	 48.0	 160.0	HDL	–	Cholesterol		 Normal	 14	 (45.2%)	 47.0	 11.4	 24.0	 70.0	Low	 15	 (48.4%)	 34.3	 9.9	 10.0	 48.0	High	 2	 (6.5%)	 71.0	 7.1	 66.0	 76.0	
Total		 31	 (100.0%)	 42.4	 14.2	 10.0	 76.0	Triglycerides	 Normal	 29	 (93.5%)	 76.5	 33.1	 39.0	 147.0	Low	 1	 (3.2%)	 36.0	 .	 36.0	 36.0	High	 1	 (3.2%)	 159.0	 .	 159.0	 159.0	
Total	 31	 (100.0%)	 77.8	 36.1	 36.0	 159.0	
Table	S52.	Lipid	profile	(mg/dL)	-	classification	according	to	reference	values	and	mean,	standard-deviation,	minimum	and	
maximum	(n=31).	
	
Essential	fatty	acids	(reference	values)		 	 n	(%)	 Mean	 SD	 Min	 Max	
Araquidonic	acid		
C20:4w6	(105.0-244.0)	
Normal	 8	(66.7%)	 194.3	 37.5	 136.0	 240.0	Low	 0	(0.0%)	 .	 .	 .	 .	High	 4	(33.3%)	 299.8	 46.5	 270.0	 369.0	
Total	 12	(100.0%)	 229.4	 64.7	 136.0	 369.0	
Docosahexaenoic		acid	C22:6w3	(4.4-30.0)	 Normal	 10	(83.3%)	 45.2	 17.6	 26.8	 77.8	Low	 2	(16.7%)	 18.4	 4.4	 15.3	 21.5	High	 0	(0.0%)	 .	 .	 .	 .	
Total	 12	(100.0%)	 40.7	 19.1	 15.3	 77.8	
Eicosapentaenoic	acid	C20:5w3	(25.9-84.2)	 Normal	 12	(100.0%)	 12.7	 6.0	 4.6	 25.0	Low	 0	(0.0%)	 .	 .	 .	 .	High	 0	(0.0%)	 .	 .	 .	 .	
Total	 12	(100.0%)	 12.7	 6.0	 4.6	 25.0	
Table	S53.	Plasma	essential	fatty	acids	levels,	in	μg/mL	-	classification	according	to	reference	values;	mean,	standard-deviation,	
minimum	and	maximum	(n=12:	three	MPS	I;	four	MPS	III;	two	MPS	IV;	three	MPS	VI).		 	
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Vitamins	 	 n	(%)	 Mean	 SD	 Min	 Max	
Folic	acid	
(nmol/L)	
Normal		 17	(85.0%)	 22.8	 10.0	 11.0	 41.0	Low	 1		(5.0%)	 4.0	 .	 4.0	 4.0	High	 2	(10.0%)	 49.5	 6.4	 45.0	 54.0	
Total	 20	(100.0%)	 24.5	 13.3	 4.0	 54.0	
Vitamin	B12	
(pmol/L)	
Normal		 19	(63.3%)	 440.9	 134.8	 691.0	 216.0	Low	 0	(0.0%)	 .	 .	 .	 .	High	 11	(36.7%)	 721.6	 108.1	 884.0	 542.0	
Total	 30	(100.0%)	 543.8	 185.0	 884.0	 216.0	
Vitamin	A		 Normal		 17	(73.9%)	 1.3	 0.4	 0.8	 2.1	
(µmol/L)	 Low	 6	(26.1%)	 0.7	 0.2	 0.4	 1.0		 High	 0	(0.0%)	 .	 .	 .	 .		 Total	 23	(100.0%)	 1.2	 0.4	 0.4	 2.1	
Vitamin	E	
(µmol/L)	
Normal		 13	(59.1%)	 19.3	 4.5	 12.8	 26.9	Low	 6	(27.3%)	 18.3	 3.9	 13.9	 23.9	High	 3	(13.6%)	 29.0	 8.1	 22.8	 38.2	
Total	 22	(100.0%)	 20.3	 5.9	 12.8	 38.2	
Table	S54.	Plasma	vitamins*	(units	mentioned	in	table)	-	classification	according	to	reference	values;	mean,	standard-deviation,	
minimum	and	maximum.		
Performed	analysis	per	type	of	MPS:	folic	acid	(three	MPS	I;	two	MPS	II;	eight	MPS	III;	one	MPS	IV;	five	MPS	VI;	one	MPS	VII);	vitamin	
B12	(five	MPS	I;	three	MPS	II;	nine	MPS	III;	three	MPS	IV;	nine	MPS	VI;	one	MPS	VII);	Vitamin	A	(four	MPS	I;	one	MPS	II;	seven	MPS	III;	
three	MPS	IV;	eight	MPS	VI);	vitamin	E	(four	MPS	I;	one	MPS	II;	seven	MPS	III;	three	MPS	IV;	seven	MPS	VI).	
(*)	Vitamin	D	–	in	the	phosphocalcium	metabolism	section	
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Minerals	 	 n	(%)	 Mean	 SD	 Min	 Max	
Magnesium	
(mmol/L)	
Normal		 21	 (77.8%)	 0.84	 0.07	 0.70	 0.93	Low	 4	 (14.8%)	 0.74	 0.03	 0.70	 0.77	High	 2	 (7.4%)	 0.95	 0.12	 0.86	 1.03	
Total	 27	 (100.0%)	 0.83	 0.08	 0.70	 1.03	
Selenium	
(mmol/L)	
Normal		 8	 (72.7%)	 0.87	 0.35	 0.18	 1.30	Low	 3	 (27.3%)	 0.35	 0.22	 0.10	 0.53	High	 0	 (0.0%)	 .	 .	 .	 .	
Total	 11	 (100.0%)	 0.73	 0.40	 0.10	 1.30	
Zinc	
(µmol/L)	
Normal		 23	 (95.8%)	 14.0	 2.3	 10.7	 20.5	Low	 1	 (4.2%)	 9.5	 .	 	 	High	 0	 (0.0%)	 .	 .	 .	 .	
Total	 24	 (100.0%)	 13.8	 2.5	 9.5	 20.5	
Potassium	
(mmol/L)	 Normal		 24	 	(92.3%)	 4.4	 0.7	 1.5	 5.5	Low	 0	 	(0.0%)	 .	 .	 .	 .	High	 2	 	(7.7%)	 6.1	 0.7	 5.6	 6.6		 Total	 26	 	(100.0%)	 4.5	 0.9	 1.5	 6.6	
Sodium	
(mmol/L)	 Normal		 24		 	(85.7%)	 138.8	 2.0	 135.0	 142.0	Low	 4	 	(14.3%)	 133.0	 2.8	 129.0	 135.0	High	 0	 	(0.0%)	 .	 .	 .	 .	
Total	 28	 	(100.0%)	 138.0	 2.9	 129.0	 142.0	
Table	S55.	Plasma	minerals	(units	mentioned	in	table)	-	classification	according	to	reference	values;	mean,	standard-deviation,	
minimum	and	maximum.	
Performed	analysis	per	type	of	MPS:	magnesium	(four	MPS	I;	three	MPS	II;	eight	MPS	III;	three	MPS	IV;	eight	MPS	VI;	one	MPS	VII);	
selenium	(three	MPS	I;	three	MPS	III;	two	MPS	IV;	three	MPS	VI);	zinc	(three	MPS	I;	three	MPS	II;	six	MPS	III;	two	MPS	IV;	eight	MPS	
VI;	one	MPS	VII);	potassium	(three	MPS	I;	three	MPS	II;	nine	MPS	III;	three	MPS	IV;	seven	MPS	VI;	one	MPS	VII);	sodium	(four	MPS	I;	
three	MPS	II;	nine	MPS	III;	three	MPS	IV;	eight	MPS	VI;	one	MPS	VII).		 	
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Liver	function	 	 n	(%)	 Mean	 SD	 Min	 Max	
Alanine	transaminase	 Normal		 23	 (79.3%)	 27.8	 7.0	 18.0	 46.7	Low	 0	 (0.0%)	 .	 .	 .	 .	High	 6	 (20.7%)	 52.9	 17.3	 34.7	 79.0	
Total	 29	 (100.0%)	 33.0	 14.1	 18.0	 79.0	
Aspartate	transaminase	 Normal		 24	 (77.4%)	 20.6	 8.6	 10.8	 47.9	Low	 0	 (0.0%)	 .	 .	 .	 .	High	 7	 (22.6%)	 69.0	 15.5	 52.1	 95.2	
Total	 31	 (100.0%)	 31.5	 23.0	 10.8	 95.2	
Gamma-glutamyl	transferase	Normal		 18	 (64.3%)	 19.5	 11.2	 9.0	 44.9	Low	 7	 (25.0%)	 9.8	 1.7	 6.0	 10.8	High	 3	 (10.7%)	 375.5	 499.7	 70.1	 952.1	
Total	 28	 (100.0%)	 55.2	 177.1	 6.0	 952.1	
Table	S56.	Liver	function	(IU/L):	classification	according	to	reference	values	and	mean,	standard-deviation,	minimum	and	
maximum.	
	Performed	analysis	per	type	of	MPS:	alanine	transaminase	(five	MPS	I;	four	MPS	II;	nine	MPS	III;	three	MPS	IV;	nine	MPS	VI;	one	
MPS	VII);	aspartate	transaminase	(four	MPS	I;	four	MPS	II;	nine	MPS	III;	three	MPS	IV;	eight	MPS	VI;	one	MPS	VII);	gamma-glutamyl	
transferase	(four	MPS	I;	three	MPS	II;	nine	MPS	III;	three	MPS	IV;	eight	MPS	VI;	one	MPS	VII).	
	
	
	
	
	
Renal	function	 	 n	(%)	 Mean	 SD	 Min	 Max	
Urea	plasma	
(mmol/L)	
Normal		 28	 (90.3%)	 5.0	 2.4	 1.5	 12.1	Low	 1	 (3.2%)	 1.1	 .	 	 	High	 2	 (6.5%)	 7.4	 1.1	 6.6	 8.1	
Total		 31	 (100.0%)	 5.1	 2.4	 1.1	 12.1	Creatinine	plasma	
(µmol/L)	
Normal		 7	 (22.6%)	 38.0	 9.4	 26.0	 49.0	Low	 24	 (77.4%)	 29.8	 9.5	 12.0	 53.0	High	 0	 (0.0%)	 .	 .	 .	 .	
Total	 31	 (100.0%)	 31.7	 9.9	 12.0	 53.0	
Table	S57.	Renal	function:	classification	according	to	reference	values;	mean,	standard-deviation,	minimum	and	maximum	(units	
mentioned	in	table)	(n=31).		
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Total	blood	count	 	 n	(%)	 Mean	 SD	 Min	 Max	
Haemoglobin	
(g/L)	
Normal		 26	(83.9%)	 133.3	 8.4	 116.0	 148.0	Low	 5	(16.1%)	 120.6	 5.0	 113.0	 126.0	High	 0	(0.0%)	 .	 .	 .	 .	
Total	 31	(100.0%)	 131.2	 9.2	 113.0	 148.0	
Leucocytes		
(x103/µL)	
Normal		 27	(87.1%)	 6.3	 1.3	 4.6	 10.7	Low	 2	(6.5%)	 3.3	 0.5	 2.9	 3.6	High	 2	(6.5%)	 13.7	 2.7	 11.8	 15.6	
Total	 31	(100.0%)	 6.6	 2.4	 2.9	 15.6	
Lymphocytes	
(x103/µL)	
Normal		 21	(77.8%)	 2.8	 1.1	 1.3	 6.8	Low	 1	(3.7%)	 3.1	 .	 	 	High	 5	(18.5%)	 3.8	 1.5	 2.3	 6.3	
Total	 27	(100.0%)	 3.0	 1.2	 1.3	 6.8	
Platelets		
(x103/µL)	
Normal		 22	(71.0%)	 224.8	 59.1	 84.0	 347.0	Low	 7	(22.6%)	 162.4	 53.2	 78.0	 248.0	High	 2	(6.5%)	 536.0	 36.8	 510.0	 562.0	
Total	 31	(100.0%)	 230.8	 101.9	 78.0	 562.0	
Table	S58.	Total	blood	count:	classification	according	to	reference	values;	mean,	standard-deviation,	minimum	and	maximum	(units	
mentioned	in	table).		
Performed	analysis	per	type	of	MPS:	haemoglobin,	leucocytes	and	platelets	(all	sample);	lymphocytes	(five	MPS	I;	four	MPS	II;	six	
MPS	III;	two	MPS	IV;	nine	MPS	VI;	one	MPS	VII).	
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Phosphocalcium	
metabolism	
	 n			(%)	 Mean	 SD	 Min	 Max	
Calcium		
(mmol/L)	
Normal		 25	 (86.2%)	 2.35	 0.08	 2.20	 2.55	Low	 2	 (6.9%)	 2.09	 0.02	 2.07	 2.10	High	 2	 (6.9%)	 2.54	 0.01	 2.53	 2.55	
Total	 29	 (100.0%)	 2.34	 0.12	 2.07	 2.55	
Phosphorus	
(mmol/L)	
Normal		 24	 (82.8%)	 1.45	 0.21	 0.94	 1.87	Low	 0	 		(0.0%)	 													.	 .	 .	 .	High	 5	 (17.2%)	 1.57	 0.08	 1.49	 1.68	
	 Total	 29	 (100.0%)	 1.47	 0.20	 0.94	 1.87	
Vitamin	D	
(nmol/L)	
Normal		 4	(12.9%)	 82.5	 3.2	 79.9	 86.6	Insufficient	 12	(38.7%)	 63.0	 7.9	 52.4	 74.9	Deficient	 15	(48.4%)	 26.7	 11.7	 10.0	 46.0	
Total	 31	(100.0%)	 47.9	 23.7	 10.0	 86.6	
	 	 	 	 	 	 	 	
	Alkaline	phosphatase	
(µkat/L)		
Normal		 21	 (77.8%)	 2.22	 1.14	 0.30	 4.40	Low	 3	 (11.1%)	 2.07	 0.50	 1.60	 2.60	High	 3	 (11.1%)	 2.37	 0.12	 2.30	 2.50	
Total	 27	 (100.0%)	 2.22	 1.01	 .30	 4.40	
Parathormone	
(pmol/L)	
Normal		 19	 (82.6%)	 4.32	 1.52	 2.40	 7.70	Low	 0	 (0.0%)	 														.	 .	 .	 .	High	 4	 (17.4%)	 11.07	 2.48	 8.59	 14.50	
Total	 23	 (100.0%)	 5.50	 3.09	 2.40	 14.50	
	 	 	 	 	 	 	 	
Calcium/creatinine	 Normal		 17	 (94.4%)	 0.20	 0.15	 0.52	 0.01		 Low	 0	 (0.0%)	 .	 .	 .	 .		 High	 1	 (5.6%)	 0.89	 .	 0.89	 0.89		 Total	 18	 (100.0%)	 0.24	 0.22	 0.89	 0.01	
Tubular	reabsorption	of	
phosphate	
Normal		 17	 (100.0%)	 0.95	 0.06	 0.99	 0.80	Low	 0	 (0.0%)	 .	 .	 .	 .	High	 0	 (0.0%)	 .	 .	 .	 .	
Total	 17	 (100.0%)	 0.95	 0.06	 0.99	 0.80	
Table	S59.	Phosphocalcium	metabolism	analytical	indicators.	Classification	according	to	reference	values;	mean,	standard-
deviation,	minimum	and	maximum	(units	mentioned	in	table).		
Performed	analysis	per	type	of	MPS:	calcium	and	phosphorus	(five	MPS	I;	four	MPS	II;	eight	MPS	III;	three	MPS	IV;	nine	MPS	VI);	
alkaline	phosphatase	(four	MPS	I;	four	MPS	II;	seven	MPS	III;	three	MPS	IV;	nine	MPS	VI);	parathormone	(four	MPS	I;	four	MPS	II;	
four	MPS	III;	two	MPS	IV;	nine	MPS	VI);	calcium	/	creatinine	(four	MPS	I;	one	MPS	II;	four	MPS	III;	one	MPS	IV;	eight	MPS	VI);	
tubular	reabsorption	of	phosphate	(four	MPS	I;	one	MPS	II;	four	MPS	III;	eight	MPS	VI).	
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Items	 N	 Mean	 SD	 Median	 Minimum	 Maximum	
1.	Eat	using	fingers	to	pick	up	food	item	 31	 3.2	 4.6	 0	 0	 11	2.	Scoop	with	a	spoon	and	bring	it	to	mouth	 30	 4.3	 4.9	 1	 0	 11	3.	Use	a	fork	for	large,	easy	to	pierce	foods	 30	 5.2	 4.9	 5	 0	 11	4.	Use	a	knife	to	butter	bread	or	cut	soft	foods	 29	 6.6	 4.9	 9	 0	 11	5.	Drink	from	an	open	jar	up	held	securely	with	one	hand	 30	 5.2	 5.4	 3	 0	 11	6.		Pour	liquid	from	carton	or	jug	 29	 6.7	 4.5	 8	 0	 11	7.	Open	a	jar	or	food	container	by	twisting	lid	 29	 8.7	 3.3	 11	 0	 11	
Table	S60.	HAQ:	activities	related	to	eating	and	drinking	(ranging	from	0	“not	difficult	at	all”	to	11	points	“unable	to	do”).	
	
	
Items	 			N	 			Mean	 				SD	 		Median	 Minimum	 Maximum	
8.	Put	on	a	T-shirt,	dress	or	jumper	 29	 7.5	 4.4	 10.0	 0	 11	9.		Put	on	trousers	with	an	elasticated	waist	 30	 7.5	 4.6	 10.5	 0	 11	10.		Put	on	a	front-opening	shirt,	not	including	fasteners	 30	 7.3	 4.8	 11.0	 0	 11	11.	Tuck	shirt	into	back	of	trousers	by	reaching	back	with	hand		 29	 8.3	 4.2	 11.0	 0	 11	12.		Button	and	unbutton	large	buttons	 30	 8.3	 4.1	 11.0	 0	 11	13.		Zip	and	unzip,	including	separating	or	hooking	up	the	zip	 28	 7.6	 4.5	 11.0	 0	 11	14.		Put	on	socks	 30	 8.8	 3.8	 11.0	 0	 11	15.		Put	on	an	unfastened	or	slip-on	shoe	 27	 7.4	 4.7	 11.0	 0	 11	16.		Tie	shoelaces	 30	 9.1	 3.7	 11.0	 0	 11	
Table	S61.	HAQ:	activities	related	to	dressing	(ranging	from	0	“not	difficult	at	all”	to	11	points	“unable	to	do”).			
Items	 			N	 			Mean	 				SD	 		Median	 Minimum	 Maximum	
17.		Turn	tap	on	and	off	 29	 5.4	 5.3	 5.0	 0	 11	18.	Wash	and	dry	upper	body	thoroughly	(neck,	arms,	chest,	upper	back)	 29	 8.3	 4.2	 11.0	 0	 11	19.	Wash	and	dry	lower	body	thoroughly	(abdomen,	lower	back,	legs,	feet)	 28	 8.0	 4.4	 11.0	 0	 11	20.	Brush	or	comb	hair	thoroughly	(including	hair	on	top	of	head	and	back	of	neck)	 19	 9.1	 3.7	 11.0	 0	 11	21.		Cut	fingernails	with	clippers	 28	 9.6	 3.3	 11.0	 0	 11	22.		Prepare	toothbrush	with	toothpaste	 30	 5.9	 5.2	 8.5	 0	 11	23.		Brush	teeth,	even	if	not	thoroughly										 29	 5.6	 5.3	 4.0	 0	 11	
Table	S62.	HAQ:	activities	related	to	bathing	(ranging	from	0	“not	difficult	at	all”	to	11	points	“unable	to	do”).	
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Items	 			N	 			Mean	 				SD	 		Median	 Minimum	 Maximum	
24.		Manage	clothes	before	and	after	toileting	 29	 6.8	 4.9	 11.0	 0	 11	25.		Manage	toilet	seat,	get	toilet	paper	and	flush	toilet	 29	 6.6	 5.1	 11.0	 0	 11	26.		Get	on	and	off	toilet	without	assistance		 29	 5.3	 5.3	 5.0	 0	 11	27.		Wipe	self	thoroughly	after	bowel	movements	 28	 7.4	 4.7	 11.0	 0	 11	
Table	S63.	HAQ:	activities	related	to	toileting	(ranging	from	0	“not	difficult	at	all”	to	11	points	“unable	to	do”). 
	
	
Items	 			N	 			Mean	 			SD	 		Median	 Minimum	 Maximum	
28.		Retrieve	objects	from	floor	while	sitting	 30 6.5 4.6 8.0 0 11 29.		Get	on	and	off	the	floor	 31 6.1 5.0 10.0 0 11 30.		Manage	a	seat	belt	or	restraint	in	car	 29 6.7 4.8 11.0 0 11 31.		Get	in	and	out	of	the	front	seat	of	a	car	 30 5.9 4.9 5.5 0 11 32.		Open	and	close	a	car	door	without	assistance	 30 6.2 5.1 8.0 0 11 
Table	S64.	HAQ:	activities	related	to	mobility	(ranging	from	0	“not	difficult	at	all”	to	11	points	“unable	to	do”).			
Items	 				N	 		Mean	 				SD	 Median	 		Minimum	 Maximum	
35.	Walk	length	of	shopping	centre	or	through	supermarket	aisles	 30 5.9 4.9 8.0 0 11 36.	Walk	across	level	surfaces,	such	as	smooth	pavements	or	driveways	 30 5.7 4.8 6.5 0 11 37.	Walk	across	rough	or	uneven	surfaces,	such	as	a	lawn	or	a	gravel	driveway	 30 6.7 4.8 10.0 0 11 38.		Step	on	and	off	curbs	 30 6.6 4.7 9.5 0 11 39.	Walk	up	a	full	flight	of	stairs	(12-15	steps)	holding	a	rail	and/or	stopping	between	steps	 30 6.3 4.8 8.0 0 11 
Table	S65.	HAQ:	activities	related	to	walking	and	climbing	stairs	(ranging	from	0	“not	difficult	at	all”	to	11	points	“unable	to	do”).	
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Domain	 								N	 Mean	 SD	 				Median	 Minimum	 Maximum	
Eating	and	drinking	 31	 5.5	 4.0	 4.4	 0	 11	Dressing	 29	 8.0	 3.9	 10.4	 0	 11	Bathing		 30	 7,1	 3,9	 8,0	 0	 11	Toileting	 29	 6.5	 4.8	 9.5	 0	 11	Mobility	 31	 6.3	 4.1	 5.8	 0	 11	Walking	and	climbing	stairs	 30	 6,3	 4,5	 7,0	 0	 11	All	domains	 31	 6.6	 3.8	 6.8	 0	 11	
Table	S66.	HAQ:	all	domains	(ranging	from	0	“not	difficult	at	all”	to	11	points	“unable	to	do”).				
Activity	domain	 Independent	 Minimal	assistance	 Moderate	assistance	 Complete	assistance	 Median	
n	 (%)	 n	 (%)	 n	 (%)	 n	 (%)	 Mdn	Eating	 3	 (10.3%)	 4	 (13.8%)	 5	 (17.2%)	 17	 (58.6%)	 4	Grooming	 4	 (13.8%)	 3	 (10.3%)	 6	 (20.7%)	 16	 (55.2%)	 4	Bathing	 2	 (6.9%)	 2	 (6.9%)	 6	 (20.7%)	 19	 (65.5%)	 4	Dressing	upper	body	 5	 (17.2%)	 2	 (6.9%)	 4	 (13.8%)	 18	 (62.1%)	 4	Dressing	lower	body	 4	 (13.8%)	 4	 (13.8%)	 2	 (6.9%)	 19	 (65.5%)	 4	Toileting	 8	 (27.6%)	 3	 (10.3%)	 3	 (10.3%)	 15	 (51.7%)	 4	Chair	and	toilet	transfers	 12	 (41.4%)	 2	 (6.9%)	 4	 (13.8%)	 11	 (37.9%)	 3	Car	transfers	 8	 (27.6%)	 3	 (10.3%)	 4	 (13.8%)	 14	 (48.3%)	 3	Bed	mobility	/	transfers	 13	 (44.8%)	 2	 (6.9%)	 3	 (10.3%)	 11	 (37.9%)	 2	Tub	transfers	 6	 (20.7%)	 3	 (10.3%)	 6	 (20.7%)	 14	 (48.3%)	 3	Indoor	locomotion	 9	 (31.0%)	 4	 (13.8%)	 3	 (10.3%)	 13	 (44.8%)	 3	Outdoor	locomotion	 7	 (25.0%)	 4	 (14.3%)	 2	 (7.1%)	 15	 (53.6%)	 4	Stairs	 10	 (34.5%)	 1	 (3.4%)	 4	 (13.8%)	 14	 (48.3%)	 3	
Table	S67.	HAQ:	relative	and	absolute	frequency	of	answers	about	autonomy	(caregiver	assistance),	by	domain.	Median	is	indicated	
and	mode	is	evidenced	in	bold.		
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